Page last updated: 2024-10-31

nevirapine and Pregnancy

nevirapine has been researched along with Pregnancy in 667 studies

Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.

Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.

Research Excerpts

ExcerptRelevanceReference
"To confirm whether 7 days of phenytoin, an enzyme inducer, would decrease the elimination half-life of single-dose nevirapine and to investigate its effect on the development of nevirapine resistance in pregnant, HIV-infected women."9.17Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. ( Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013)
"Pharmacokinetic data for lopinavir in late pregnancy and in breastfeeding are limited, and no data for abacavir in breast milk are available."9.17Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. ( Capparelli, E; Essex, M; Leidner, J; Lockman, S; Makhema, J; Moffat, C; Moss, M; Moyo, S; Ogwu, A; Rossi, S; Shapiro, RL, 2013)
"Nevirapine (NVP) resistance emerges in up to 70% of women exposed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency virus (HIV)."9.17Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. ( Bonhomme, J; Chan, ES; Halvas, EK; Hitti, J; Hong, F; Hughes, MD; Kabanda, J; Klingman, KL; Kumarasamy, N; McMahon, DK; Mellors, JW; Taulo, F; Wallis, CL; Zheng, L, 2013)
"Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy."9.16A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. ( Achalapong, J; Beck, IA; Britto, P; Chotivanich, N; Cressey, TR; Frenkel, L; Jourdain, G; Maupin, R; Mirochnick, M; Ngo-Giang-Huong, N; Prommas, S; Puthanakit, T; Rasri, W; Roongpisuthipong, A; Shapiro, DE; Van Dyke, RB; Yuthavisuthi, P, 2012)
"Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission."9.14Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. ( Balasubramaniam, U; Bharadwaj, R; Bhore, AV; Bhosale, R; Bollinger, R; Gupta, A; Gupte, N; Kagal, A; Kulkarni, S; Kulkarni, V; Moorthy, A; Patil, S; Persaud, D; Sastry, J; Suryavanshi, N; Thakar, M; Tripathy, S; Venkataramani, V; Ziemniak, C, 2009)
"Nevirapine has been widely used in pregnancy for its efficacy, low pill burden, bioavailability and rapid transplacental transfer."9.12Safety of nevirapine in pregnancy. ( Anderson, J; de Ruiter, A; Edwards, SG; Hay, P; McDonald, C; Natarajan, U; Pym, A; Taylor, GP; Velisetty, P; Welch, J, 2007)
" We aimed to establish whether pregnancy rates differ between HIV-positive women who use various contraceptive methods and either efavirenz-based or nevirapine-based antiretroviral therapy (ART) regimens."8.91Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study. ( Blat, C; Bukusi, EA; Cohen, CR; Gandhi, M; Hagey, J; Newmann, SJ; Onono, M; Patel, RC; Shade, SB; Vittinghoff, E, 2015)
" Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance."8.85Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009)
"Clinical trials demonstrated intermittent preventive treatment in pregnancy with mefloquine (MQ) reduced malaria rates among pregnant women, yet an unexpected higher risk of mother-to-child transmission (MTCT) of HIV among HIV-positive women receiving MQ has also been observed."7.88Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy. ( Desai, M; Dinh, C; Gonzalez, R; Haaland, RE; Heneine, W; Katana, A; Martin, A; Menendez, C; Otieno, K; Slutsker, L; Williamson, J, 2018)
" Patients were allocated to 2groups according to exposure to nevirapine during pregnancy."7.83[Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy]. ( Figueras-Nadal, C; Fortuny-Guasch, C; Iveli, P; Martín-Nalda, A; Noguera-Julian, A; Rovira-Girabal, N; Soler-Palacín, P, 2016)
"Previous studies on nevirapine pharmacokinetics during pregnancy reported contradictory findings."7.83Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. ( Back, D; Bolaji, O; Khoo, S; Neary, M; Olagunju, A; Owen, A, 2016)
"The objective of this study was to determine the prevalence of drug resistance mutations among HIV-positive women in Malawi 18 months after discontinuing nevirapine-based ART for the prevention of mother-to-child transmission."7.81Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. ( Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Vella, S, 2015)
"An exit interview was conducted one year post-partum for 85 HIV-infected women who participated in a study of HIV-1 transmission rates among NVP-experienced compared with NVP-naïve women in "The Nevirapine Repeat Pregnancy (NVP-RP) Study" at the Makerere University-Johns Hopkins University Research Collaboration, Kampala-Uganda, between June 2004 and June 2006."7.81A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study". ( Bakaki, PM; Fowler, MG; Kiweewa, FM; Kusasira, F; McConnell, MS; Mubiru, MC; Musisi, M; Musoke, P; Nakayiwa, F; Nakintu, D; Namirembe, C, 2015)
"Data from a prospective multisite cohort study were used to examine the effect of HIV exposure, untreated HIV infection, and single-dose nevirapine on infant growth velocity."7.80HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants. ( Chhagan, M; Doherty, T; Fadnes, LT; Goga, AE; Jackson, DJ; Lombard, C; Ramokolo, V; Van den Broeck, J, 2014)
" We compared the pregnancy outcomes of women exposed to EFV and to nevirapine (NVP) during the first trimester."7.77Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire. ( Amani-Bosse, C; Anglaret, X; Coffie, PA; Dabis, F; Danel, C; Eholié, SP; Ekouevi, DK; Messou, E; Moh, R; Ouattara, E; Sissoko, M, 2011)
"Use of single dose nevirapine (sdNVP) to prevent HIV mother-to-child transmission is associated with the emergence of NVP resistance in many infants who are HIV infected despite prophylaxis."7.75In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. ( Bagenda, D; Bakaki, P; Church, JD; Donnell, D; Eshleman, SH; Eure, C; Fowler, MG; Guay, LA; Jackson, JB; Matovu, F; McConnell, M; Musoke, P; Mwatha, A; Nakabiito, C; Omer, SB; Thigpen, MC, 2009)
"Single-dose nevirapine (SDNVP) for the prevention of mother-to-child HIV transmission (PMTCT) results in the selection of resistance mutants among HIV-infected mothers."7.74Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study. ( Aldrovandi, GM; Kankasa, C; Kuhn, L; Semrau, K; Sinkala, M; Thea, DM; Walter, J, 2008)
"Single-dose nevirapine (SDNVP) is widely used to prevent mother-to-child HIV transmission in resource-limited settings."7.74Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. ( Bagenda, D; Bakaki, P; Downing, R; Eure, C; Fowler, MG; Greenberg, AE; Matovu, F; McConnell, M; Mubiru, M; Thigpen, MC, 2007)
"To determine the impact of pregnancy on the pharmacokinetics (PK) of nevirapine (NVP) during chronic dosing in HIV-infected women and appropriate NVP dosing in this population."7.74Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. ( Aweeka, F; Best, B; Burchett, SK; Capparelli, EV; Foca, M; Hitti, J; Hu, C; Jimenez, E; Mirochnick, M; Nachman, S; Read, JS; Shearer, WT; Smith, E; Spector, SA; Stek, A; Thorpe, EM; Watts, H, 2008)
"Nelfinavir- or nevirapine-containing HAART regimens during pregnancy are well tolerated."7.73Nelfinavir and nevirapine side effects during pregnancy. ( Boer, K; de Wolf, F; Dieleman, J; Godfried, MH; Nellen, J; Schneider, ME; Sprenger, H; Tempelman, C; Timmermans, S; van der Ende, ME, 2005)
"The incidence of adverse events with nevirapine may be lower than previously reported (13% versus 29%) and may be primarily noted with initiating the drug late in pregnancy."7.73Third-trimester maternal toxicity with nevirapine use in pregnancy. ( Brady, MT; Fan-Havard, P; Hughes, L; Joy, S; Koletar, SL; Para, MF; Poi, M, 2005)
"To describe the maternal tolerability of nevirapine as part of combination antiretroviral therapy in pregnancy at three HIV centres in Dublin, Ireland and to determine risk factors for development of significant hepatotoxicity."7.73Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. ( Bergin, C; Geoghegan, J; Hopkins, S; Kelleher, B; Lyons, F; McCormick, PA; McGeary, A; Mulcahy, FM; Sheehan, G, 2006)
" We report the case of a pregnant human immunodeficiency virus type 1-infected woman who developed drug rash with eosinophilia and systemic symptoms syndrome and renal failure shortly after initiation of a nevirapine-containing antiretroviral regimen at 27 weeks' gestation."7.72Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. ( Boswell, H; Fan-Havard, P; Knudtson, E; Para, M, 2003)
" The one adverse event associated with nelfinavir occurred in a subject with a CD4 cell count less than 250 cells/microL."6.71Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. ( Baker, D; Foca, M; Frenkel, LM; Gandia, J; Gonzalez-Garcia, A; Hitti, J; Huang, S; McNamara, J; Nachman, SA; Paul, ME; Provisor, A; Stek, AM; Stevens, LM; Thorpe, EM; Watts, DH; Wei, LJ, 2004)
"The risk of adverse drug events associated with nevirapine (NVP) is suggested to be greater in pregnant women."6.49Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. ( Andrieux-Meyer, I; Calmy, A; Ford, N; Hargreaves, S; Mills, EJ; Shubber, Z, 2013)
"To investigate if pregnancy is a risk factor for SJS among HIV-infected women taking NVP-containing regimens and registered within the Medunsa National Pharmacovigilance Centre database."5.39Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007 - 2012. ( Adewusi, E; Dube, N; Summers, R, 2013)
"Pregnancy has a moderate but significant lowering effect on NVP plasma concentrations."5.35Steady-state nevirapine plasma concentrations are influenced by pregnancy. ( Boer, K; Burger, DM; Damming, M; de Wolf, F; Godfried, MH; Nellen, JF; Prins, JM; van der Ende, ME; Wit, FW, 2008)
" The influence of gender, age, body weight and comedication on minimum and maximum concentrations (C(min), C(max)), area under the concentration-time curve (AUC), total clearance (CL(tot)), half-life (t(1/2)) and volume of distribution (V(d)) was analysed by multivariate techniques."5.33A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. ( Carlebach, A; Gute, P; Haberl, A; Harder, S; Klauke, S; Knecht, G; Kurowski, M; Rohrbacher, M; Staszewski, S; Stocker, H; von Hentig, N, 2006)
"To confirm whether 7 days of phenytoin, an enzyme inducer, would decrease the elimination half-life of single-dose nevirapine and to investigate its effect on the development of nevirapine resistance in pregnant, HIV-infected women."5.17Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. ( Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013)
"ART use did not affect risk of ovulation or pregnancy in women taking COCs, suggesting that nevirapine-containing ART does not interfere with COC contraceptive effectiveness."5.17Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness. ( Delany-Moretlwe, S; Dubé, K; Edward, VA; Kwok, C; Lendvay, A; Mirembe, FM; Molife, L; Mpairwe, B; Nakubulwa, S; Nanda, K, 2013)
"Although substantiated by little evidence, concerns about zidovudine-related anaemia in pregnancy have influenced antiretroviral (ARV) regimen choice for preventing mother-to-child transmission of HIV-1, especially in settings where anaemia is common."5.17Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three African countries. ( Chersich, MF; Farley, TM; Luchters, S; Meda, N; Mwaura, M; Newell, ML; Sartorius, BK; Temmerman, M, 2013)
"Pharmacokinetic data for lopinavir in late pregnancy and in breastfeeding are limited, and no data for abacavir in breast milk are available."5.17Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. ( Capparelli, E; Essex, M; Leidner, J; Lockman, S; Makhema, J; Moffat, C; Moss, M; Moyo, S; Ogwu, A; Rossi, S; Shapiro, RL, 2013)
"Nevirapine (NVP) resistance emerges in up to 70% of women exposed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency virus (HIV)."5.17Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. ( Bonhomme, J; Chan, ES; Halvas, EK; Hitti, J; Hong, F; Hughes, MD; Kabanda, J; Klingman, KL; Kumarasamy, N; McMahon, DK; Mellors, JW; Taulo, F; Wallis, CL; Zheng, L, 2013)
"Extended nevirapine and cotrimoxazole prophylaxis through 6 months of age among HIV-exposed uninfected infants did not appear to increase the immediate or long-term risk of neutropenia, anemia or skin-rash."5.16Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated. ( Aizire, J; Bolton, SG; Brown, ER; Coovadia, H; Fowler, MG; Kamateeka, M; Musoke, PM; Shetty, AK; Stranix-Chibanda, L; Wang, J, 2012)
"Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy."5.16A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. ( Achalapong, J; Beck, IA; Britto, P; Chotivanich, N; Cressey, TR; Frenkel, L; Jourdain, G; Maupin, R; Mirochnick, M; Ngo-Giang-Huong, N; Prommas, S; Puthanakit, T; Rasri, W; Roongpisuthipong, A; Shapiro, DE; Van Dyke, RB; Yuthavisuthi, P, 2012)
"Women randomized to valacyclovir suppressive therapy during pregnancy and postpartum had greater increases in CD4 counts and smaller increases in plasma HIV-1 RNA levels than women in the placebo arm."5.16Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2. ( Drake, AL; Emery, S; Farquhar, C; John-Stewart, GC; Kiarie, JN; Matemo, DN; Ongecha-Owuor, F; Overbaugh, J; Richardson, B; Roxby, AC; Wald, A, 2012)
"In neonates whose mothers did not receive ART during pregnancy, prophylaxis with a two- or three-drug ART regimen is superior to zidovudine alone for the prevention of intrapartum HIV transmission; the two-drug regimen has less toxicity than the three-drug regimen."5.16Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. ( Bastos, FI; Bethel, J; Bryson, YJ; Camarca, M; Ceriotto, M; Dickover, R; Fonseca, R; Gray, G; Grinsztejn, B; Joao, EC; Kreitchmann, R; Machado, D; Mirochnick, M; Mofenson, LM; Moreira, RI; Morgado, MG; Moye, J; Mussi-Pinhata, MM; Nielsen-Saines, K; Pilotto, JH; Pinto, J; Santos, B; Siberry, G; Theron, G; Veloso, VG; Watts, DH; Xu, J, 2012)
"Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission."5.14Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. ( Balasubramaniam, U; Bharadwaj, R; Bhore, AV; Bhosale, R; Bollinger, R; Gupta, A; Gupte, N; Kagal, A; Kulkarni, S; Kulkarni, V; Moorthy, A; Patil, S; Persaud, D; Sastry, J; Suryavanshi, N; Thakar, M; Tripathy, S; Venkataramani, V; Ziemniak, C, 2009)
"For almost a decade, single-dose nevirapine (sdNVP) has been proven to be a safe and effective drug for the prevention of mother-to-child transmission (PMTCT) of HIV."5.14Is single-dose NVP relevant in the era of more efficacious PMTCT regimens? Lessons from Zambia. ( Bweupe, M; Dirks, R; Kabaso, M; Kasonde, P; Mandala, J; Sangiwa, G; Torpey, K, 2010)
"Pregnant HIV-1 seropositive women (CD4+ T-cell count >250 and <500 cells/mm3) electing to breastfeed in Nairobi, Kenya were randomized to highly active antiretroviral therapy (HAART; zidovudine [ZDV], lamivudine and nevirapine [NVP]) during pregnancy and 6 months post-partum or to short-course ZDV plus single-dose NVP (ZDV/NVP)."5.13Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial. ( Chung, MH; John-Stewart, GC; Kiarie, JN; Kinuthia, J; Lehman, DA; Njiri, F; Overbaugh, J; Richardson, BA, 2008)
"In a setting of high perinatal nevirapine use, acute chorioamnionitis was not associated with vertical HIV-1 transmission."5.12Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-1 transmission. ( Chi, BH; Goldenberg, RL; Levy, J; Mudenda, V; Sinkala, M; Stringer, JS, 2006)
"Nevirapine has been widely used in pregnancy for its efficacy, low pill burden, bioavailability and rapid transplacental transfer."5.12Safety of nevirapine in pregnancy. ( Anderson, J; de Ruiter, A; Edwards, SG; Hay, P; McDonald, C; Natarajan, U; Pym, A; Taylor, GP; Velisetty, P; Welch, J, 2007)
"Large numbers of women receive single-dose nevirapine (sdNVP) to prevent mother-to-child transmission (MTCT) of HIV; over time, an increasing proportion will return to prevention of MTCT programs for a second pregnancy."5.12Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire. ( Becquet, R; Dabis, F; Dhlamini, P; Ekouevi, DK; Gray, GE; Leroy, V; Lupodwana, P; Martinson, NA; McIntyre, JA; Morris, L; Steyn, JG; Tonwe-Gold, B; Viho, I, 2007)
"We conducted a randomized, double-blind trial of three treatment regimens in Thai women who were receiving zidovudine therapy during the third trimester of pregnancy."5.11Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. ( Jourdain, G; Kanshana, S; Koetsawang, S; Lallemant, M; Le Coeur, S; Mary, JY; McIntosh, K; Ngo-Giang-Huong, N; Thaineua, V, 2004)
"We randomly assigned 1844 women in Thailand who received zidovudine during the third trimester of pregnancy to receive intrapartum nevirapine or placebo."5.11Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. ( Ariyadej, S; Bowonwatanuwong, C; Hammer, S; Jourdain, G; Kantipong, P; Lallemant, M; Le Coeur, S; Leechanachai, P; Leenasirimakul, P; Ngo-Giang-Huong, N, 2004)
" However, zidovudine administered with lamivudine and indinavir was associated with increased risk of preterm births, zidovudine administered with nevirapine was associated with increased risk of stillbirths, and lamivudine administered with stavudine and efavirenz was associated with increased risk of low birth weight."4.98Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs. ( Antony, J; Ashoor, HM; Blondal, E; Finkelstein, Y; Ghassemi, M; Gough, K; Hemmelgarn, BR; Hutton, B; Ivory, JD; Khan, PA; Lillie, E; Straus, SE; Tricco, AC; Vafaei, A; Veroniki, AA, 2018)
" Second, we discuss the existing clinical data on this topic, including the observational study from Kenya showing women using implants plus efavirenz-based ART had three-fold higher rates of pregnancy than women using implants plus nevirapine-based ART."4.95Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines. ( Cohen, CR; Kiarie, J; Morroni, C; Patel, RC; Scarsi, KK; Sripipatana, T, 2017)
" We aimed to establish whether pregnancy rates differ between HIV-positive women who use various contraceptive methods and either efavirenz-based or nevirapine-based antiretroviral therapy (ART) regimens."4.91Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study. ( Blat, C; Bukusi, EA; Cohen, CR; Gandhi, M; Hagey, J; Newmann, SJ; Onono, M; Patel, RC; Shade, SB; Vittinghoff, E, 2015)
" Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance."4.85Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009)
" Women appear to be at an especially high risk for lactic acidosis, nevirapine-associated rashes and hepatotoxicity, and fat redistribution after highly active antiretroviral therapy exposure."4.82Sex differences in antiretroviral therapy-associated intolerance and adverse events. ( Clark, R, 2005)
"Maternal HIV drug resistance and maternal viral load were independent risk factors for vertical transmission during breastfeeding, suggesting that nevirapine alone may be insufficient infant prophylaxis against drug-resistant variants in maternal breast milk."4.12Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants. ( Beck, IA; Boyce, CL; DeMarrais, P; Flynn, PM; Fowler, MG; Frenkel, LM; Ko, D; Owor, M; Sils, T; Stranix-Chibanda, L; Styrchak, SM; Taha, TE; Tierney, C; Wong-On-Wing, A, 2022)
"Despite improved policies to prevent mother-to-child HIV transmission (MTCT), adherence to maternal antiretroviral therapy (ART) and infant Nevirapine prophylaxis (NVP) is low in South Africa."3.91Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa. ( Ayalew, K; Cheyip, M; Chirinda, W; Dinh, TH; Goga, A; Jackson, D; Kindra, G; Larsen, A; Lombard, C; Magasana, V; Ngandu, N, 2019)
" This study utilized Bayesian logistic regression to examine maternal-level predictors of adherence to infant nevirapine prophylaxis, including intimate partner violence, maternal adherence, HIV serostatus disclosure reaction, recency of HIV diagnosis, and depression."3.88A Bayesian Analysis of Prenatal Maternal Factors Predicting Nonadherence to Infant HIV Medication in South Africa. ( Cook, RR; Jones, DL; Peltzer, K; Rodriguez, VJ; Weiss, SM, 2018)
"Clinical trials demonstrated intermittent preventive treatment in pregnancy with mefloquine (MQ) reduced malaria rates among pregnant women, yet an unexpected higher risk of mother-to-child transmission (MTCT) of HIV among HIV-positive women receiving MQ has also been observed."3.88Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy. ( Desai, M; Dinh, C; Gonzalez, R; Haaland, RE; Heneine, W; Katana, A; Martin, A; Menendez, C; Otieno, K; Slutsker, L; Williamson, J, 2018)
"Syphilis is associated with increased human immunodeficiency virus acquisition and sexual transmission; we examined impact on human immunodeficiency virus mother-to-child transmission among mother-infant pairs enrolled in the India Six-Week Extended-Dose Nevirapine study."3.85Maternal Syphilis: An Independent Risk Factor for Mother to Infant Human Immunodeficiency Virus Transmission. ( Bharadwaj, R; Bhat, J; Bhosale, R; Bollinger, R; Gupta, A; Gupte, N; Kinikar, A; Kulkarni, V; Mave, V; McIntire, KN; Patil, S; Suryavanshi, N, 2017)
" Patients were allocated to 2groups according to exposure to nevirapine during pregnancy."3.83[Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy]. ( Figueras-Nadal, C; Fortuny-Guasch, C; Iveli, P; Martín-Nalda, A; Noguera-Julian, A; Rovira-Girabal, N; Soler-Palacín, P, 2016)
" Antiretroviral treatment-naive women started a nevirapine-based triple combination regimen from the third trimester of pregnancy until at least 6 months of exclusive breastfeeding."3.83Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children. ( Amici, R; Andreotti, M; Baroncelli, S; Galluzzo, CM; Giuliano, M; Jere, H; Mancinelli, S; Marazzi, MC; Palombi, L; Vella, S, 2016)
" In the study, women with baseline CD4(+) <350/mm(3) received a combination of stavudine, lamivudine, and nevirapine during pregnancy (from week 25 of gestation) and continued it indefinitely after delivery."3.83Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi. ( Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Mancinelli, S; Marazzi, MC; Palombi, L; Pirillo, MF; Sagno, JB; Scarcella, P; Vella, S, 2016)
" We found that nevirapine use and pregnancy are independently associated with severe skin reaction."3.83Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis. ( Boulle, A; Cohen, K; de Waal, R; Lehloenya, R; Maartens, G; Stewart, A, 2016)
"The objective of this study was to determine the prevalence of drug resistance mutations among HIV-positive women in Malawi 18 months after discontinuing nevirapine-based ART for the prevention of mother-to-child transmission."3.81Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. ( Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Vella, S, 2015)
"An exit interview was conducted one year post-partum for 85 HIV-infected women who participated in a study of HIV-1 transmission rates among NVP-experienced compared with NVP-naïve women in "The Nevirapine Repeat Pregnancy (NVP-RP) Study" at the Makerere University-Johns Hopkins University Research Collaboration, Kampala-Uganda, between June 2004 and June 2006."3.81A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study". ( Bakaki, PM; Fowler, MG; Kiweewa, FM; Kusasira, F; McConnell, MS; Mubiru, MC; Musisi, M; Musoke, P; Nakayiwa, F; Nakintu, D; Namirembe, C, 2015)
", maternal zidovudine and infant ARV prophylaxis) of the World Health Organization's 2010 guidelines, no studies have assessed adherence to ARVs during pregnancy up to the postpartum period."3.81Longitudinal adherence to antiretroviral drugs for preventing mother-to-child transmission of HIV in Zambia. ( Chirwa, M; Ishikawa, N; Jimba, M; Kapyata, H; Komada, K; Miyano, S; Msiska, CY; Okawa, S; Syakantu, G; Yasuoka, J, 2015)
"Data from a prospective multisite cohort study were used to examine the effect of HIV exposure, untreated HIV infection, and single-dose nevirapine on infant growth velocity."3.80HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants. ( Chhagan, M; Doherty, T; Fadnes, LT; Goga, AE; Jackson, DJ; Lombard, C; Ramokolo, V; Van den Broeck, J, 2014)
"Data from cost studies and other published sources were used to determine the cost, per woman and per cohort (1000 breastfeeding and 1000 non-breastfeeding women), of switching from Option B (maternal triple antiretroviral [ARV] regimen during pregnancy and breastfeeding plus daily nevirapine for the infant for 6 weeks) to Option B+ (maternal triple ARV regimen initiated during pregnancy and continued for life)."3.80The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV. ( Abimbola, TO; O'Brien, L; Sangrujee, N; Shaffer, N, 2014)
" We compared the pregnancy outcomes of women exposed to EFV and to nevirapine (NVP) during the first trimester."3.77Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire. ( Amani-Bosse, C; Anglaret, X; Coffie, PA; Dabis, F; Danel, C; Eholié, SP; Ekouevi, DK; Messou, E; Moh, R; Ouattara, E; Sissoko, M, 2011)
"From the ATHENA cohort study, three scenarios were selected for which the guideline recommended TDM: 1) start of a combination of lopinavir/ritonavir + efavirenz or nevirapine (drug-drug interaction); 2) start of efavirenz (routine TDM); and 3) use of nelfinavir during pregnancy."3.77Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands. ( Burger, DM; de Wolf, F; Franssen, EJ; Kroon, F; Richter, C; Rigter, IM; Smit, C; van Luin, M; Wit, FW, 2011)
" We compared five PMTCT regimens at a fixed level of PMTCT medication uptake: 1) no antenatal ARVs (comparator); 2) sdNVP; 3) WHO 2010 guidelines using "Option A" (zidovudine during pregnancy/infant NVP during breastfeeding for women without advanced HIV disease; lifelong 3-drug antiretroviral therapy (ART) for women with advanced disease); 4) WHO "Option B" (ART during pregnancy/breastfeeding without advanced disease; lifelong ART with advanced disease); and 5) "Option B+:" lifelong ART for all pregnant/breastfeeding, HIV-infected women."3.77WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers. ( Chu, J; Ciaranello, AL; Dabis, F; Engelsmann, B; Freedberg, KA; Keatinge, J; Maruva, M; Mugwagwa, R; Mushavi, A; Perez, F; Walensky, RP, 2011)
" Patients were offered nevirapine-based triple ART initiated in pregnancy until 6 months postpartum."3.77Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. ( Buonomo, E; Ceffa, S; Haswell, J; Liotta, G; Magid, NA; Marazzi, MC; Narciso, P; Nielsen-Saines, K; Palombi, L; Paturzo, G; Scarcella, P; Zimba, I, 2011)
" Unbooked HIV positive pregnant women, who had not received antiretroviral drugs during the antenatal period but received nevirapine in labour, referred to as untreated-maternal HIV infection, were compared with women who received HAART early in pregnancy."3.77Pregnancy outcome among HIV positive women receiving antenatal HAART versus untreated maternal HIV infection. ( Biodun, O; Joseph, O; Michael, E, 2011)
"Compare the risk of HIV drug resistance in women stopping suppressive nelfinavir (NFV)-based or Nevirapine (NVP)-based antiretroviral therapy (ART) after pregnancy."3.77Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum. ( Ellis, GM; Frenkel, LM; Hitti, J; Huang, S, 2011)
" Baseline median CD4 T-cell count: 417 cell/ųl; 98% received antiretroviral drugs during pregnancy [2 nucleoside analogs plus either nevirapine (55%) or a protease inhibitor (32%)]."3.77HIV and pregnancy: maternal and neonatal evolution. ( Cecchini, D; Mecikovsky, D; Trinidad, P; Urueña, A; Vesperoni, F, 2011)
" All women received zidovudine and lamivudine during pregnancy; 76% also received nelfinavir and 8."3.76Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy. ( Cheng, I; Kuritzkes, DR; Paredes, R; Tuomala, RE, 2010)
"Conflicting data exist regarding the effect of pregnancy on steady-state nevirapine pharmacokinetics (PK), although steady-state nevirapine concentrations during pregnancy have never been characterized in sub-Saharan Africa."3.76Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women. ( Back, DJ; Boffito, M; Byakika-Kibwika, P; Flaherty, JP; Khoo, S; Lamorde, M; Merry, C; Nakabiito, C; Namakula, R; Okaba-Kayom, V; Ryan, M; Scarsi, KK, 2010)
"Use of single dose nevirapine (sdNVP) to prevent HIV mother-to-child transmission is associated with the emergence of NVP resistance in many infants who are HIV infected despite prophylaxis."3.75In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. ( Bagenda, D; Bakaki, P; Church, JD; Donnell, D; Eshleman, SH; Eure, C; Fowler, MG; Guay, LA; Jackson, JB; Matovu, F; McConnell, M; Musoke, P; Mwatha, A; Nakabiito, C; Omer, SB; Thigpen, MC, 2009)
"To estimate whether the association between nevirapine (NVP) and hepatotoxicity differs according to pregnancy status in HIV-infected women."3.75Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. ( Brogly, SB; French, AL; Hershow, RC; Leighty, RM; Lu, M; Ouyang, DW; Shapiro, DE; Thompson, B; Tuomala, RE, 2009)
"Limited information is currently available on the metabolic profile of nevirapine in pregnancy."3.75Plasma lipid profile in pregnant women with HIV receiving nevirapine. ( Anzidei, G; Dalzero, S; Floridia, M; Guaraldi, G; Guerra, B; Meloni, AM; Molinari, A; Pinnetti, C; Ravizza, M; Tamburrini, E; Tibaldi, C; Vimercati, A, 2009)
"Single-dose nevirapine (SDNVP) for the prevention of mother-to-child HIV transmission (PMTCT) results in the selection of resistance mutants among HIV-infected mothers."3.74Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study. ( Aldrovandi, GM; Kankasa, C; Kuhn, L; Semrau, K; Sinkala, M; Thea, DM; Walter, J, 2008)
"a retrospective study was performed between January 2003 and December 2006 analysing all women prescribed nevirapine in pregnancy."3.74[Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital]. ( Astori, Ade A; Fernandes, Rde B; Gomes, Sel-K; Kondo, W; Sasaki, Md; Sbalqueiro, RL, 2008)
"Single-dose nevirapine (SDNVP) is widely used to prevent mother-to-child HIV transmission in resource-limited settings."3.74Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. ( Bagenda, D; Bakaki, P; Downing, R; Eure, C; Fowler, MG; Greenberg, AE; Matovu, F; McConnell, M; Mubiru, M; Thigpen, MC, 2007)
"To determine the impact of pregnancy on the pharmacokinetics (PK) of nevirapine (NVP) during chronic dosing in HIV-infected women and appropriate NVP dosing in this population."3.74Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. ( Aweeka, F; Best, B; Burchett, SK; Capparelli, EV; Foca, M; Hitti, J; Hu, C; Jimenez, E; Mirochnick, M; Nachman, S; Read, JS; Shearer, WT; Smith, E; Spector, SA; Stek, A; Thorpe, EM; Watts, H, 2008)
"In the Western Cape province of South Africa, an intensified regimen for the prevention-of-mother-to-child-transmission-of-HIV consisting of zidovudine (AZT) from 34 weeks of pregnancy plus single dose (sd) nevirapine (NVP) during labor was instituted in 2004."3.74Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. ( Claassen, M; Cotton, MF; Engelbrecht, S; Laten, JD; Preiser, W; Theron, GB; van Zyl, GU, 2008)
"This study used Markov modeling to define the circumstances under which the following interventions would be cost-effective: BF for 6 months with daily infant nevirapine (NVP) prophylaxis; maternal combination antiretroviral therapy (ART) during pregnancy and for 6 months of BF; and maternal combination ART only for women who meet CD4 criteria."3.73Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding. ( Maclean, CC; Stringer, JS, 2005)
"Nelfinavir- or nevirapine-containing HAART regimens during pregnancy are well tolerated."3.73Nelfinavir and nevirapine side effects during pregnancy. ( Boer, K; de Wolf, F; Dieleman, J; Godfried, MH; Nellen, J; Schneider, ME; Sprenger, H; Tempelman, C; Timmermans, S; van der Ende, ME, 2005)
"The incidence of adverse events with nevirapine may be lower than previously reported (13% versus 29%) and may be primarily noted with initiating the drug late in pregnancy."3.73Third-trimester maternal toxicity with nevirapine use in pregnancy. ( Brady, MT; Fan-Havard, P; Hughes, L; Joy, S; Koletar, SL; Para, MF; Poi, M, 2005)
"To describe the maternal tolerability of nevirapine as part of combination antiretroviral therapy in pregnancy at three HIV centres in Dublin, Ireland and to determine risk factors for development of significant hepatotoxicity."3.73Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. ( Bergin, C; Geoghegan, J; Hopkins, S; Kelleher, B; Lyons, F; McCormick, PA; McGeary, A; Mulcahy, FM; Sheehan, G, 2006)
" We report the case of a pregnant human immunodeficiency virus type 1-infected woman who developed drug rash with eosinophilia and systemic symptoms syndrome and renal failure shortly after initiation of a nevirapine-containing antiretroviral regimen at 27 weeks' gestation."3.72Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. ( Boswell, H; Fan-Havard, P; Knudtson, E; Para, M, 2003)
" The majority of the HIV positive mothers received nevirapine in labour while 35% had combination ARV drugs in pregnancy."3.72Prevention of mother-to-child transmission of HIV at Maiduguri, Nigeria. ( Audu, BM; Chama, CM; Kyari, O, 2004)
"The following were determined using data from eight African countries: national program costs and impact on infant infections; reductions in adult HIV prevalence and unintended pregnancies among HIV-infected women that would have equivalent impact on infant HIV infections averted as the nevirapine intervention; and the cost threshold for drugs with greater efficacy than nevirapine yielding an equivalent cost per DALY saved."3.72Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries. ( de Zoysa, I; Denison, J; O'Reilly, KR; Schmid, GP; Sweat, MD, 2004)
"To describe the experience of four London HIV centres prescribing nevirapine (NVP) to HIV-1 infected pregnant women with respect to immunological and virological response, tolerability and pregnancy outcome."3.71Experience of nevirapine use in a London cohort of HIV-infected pregnant women. ( de Ruiter, A; Easterbrook, P; Edwards, SG; Hay, P; Larbalestier, N; Taylor, GP; Welch, J, 2001)
"Results of ACTG 076, a clinical trial funded by the National Institute of Allergy and Infectious Disease (NIAID), indicate that perinatal HIV transmission rates could be significantly reduced by treating HIV-positive pregnant women with an intensive zidovudine (AZT) regimen during the second half of pregnancy and during labor and delivery, and by treating the infants for the first six weeks of life."3.69Preventing HIV infection in infants in developing countries: NIAID's role. National Institute of Allergy and Infectious Diseases. ( , 1997)
"Nevirapine exposure was assessed in all patients with available blood samples and safety was assessed in all participants."3.01Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. ( Bryson, Y; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Coletti, A; Cotton, MF; Hazra, R; Jean-Philippe, P; LeBlanc, R; Mirochnick, M; Naidoo, KL; Nelson, BS; Persaud, D; Reding, C; Ruel, TD; Spector, SA; Tierney, C; Zimmer, B, 2021)
"Nevirapine (NVP) is a key component of antiretroviral prophylaxis and treatment for neonates."2.84Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates. ( Aarons, L; Borkird, T; Capparelli, EV; Cressey, TR; Jittayanun, K; Jourdain, G; Lallemant, M; Le Coeur, S; Luvira, A; Phanomcheong, S; Puangsombat, A; Punyawudho, B; Saenjum, C; Sukrakanchana, PO; Urien, S, 2017)
"Levonorgestrel implants were inserted at baseline in all women."2.82Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. ( Back, DJ; Buzibye, A; Byakika-Kibwika, P; Cohn, SE; Darin, KM; Dilly Penchala, S; Else, LJ; Lamorde, M; Merry, C; Nakalema, S; Scarsi, KK, 2016)
" In a pharmacokinetic investigation, breast milk and plasma samples of mothers and newborns were collected."2.78Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns. ( Frank, M; Harms, G; Kloft, C; Kunz, A, 2013)
"We evaluated disease progression among HIV-infected women not on ART with CD4⁺ lymphocyte counts above 200 cells per microliter at delivery."2.78HIV disease progression in the first year after delivery among African women followed in the HPTN 046 clinical trial. ( Brown, ER; Chipato, T; Coovadia, H; Fawzi, W; Fowler, M; George, K; Herron, C; Maldonado, Y; Manji, K; Moodley, D; Nakabiito, C; Reddy, L; Richardson, P; Watts, DH; Zwerski, S, 2013)
" The primary efficacy endpoint was HIV-1 infection in infants at 6 months and safety endpoints were adverse reactions in both groups."2.77Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. ( Andrew, P; Brown, ER; Chetty, V; Chipato, T; Coovadia, HM; Eshleman, SH; Fawzi, W; Fowler, MG; George, K; Guay, L; Kisenge, R; Lynn, DJ; Maldonado, Y; Manji, K; Mofenson, LM; Moodley, D; Msweli, L; Musoke, P; Mwatha, A; Nakabiito, C; Richardson, P; Stranix-Chibanda, L; Zwerski, S, 2012)
"Lamivudine resistance was detected by ASP in only 1 of 51 women who received CBV."2.77Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women. ( Boltz, VF; Chow, JY; Coffin, JM; Gray, GE; Hall, DB; Hopley, MJ; Maldarelli, F; Martinson, NA; Mayers, D; McIntyre, JA; Mellors, JW; Palmer, S; Robinson, P, 2012)
"46%), underweight (27% vs."2.77Growth patterns among HIV-exposed infants receiving nevirapine prophylaxis in Pune, India. ( Bollinger, RC; Gupta, A; Gupte, N; Khandave, M; Kinikar, AA; Nayak, U; Ram, M; Sastry, J; Shankar, AV, 2012)
" A one-compartment model was used for mothers and neonates; the absorption rate constants for mothers and neonates were 0."2.76Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. ( Arrivé, E; Avit, D; Benaboud, S; Blanche, S; Dabis, F; Ekouévi, DK; Gray, G; Hirt, D; McIntyre, J; Nerrienet, E; Rey, E; Sim, KL; Tréluyer, JM; Urien, S, 2011)
"Birth defects were evaluated among infants on the Pediatric AIDS Clinical Trials Group 316 trial that studied addition of peripartum nevirapine to established ARV regimen for prevention of mother-to-child transmission."2.76Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. ( Culnane, M; Cunningham, CK; Delfraissy, JF; Huang, S; Kaiser, KA; Mandelbrot, L; Mofenson, L; Newell, ML; Scheuerle, A; Stanley, K; Watts, DH, 2011)
" Similarly, the proportion of serious adverse events in the HIVIGLOB/sdNVP and sdNVP arms, respectively, for mothers (18."2.76Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). ( Antelman, G; Falksveden, L; Fowler, MG; Guay, L; Jackson, JB; Mmiro, F; Moulton, LH; Mubiru, M; Musoke, P; Nakabiito, C; Omer, SB; Onyango-Makumbi, C; Wahren, B; Wigzell, H; Zwerski, S, 2011)
"However, neutropenia was no longer associated with antenatal exposure to HAART after 1 month of age."2.73Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. ( Bae, WH; Essex, M; Lockman, S; Onyait, K; Shapiro, RL; Smeaton, LM; Thior, I; Wester, C, 2008)
" Mothers in the usZDV/sdNVP group received a loading dose of zidovudine (600 mg administered orally) and continued to receive 300-mg doses of zidovudine orally every 3 h while in labor, and their infants received zidovudine at a dosage of 2 mg per kg of body weight 4 times per day orally for 72 h."2.73A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe. ( Arbess, G; Boyle, E; Chipato, T; Chitsike, I; Glazier, RH; Gottesman, M; Pilon, R; Silverman, M; Simor, A; Spitzer, RF; Thistle, P, 2007)
"Nevirapine was detected in the cord blood of 244 of 259 (94%) infants whose mothers reported they took nevirapine in labor more than 1 h before delivery and in 12 of 13 (92%) infants whose mothers reported they took nevirapine less than 1 h before delivery."2.72Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission. ( Donnell, D; Fleming, T; Fowler, MG; Guay, L; Jackson, JB; Mirochnick, M; Mmiro, F; Mofenson, L; Musoke, P; Nakabiito, C; Parsons, T, 2006)
" Lower predose nevirapine concentrations were associated with lower cord blood concentrations and a shorter interval between maternal dosing and delivery."2.71Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. ( Blanchard, S; Culnane, M; Cunningham, CK; Dorenbaum, A; Gelber, RD; Mirochnick, M; Mofenson, L; Sullivan, JL, 2003)
"Nevirapine was associated with a 41% (95% CI 16-59) reduction in relative risk of transmission through to age 18 months."2.71Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. ( Allen, M; Bagenda, D; Bakaki, P; Bray, D; Deseyve, M; Ducar, C; Duefield, C; Emel, L; Fleming, T; Fowler, MG; Gigliotti, M; Guay, LA; Jackson, JB; Miotti, P; Mirochnick, M; Mmiro, F; Mofenson, L; Musoke, P; Mwatha, A; Nakabiito, C; Owor, M; Sherman, J, 2003)
" Our data indicate that NVP prophylaxis for 6 months was safe and well tolerated in infants."2.71Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. ( Abdool Karim, SS; Bassett, MT; Coovadia, HM; Emel, L; Eshleman, SH; Fleming, T; George, K; Jones, SA; Katzenstein, DA; Maldonado, Y; Maponga, CC; Mirochnick, MM; Mofenson, LM; Mwatha, A; Shetty, AK; Wells, J, 2003)
" The one adverse event associated with nelfinavir occurred in a subject with a CD4 cell count less than 250 cells/microL."2.71Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. ( Baker, D; Foca, M; Frenkel, LM; Gandia, J; Gonzalez-Garcia, A; Hitti, J; Huang, S; McNamara, J; Nachman, SA; Paul, ME; Provisor, A; Stek, AM; Stevens, LM; Thorpe, EM; Watts, DH; Wei, LJ, 2004)
"The median NVP level fell to 68 ng/mL (range: <50-228, n = 43) 8 to 14 days after dosing and to 51 ng/mL (range: <50-166, n = 25) between 15 and 21 days."2.71Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. ( Capparelli, E; Cressey, TR; Jackson, JB; Jourdain, G; Kunkeaw, S; Lallemant, MJ; Mirochnick, M; Musoke, P, 2005)
"Nevirapine resistance was more frequent in infants with subtype C than with subtypes A and D (87 versus 50%, P = 0."2.71Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. ( Chen, S; Eshleman, SH; Fiscus, SA; Guay, LA; Hoover, DR; Hudelson, SE; Jackson, JB; Kumwenda, N; Mmiro, F; Musoke, P; Mwatha, A; Taha, T, 2005)
"Pediatric AIDS Clinical Trials Group protocol 316 was an international, multicenter, placebo-controlled trial comparing single-dose oral nevirapine (200 mg to mother and 2 mg/kg to infant) with placebo in human immunodeficiency virus (HIV)-infected pregnant women receiving standard antiretroviral therapy."2.70Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3 ( Bazin, B; Britto, P; Chaix, ML; Cunningham, CK; Delfraissy, JF; Dorenbaum, A; Gelber, RD; Mofenson, L; Rekacewicz, C; Rouzioux, C; Sullivan, JL, 2002)
" Initial dose pharmacokinetic profiles in the pregnant women were similar to those seen in nonpregnant adults."2.70Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. ( Fenton, T; Lugo, M; Mirochnick, M; Siminski, S; Sullivan, JL, 2001)
"As part of an on-going clinical trial in Malawi, infants born to women who received (early presenters) or did not receive (late presenters) standard intrapartum nevirapine (NVP) dosing were randomized to receive orally either single dose NVP alone or NVP plus zidovudine (twice daily for 1 week)."2.70Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants. ( Broadhead, R; Fiscus, S; Gibbons, A; Hoover, D; Kumwenda, N; Lema, V; Liomba, G; Mukiibi, J; Taha, TE, 2002)
"Nevirapine elimination was prolonged in both mothers and infants, with median half-lives ranging from 36."2.69Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. ( Beckerman, K; Fenton, T; Gagnier, P; Gwynne, M; Jimenez, E; Mirochnick, M; Pav, J; Siminski, S; Spector, SA; Sperling, RS; Sullivan, JL; Yogev, R, 1998)
"Nevirapine, 200 mg, was given as a single dose during labor to 21 HIV-1-infected pregnant Ugandan women."2.69A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). ( Allen, M; Bagenda, D; Dransfield, K; Elliott, T; Fleming, T; Fowler, MG; Guay, LA; Hom, D; Horton, S; Jackson, JB; Mirochnick, M; Mmiro, F; Mofenson, L; Murarka, A; Musoke, P; Nakabiito, C; Pav, JW, 1999)
"Drugs most likely to interact with combined oral contraceptives, transdermal and implant contraceptives include protease inhibitors, the NNRTIs efavirenz and nevirapine, and cobicistat-boosted elvitegravir."2.49Drug interactions between antiretrovirals and hormonal contraceptives. ( Hills-Nieminen, C; Tseng, A, 2013)
"The risk of adverse drug events associated with nevirapine (NVP) is suggested to be greater in pregnant women."2.49Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. ( Andrieux-Meyer, I; Calmy, A; Ford, N; Hargreaves, S; Mills, EJ; Shubber, Z, 2013)
"We reviewed studies comparing serious adverse NVP-related events among ART-naive pregnant women who commenced therapy at higher v."2.48Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis. ( Bera, E; Mia, R, 2012)
" The first trial began in April 1991 and assessed zidovudine (ZDV) versus placebo and since then, the type, dosage and duration of drugs to be compared has been modified in each subsequent trial."2.47Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. ( Brocklehurst, P; Siegfried, N; Sint, TT; van der Merwe, L, 2011)
" More comprehensive in vivo pharmacokinetic data are required to justify the potential use of these agents as safe and effective options during pregnancy."2.47Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). ( Back, DJ; Else, LJ; Khoo, SH; Taylor, S, 2011)
" Sources included adverse event reports from pharmaceutical manufacturers and the US FDA, reports from peer-reviewed journals/scientific meetings and the Research on Adverse Drug events And Reports (RADAR) project."2.45Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. ( Bennett, CL; Chandler, KL; Differding, V; Johnson, S; McKoy, JM; Obadina, E; Palella, F; Parada, JP; Raisch, DW; Scarsi, KK; Scheetz, MH; Sutton, S; Yarnold, PR, 2009)
" The first trial began in April 1991 and assessed zidovudine (ZDV) versus placebo and since then, the type, dosage and duration of drugs to be compared has been modified in each subsequent trial."2.44Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. ( Brocklehurst, P; Siegfried, NL; van der Merwe, L; Volmink, J, 2007)
"Nevirapine resistance has been detected in a considerable proportion of women after single-dose nevirapine (SD-NVP) for the prevention of mother-to-child human immunodeficiency virus-1 transmission."2.44Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter? ( Eshleman, SH; Kourtis, AP; McConnell, MS; Stringer, JS; Weidle, PJ, 2007)
" Based on current knowledge, the immense benefits of antiretroviral prophylaxis in reducing the risk of MTCT, far outweigh the potential for adverse effects."2.43The safety of antiretroviral drugs in pregnancy. ( Newell, ML; Thorne, C, 2005)
" To minimize toxicity, clinicians must adhere to dosing guidelines, avoid prescribing the drug in patients with known increased risk of toxicity, and promptly recognize toxicities, which are mainly cutaneous and hepatic."2.43Nevirapine toxicity. ( Taiwo, BO, 2006)
"Nevirapine is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase."2.41Nevirapine: pharmacokinetic considerations in children and pregnant women. ( Clarke, DF; Dorenbaum, A; Mirochnick, M, 2000)
" Although possessing a common mechanism of action, these agents can be differentiated by both molecular and pharmacokinetic characteristics."2.41Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. ( DiCenzo, R; Morse, GD; Smith, PF, 2001)
"Lopinavir was mostly requested in patients when adherence measures did not correlate with the clinical picture, suspected non-adherence, lopinavir-rifampicin interactions and for neonatal safety monitoring."1.56Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital. ( Decloedt, EH; Engelbrecht, AE; Norman, J; Rabie, H; Wiesner, L, 2020)
"A physiologically-based pharmacokinetic (PBPK) model for nevirapine, which is metabolized by the cytochrome P450 (CYP) 3A4, 2B6 and 2D6 pathways, was developed to predict maternal and fetal pharmacokinetics (PK)."1.46A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways. ( Benaboud, S; Blanche, S; Bouazza, N; De Sousa Mendes, M; Foissac, F; Hirt, D; Lui, G; Pressiat, C; Treluyer, JM; Urien, S; Valade, E; Zheng, Y, 2017)
"Universal multi drug antiretroviral treatment in pregnancy is a global priority in our bid to eliminate paediatric HIV infections although few studies have documented the impact of antiretroviral coverage on overall pregnancy outcomes."1.43Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa. ( Maharaj, N; Moodley, D; Moodley, T; Sartorius, B; Sebitloane, M, 2016)
" We investigated the frequency and severity of adverse events (AE) in infants receiving multiple drug prophylaxis compared to ZDV alone."1.42Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review. ( Barr, E; Davies, J; Forster, JE; Kinzie, K; Levin, MJ; McFarland, EJ; Pappas, J; Paul, S; Smith, C; Weinberg, A, 2015)
"Nevirapine was the offending drug in 21/22 (95%) cases."1.42Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women. ( Knight, L; Lehloenya, RJ; Matjila, M; Muloiwa, R; Todd, G, 2015)
"Only zidovudine has adequate dosing recommendations for treating term and preterm infants and has an intravenous formulation, essential if feeding intolerance occurs."1.42The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants. ( Cotton, MF; Holgate, S; Mirochnick, M; Nelson, A; Rabie, H; Wedderburn, C, 2015)
"To investigate if pregnancy is a risk factor for SJS among HIV-infected women taking NVP-containing regimens and registered within the Medunsa National Pharmacovigilance Centre database."1.39Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007 - 2012. ( Adewusi, E; Dube, N; Summers, R, 2013)
" Mice were dosed twice daily until PND 28."1.39Toxicology and Carcinogenesis Studies of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in u ( , 2013)
"Demographic, treatment and pregnancy related data were collected."1.38Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy. ( Boer, K; de Wolf, F; Godfried, MH; Nellen, JF; Smit, C; Snijdewind, IJ; van der Ende, ME, 2012)
"We compared adverse events among breast-feeding neonates born to Kenyan mothers receiving triple-antiretroviral therapy, including either nevirapine or nelfinavir."1.38Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission. ( Akoth, B; Angira, F; Masaba, R; Mills, LA; Minniear, TD; Ndivo, R; Oyaro, B; Peters, PJ; Polle, N; Thomas, TK; Zeh, C, 2012)
"Nevirapine was given at delivery to 93/135 (69%) women, and to 128/135 (95%) children."1.38HIV-1 mother-to-child transmission, post-test counselling, and antiretroviral prophylaxis in Northern Viet Nam: a prospective observational study. ( Anh, NM; Bao, NH; Cam, PD; Caridha, R; Ehrnst, A; Gaseitsiwe, S; Ha, TT; Hien, NT; Tuan, PL, 2012)
" Our study suggests that NVP dosing of preterm infants as soon as possible after birth without maternal intrapartum dosing may be as effective as combined maternal and infant dosing."1.37Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1. ( Cotton, MF; Els, I; Hall, D; Madsen, R; Mirochnick, M; Mugabo, P; Rabie, H; Smith, J; Smith, P; Steyn, W, 2011)
" Pharmacokinetic parameter estimates and model-predicted HIV-1 transmission rates were very consistent with other studies."1.37Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes. ( Frank, M; Harms, G; Kloft, C; Kunz, A; Schütte, C; von Kleist, M, 2011)
"Nevirapine is widely used to treat HIV-1 infection to prevent mother-to-child transmission; unfortunately adverse drug reactions have been reported."1.36Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. ( Altan, AM; Borgiani, P; Bramanti, P; Ceffa, S; Ciccacci, C; Marazzi, MC; Novelli, G; Palombi, L; Paturzo, G; Sirianni, E, 2010)
"To investigate uptake and provision of antenatal care (ANC) services in the Uzazi Bora project: a demonstration-intervention project for Safe Motherhood and prevention of mother-to-child transmission of HIV in Kenya."1.36A Safe Motherhood project in Kenya: assessment of antenatal attendance, service provision and implications for PMTCT. ( Chersich, MF; Delva, W; Luchters, S; Muigai, E; Oyier, V; Temmerman, M; Yard, E, 2010)
"Predictors of adverse events (AE) associated with nevirapine use are needed to better understand reports of severe rash or liver enzyme elevation (LEE) in HIV+ women."1.36Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. ( Aaron, E; Bachmann, LH; Criniti, S; Gracely, E; Kempf, MC; Kumar, R; Tedaldi, E; Warriner, A, 2010)
"Zidovudine was not detectable in any infant plasma samples obtained after the day of delivery, while the median concentrations in infant plasma samples from postpartum weeks 2, 6, and 14 were 67 ng/ml, 32 ng/ml, and 24 ng/ml for lamivudine and 987 ng/ml, 1,032 ng/ml, and 734 ng/ml for nevirapine, respectively."1.35Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. ( Capparelli, E; Fowler, MG; Holland, D; Masaba, R; Mirochnick, M; Odhiambo, P; Thigpen, MC; Thomas, T; Weidle, PJ; Zeh, C, 2009)
"Non-nevirapine regimens were initiated following biochemical and symptomatic improvement; symptoms did not recur."1.35Incidence of nevirapine-associated hepatitis in an antenatal clinic. ( Black, V; Rees, H, 2008)
"Pregnancy has a moderate but significant lowering effect on NVP plasma concentrations."1.35Steady-state nevirapine plasma concentrations are influenced by pregnancy. ( Boer, K; Burger, DM; Damming, M; de Wolf, F; Godfried, MH; Nellen, JF; Prins, JM; van der Ende, ME; Wit, FW, 2008)
" The objectives were to compare NVP levels, adverse events, and 36-week efficacy of NVP-based ART between patients who did not receive FLU (group A) and those who received FLU 200 mg/day or 400 mg/day (group B)."1.34Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. ( Athichathanabadi, C; Manosuthi, W; Phoorisri, T; Sungkanuparph, S; Uttayamakul, S, 2007)
" Neutropenia (usually transient) was the most common severe adverse event."1.34Safety of HIV-1 Perinatal Transmission Prophylaxis With Zidovudine and Nevirapine in Rural South India. ( Bethel, J; Dharmarajan, S; Jacob, SM; Junankar, V; Parameshwari, S; Read, JS; Samuel, NM; Stoszek, SK; Van Hook, HM; Xu, J, 2007)
"Nevirapine was quantifiable for up to 17 days after discontinuation of therapy; total nevirapine concentrations remained above the 90% inhibitory concentration for 6 days, and no differences were observed between breasts."1.34Persistence of nevirapine in breast milk after discontinuation of treatment. ( Acosta, EP; Aldrovandi, GM; Ashouri, N; Bennetto-Hood, C; King, JR; Woodman, K, 2007)
"Transmission prophylaxis in offspring of HIV-positive mothers may give rise to adverse effects."1.34[Side effects of antiretroviral treatment for transmission prophylaxis in preterm and near-term infants]. ( Bauer, K; Dunsch, D; Haberl, A; Linde, R; Reitter, A; Schlösser, R, 2007)
"All nevirapine side effects were developed in less than seven weeks."1.34Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital. ( Carraro, EA; Cornelsen, TC; Dias, JM; Kondo, W; Macedo, RL; Perini, J; Prandel, E; Sasaki, Md; Sbalquiero, R, 2007)
"Zidovudine (AZT) was provided antenatally from week 34 of gestation and during labour."1.33Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa. ( Abdullah, F; Boulle, A; Coetzee, D; Draper, B; Goemaere, E; Hilderbrand, K, 2005)
" Multivariate logistic regression was used to test independent association of CD4 and hepatitis C virus (HCV) infection related to the outcome of toxic effects of NVP."1.33Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. ( Calvet, GA; Cruz, ML; D'Ippolito, MM; João, EC; Matos, HJ; Menezes, JA; Salgado, LA, 2006)
" In a multivariate model, K103N detection was associated with HIV-1 subtype (C > A), after adjusting for log10 delivery viral load, the number of days between NVP dosing and sample collection, age, and parity."1.33Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. ( Chen, S; Church, JD; Eshleman, SH; Fiscus, SA; Flys, TS; Guay, LA; Hoover, DR; Jackson, JB; Jones, DC; Kumwenda, N; Mmiro, F; Musoke, P; Mwatha, A; Taha, TE, 2006)
" A pre-dose to 6 h post-dose steady-state pharmacokinetic analysis (n = 35) of the drugs on the day of the scheduled Caesarean section was performed."1.33Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. ( Belohradsky, BH; Eberle, J; Friese, K; Gingelmaier, A; Grubert, TA; Kästner, R; Kurowski, M; Mylonas, I, 2006)
"To assess the incidence and consequences of adverse reactions among African HIV-positive pregnant women treated with fixed-dose combinations of a nevirapine-containing antiretroviral (ARV) triple therapy."1.33Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. ( da Cruz Gomes, A; Germano, P; Guidotti, G; Liotta, G; Loureiro, S; Mancinelli, S; Marazzi, MC; Narciso, P; Palombi, L; Perno, CF; Valls Blazquez, MC, 2006)
"To reduce mother-to-child transmission (MTCT) of HIV, we assessed the stability of nevirapine suspension in an oral dosing syringe over a range of storage conditions."1.33Stability of nevirapine suspension in prefilled oral syringes used for reduction of mother-to-child HIV transmission. ( Dreyfuss, ML; Gray, RH; Hamzeh, FM; Li, X; Parsons, TL; Rexroad, VE; Stamper, PD, 2006)
" The influence of gender, age, body weight and comedication on minimum and maximum concentrations (C(min), C(max)), area under the concentration-time curve (AUC), total clearance (CL(tot)), half-life (t(1/2)) and volume of distribution (V(d)) was analysed by multivariate techniques."1.33A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. ( Carlebach, A; Gute, P; Haberl, A; Harder, S; Klauke, S; Knecht, G; Kurowski, M; Rohrbacher, M; Staszewski, S; Stocker, H; von Hentig, N, 2006)
"In HIV-infected women receiving prenatal care and ART, adverse events were uncommon."1.32Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. ( Balasubramanian, R; Culnane, M; Cunningham, CK; Delfraissy, JF; Delke, I; Dorenbaum, A; Fiore, S; Gelber, RD; Maupin, RT; Mofenson, LM; Newell, ML; Watts, DH, 2004)
" Labor ward dosing to enhance nevirapine coverage should be considered as an adjunct to antenatal nevirapine administration for prevention of mother-to-child transmission of HIV."1.32Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings. ( Acosta, EP; Aldrovandi, GM; Goldenberg, RL; Kumwenda, R; Sinkala, M; Stout, JP; Stringer, JS; Vermund, SH, 2004)
"Nevirapine was provided to HIV-1-seropositive women and condoms distributed to all participants."1.32Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission. ( Farquhar, C; John, FN; John-Stewart, GC; Kabura, MN; Kiarie, JN; Mbori-Ngacha, DA; Nduati, RW; Richardson, BA, 2004)
"Mass treatment of nevirapine would increase access to antiretroviral drugs among pregnant women because they can access nevirapine without volunteer counseling and testing, which 31% of pregnant women in developing countries refused to accept due to the fear of stigmatization."1.31Mass treatment with nevirapine to prevent mother-to-child transmission of HIV/AIDS in sub-Saharan African countries. ( Hashimoto, H; Kapiga, SH; Murata, Y, 2002)
" Nevirapine is well absorbed during labor, and sufficient drug for prophylaxis against perinatal transmission crosses the placenta if an oral dose is administered to the mother at least 1 hour before delivery."1.31Antiretroviral pharmacology in pregnant women and their newborns. ( Mirochnick, M, 2000)
"Nevirapine is a non-nucleoside HIV reverse transcriptase inhibitor."1.29Nevirapine: ethical dilemmas and care for HIV-infected mothers. ( Benson, M; Shannon, M, 1995)

Research

Studies (667)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's38 (5.70)18.2507
2000's386 (57.87)29.6817
2010's221 (33.13)24.3611
2020's22 (3.30)2.80

Authors

AuthorsStudies
Yeh, RF1
Rezk, NL1
Kashuba, AD2
Dumond, JB1
Tappouni, HL1
Tien, HC1
Chen, YC1
Vourvahis, M1
Horton, AL1
Fiscus, SA13
Patterson, KB1
Boyce, CL1
Sils, T1
Ko, D1
Wong-On-Wing, A1
Beck, IA5
Styrchak, SM1
DeMarrais, P1
Tierney, C2
Stranix-Chibanda, L6
Flynn, PM3
Taha, TE14
Owor, M7
Fowler, MG30
Frenkel, LM9
Chaúque, S1
Mohole, J1
Zucula, H1
Lambo, L1
Lisboa, A1
Ferreira, D1
Nguyen, H1
Chowdhary, H1
Macmillian, B1
Elias, B1
Seni, A1
Buck, WC1
Dollfus, C1
Le Chenadec, J1
Mandelbrot, L2
Tubiana, R1
Faye, A2
Brossard, M1
Frange, P1
Blanche, S5
Warszawski, J1
Cuco, RM1
Loquiha, O1
Juga, A1
Couto, A1
Meggi, B1
Vubil, A1
Sevene, E1
Osman, N2
Temermam, M1
Degomme, O1
Sidat, M2
Bhatt, N1
Stalter, RM1
Amorim, G1
Mocello, AR1
Jakait, B2
Shepherd, BE2
Musick, B1
Bernard, C1
Bukusi, EA3
Wools-Kaloustian, K2
Cohen, CR4
Yiannoutsos, CT1
Patel, RC4
Jao, J2
Sun, S1
Bonner, LB1
Legbedze, J1
Mmasa, KN1
Makhema, J7
Mmalane, M1
Kgole, S1
Masasa, G1
Moyo, S4
Gerschenson, M1
Mohammed, T1
Abrams, EJ10
Kurland, IJ2
Geffner, ME2
Powis, KM1
Namara-Lugolobi, E1
Namukwaya, Z2
Ouma, J1
Namale-Matovu, J1
Nakabiito, C14
Ndugwa, C1
Musoke, P30
Penazzato, M2
Kasirye, I1
Ruel, T1
Mukui, I1
Bekker, A1
Archary, M1
Essajee, S1
Siberry, GK2
Mahy, M1
Simnoue, D1
Simione, B1
Zech, JM1
Mushavi, A2
Larsen, A1
Magasana, V1
Dinh, TH2
Ngandu, N1
Lombard, C3
Cheyip, M1
Ayalew, K1
Chirinda, W1
Kindra, G1
Jackson, D2
Goga, A2
Onyango-Makumbi, C2
Owora, AH1
Mwiru, RS1
Mwatha, A14
Young, AM1
Moodley, D13
Coovadia, HM5
Manji, K3
Maldonado, Y6
Richardson, P3
Andrew, P2
George, K4
Fawzi, W3
Hompe, ED1
Jacobson, DL1
Eudailey, JA1
Butler, K2
Edwards, W1
Pollara, J1
Brummel, SS1
Fouda, GG1
Chinula, L1
Kamanga, M1
Kinikar, A3
Permar, SR2
Engelbrecht, AE1
Wiesner, L2
Norman, J1
Rabie, H5
Decloedt, EH1
Venkatesh, KK2
Farhad, M1
Fenton, T4
Naik, S1
Fairlie, L1
Stringer, JSA1
Chi, BH14
Lallemant, M10
Amzal, B1
Sripan, P1
Urien, S4
Cressey, TR7
Ngo-Giang-Huong, N9
Klinbuayaem, V2
Rawangban, B1
Sabsanong, P3
Siriwachirachai, T1
Jarupanich, T2
Kanjanavikai, P2
Wanasiri, P1
Koetsawang, S4
Jourdain, G11
Le Coeur, S7
Suryavanshi, N5
Kadam, A1
Gupte, N7
Hegde, A1
Kanade, S1
Sivalenka, S1
Kumar, VS1
Gupta, A8
Bollinger, RC6
Shankar, A2
McKenzie-White, J1
Mave, V3
Napyo, A1
Tylleskär, T1
Mukunya, D1
Tumuhamye, J1
Musaba, MW1
Ojok Arach, AA1
Waako, P1
Tumwine, JK1
Ndeezi, G1
Bhattacharya, D1
Guo, R1
Tseng, CH1
Emel, L5
Sun, R1
Chiu, SH1
Chipato, T6
Mohtashemi, NZ1
Kintu, K1
Manji, KP1
Thio, CL1
Currier, JS3
Waitt, C1
Myer, L1
Khoo, S3
Ruel, TD1
Capparelli, EV4
Nelson, BS1
Coletti, A1
Bryson, Y2
Cotton, MF6
Spector, SA3
Mirochnick, M20
LeBlanc, R1
Reding, C1
Zimmer, B1
Persaud, D3
Bwakura-Dangarembizi, M2
Naidoo, KL1
Hazra, R1
Jean-Philippe, P2
Chadwick, EG1
Celerino da Silva, R1
Segat, L1
Kuhn, L14
Chies, JAB1
Crovella, S1
Menegotto, M1
Magdaleno, AM1
da Silva, CLO1
Friedrich, L1
da Silva, CH1
Aguti, I1
Kimbugwe, C1
Apai, P1
Munyaga, S1
Nyeko, R1
Bitarakwate, E2
Ashburn, K1
Kazooba, P1
Khamasi, R1
Natumanya, E1
Herrera, N1
Owomugisha, B1
Malkin, RA2
Kisaakye, L1
Hirt, D3
Kubota Kilengelela, J1
Jarreau, PH1
Tréluyer, JM3
Marcou, V1
Kebaya, LMN1
Wamalwa, D1
Kariuki, N1
Admani, B1
Ayieko, P1
Nduati, R1
Cababasay, M1
Mofenson, LM12
Fiscus, S4
Coutsoudis, A2
Gnanashanmugam, D2
Chakhtoura, N1
McCarthy, K1
Frenkel, L4
Beck, I2
Mukuzunga, C1
Makanani, B1
Nematadzira, T1
Kusakara, B1
Patil, S5
Vhembo, T1
Bobat, R3
Mmbaga, BT2
Masenya, M1
Nyati, M1
Theron, G3
Mulenga, H1
Shapiro, DE6
Girma, M1
Wendaferash, R1
Shibru, H1
Berhane, Y1
Hoelscher, M1
Kroidl, A1
McIlleron, H1
Denti, P1
Cohn, S1
Mashabela, F1
Hoffmann, JD1
Shembe, S1
Msandiwa, R1
Velaphi, S1
Lala, SG2
Chaisson, RE1
Martinson, N7
Dooley, KE1
Punyawudho, B1
Saenjum, C1
Jittayanun, K1
Phanomcheong, S1
Luvira, A1
Borkird, T1
Puangsombat, A1
Aarons, L1
Sukrakanchana, PO1
Bhat, J1
Bharadwaj, R3
Kulkarni, V4
Bhosale, R7
McIntire, KN1
Bollinger, R2
Morroni, C1
Scarsi, KK4
Sripipatana, T2
Kiarie, J4
Birlie, B1
Braekers, R1
Awoke, T1
Kasim, A1
Shkedy, Z1
Mwau, M1
Bwana, P1
Kithinji, L1
Ogollah, F1
Ochieng, S1
Akinyi, C1
Adhiambo, M1
Ogumbo, F1
Sirengo, M1
Boeke, C1
Cook, RR1
Peltzer, K2
Weiss, SM1
Rodriguez, VJ1
Jones, DL1
Veroniki, AA1
Antony, J1
Straus, SE1
Ashoor, HM1
Finkelstein, Y1
Khan, PA1
Ghassemi, M1
Blondal, E1
Ivory, JD1
Hutton, B1
Gough, K1
Hemmelgarn, BR1
Lillie, E1
Vafaei, A1
Tricco, AC1
Nkenfou, CN1
Temgoua, ES1
Ndzi, EN1
Mekue, LCM1
Ngoufack, MN1
Dambaya, B1
Anoubissi, JD1
Domkam, I2
Elong, E1
Fainguem, N1
Thèze, J1
Colizzi, V2
Bissek, ACZK1
Ndjolo, A1
Haaland, RE1
Otieno, K1
Martin, A1
Katana, A1
Dinh, C1
Slutsker, L1
Menendez, C2
Gonzalez, R1
Williamson, J1
Heneine, W4
Desai, M1
Ogalo, EA1
Adina, JO1
Ooko, H1
Batuka, J1
Kimaiyo, S1
Torimiro, JN1
Nanfack, A1
Takang, W1
Keou, CK1
Joyce, AN1
Njefi, K1
Agyingi, K1
Takou, D1
Moudourou, S1
Sosso, S1
Mbu, RE2
Liu, JX1
Shen, J1
Wilson, N1
Janumpalli, S1
Stadler, P1
Padian, N1
Wang, X2
Guo, G1
Zheng, J1
Lu, L1
Potty, RS1
Sinha, A1
Sethumadhavan, R1
Isac, S1
Washington, R1
Apangu, P1
Izudi, J1
Bajunirwe, F2
Mulogo, E1
Batwala, V1
Strehlau, R2
Paximadis, M1
Patel, F1
Burke, M1
Technau, KG1
Shiau, S2
Sherman, GG3
Hunt, G1
Ledwaba, J2
Mazanderani, AH1
Tiemessen, CT4
Thomas, K1
Yiannoutsos, C1
Onono, M2
Wools-Kaloustian, KK1
Tseng, A1
Hills-Nieminen, C1
Ton, Q1
Frank, M2
Harms, G7
Kunz, A7
Kloft, C2
Reynolds, HW2
Gachuno, O1
Kayita, J2
Hays, MA1
Otterness, C1
Rakwar, J1
Darak, S1
Darak, T1
Kulkarni, S3
Parchure, R1
Hutter, I1
Janssen, F1
Wang, R1
Weng, J1
Pain, D1
Barr, CD1
Maruapula, D1
Mongwato, D1
Novitsky, V3
Essex, M8
Audureau, E1
Kahn, JG5
Besson, MH1
Saba, J1
Ladner, J1
Vardhanabhuti, S1
Acosta, EP7
Ribaudo, HJ2
Severe, P1
Lalloo, U1
Kumarasamy, N2
Taulo, F2
Kabanda, J2
Oneko, O1
Ive, P1
Sambarey, P2
Chan, ES2
Hitti, J7
Hong, F2
McMahon, D1
Haas, DW1
Kourtis, AP7
Wiener, J4
Kayira, D5
Chasela, C3
Ellington, SR3
Hyde, L1
Hosseinipour, M1
van der Horst, C6
Jamieson, DJ6
Werayingyong, P1
Phanuphak, N2
Chokephaibulkit, K1
Tantivess, S1
Kullert, N1
Tosanguan, K1
Butchon, R1
Voramongkol, N1
Boonsuk, S1
Pilasant, S1
Kulpeng, W1
Teerawattananon, Y1
Bendle, M1
Bajpai, S1
Choudhary, A1
Pazare, A1
Watts, DH8
Brown, ER4
Herron, C1
Reddy, L1
Zwerski, S5
Coovadia, H7
Fowler, M1
Fillekes, Q3
Muro, EP2
Chunda, C1
Aitken, S1
Kisanga, ER2
Kankasa, C11
Thomason, MJ1
Gibb, DM3
Walker, AS2
Burger, DM4
Cohan, D1
Mwesigwa, J1
Natureeba, P1
Aliba Luwedde, F1
Ades, V1
Plenty, A1
Kakuru, A1
Achan, J1
Clark, T1
Osterbauer, B1
Kamya, M1
Havlir, D1
Salazar, MG1
Gao, F1
Cai, F1
Learn, GH1
Kalilani, L1
Hahn, BH1
Shaw, GM1
Salazar-Gonzalez, JF1
Dube, N1
Adewusi, E1
Summers, R1
Bock, P1
Fatti, G1
Grimwood, A1
Nanda, K1
Delany-Moretlwe, S1
Dubé, K1
Lendvay, A1
Kwok, C1
Molife, L1
Nakubulwa, S1
Edward, VA1
Mpairwe, B1
Mirembe, FM1
Donnell, D5
Mmiro, F23
Allen, M4
Jackson, JB25
Guay, LA18
Sartorius, BK1
Chersich, MF4
Mwaura, M1
Meda, N1
Temmerman, M6
Newell, ML13
Farley, TM1
Luchters, S3
Ramokolo, V2
Fadnes, LT1
Doherty, T3
Jackson, DJ1
Goga, AE1
Chhagan, M1
Van den Broeck, J1
Perry, SH1
Swamy, P1
Preidis, GA1
Mwanyumba, A1
Motsa, N1
Sarero, HN1
Kayentao, K1
Guirou, EA1
Doumbo, OK1
Venkatesan, M1
Plowe, CV1
Parsons, TL4
Hendrix, CW1
Nyunt, MM1
Ngemu, EK1
Khayeka-Wandabwa, C1
Kweka, EJ1
Choge, JK1
Anino, E1
Oyoo-Okoth, E1
Buchanan, AM1
Dow, DE2
Massambu, CG1
Nyombi, B1
Shayo, A1
Musoke, R1
Feng, S1
Bartlett, JA1
Cunningham, CK7
Schimana, W2
Manicklal, S1
van Niekerk, AM1
Kroon, SM1
Hutto, C1
Novak, Z1
Pati, SK1
Chowdhury, N1
Hsiao, NY1
Boppana, SB1
Micek, MA3
Dross, S2
Blanco, AJ3
Matunha, L2
Seidel, K2
Montoya, P3
Matediana, E2
Gantt, S2
Gloyd, S3
Baranyai, D1
Muro, E1
Gödtel-Armbrust, U1
Schirmer, MA1
Kisanga, E1
Diczfalusy, U1
Schuurman, R2
Burger, D1
Wojnowski, L1
O'Brien, L1
Shaffer, N6
Sangrujee, N1
Abimbola, TO1
Andreotti, M5
Pirillo, MF4
Liotta, G7
Jere, H4
Maulidi, M1
Sagno, JB3
Luhanga, R2
Amici, R6
Mancini, MG2
Gennaro, E1
Marazzi, MC10
Vella, S6
Giuliano, M7
Palombi, L10
Mancinelli, S6
Price, AJ1
Kayange, M1
Zaba, B1
Chimbwandira, FM1
Jahn, A2
Chirwa, Z2
Dasgupta, AN1
Katundu, C1
Saul, JL1
Glynn, JR1
Koole, O1
Crampin, AC1
Chetty, T1
Carter, RJ2
Bland, RM2
Hamela, G1
Kabondo, C1
Tembo, T1
Zimba, C1
Kamanga, E1
Mofolo, I1
Bulla, B1
Sellers, C1
Nakanga, RC1
Lee, C1
Martinson, F3
Hoffman, I2
Hosseinipour, MC5
Saegusa, T1
Di, C1
Chen, YQ2
Onwuamah, CK1
Ezechi, OC1
Herbertson, EC1
Audu, RA2
Ujah, IA1
Odeigah, PG1
Dross, SE1
Rossi, SS1
Seidel, KD1
Mistry, N1
Sereboe, L1
Oakeshott, P1
Iveli, P1
Noguera-Julian, A1
Soler-Palacín, P1
Martín-Nalda, A1
Rovira-Girabal, N1
Fortuny-Guasch, C1
Figueras-Nadal, C1
Phan, CT1
Pham, HV1
Bi, X1
Ishizaki, A1
Saina, M1
Phung, CD1
Khu, DT1
Ichimura, H1
Desmond, AC1
Conolly, CA1
Castel, SA1
Samuel, R2
Paredes, R3
Parboosing, R2
Moodley, P2
Singh, L2
Naidoo, A2
Gordon, M2
Dominguez, K2
Cotton, M1
Barlow-Mosha, L1
Ford, N2
Smith, C1
Forster, JE1
Levin, MJ1
Davies, J1
Pappas, J1
Kinzie, K1
Barr, E1
Paul, S1
McFarland, EJ1
Weinberg, A1
Galluzzo, CM5
Kirmse, B1
Yu, C1
Qiu, Y1
Powis, K3
Nshom, E1
Epie, F1
Tih, PM3
Sperling, RS2
LeRoith, D1
Woldesenbet, S1
Puren, A4
Sherman, G3
Mogashoa, M1
Bhardwaj, S1
Chopra, M2
Pillay, Y1
Knight, L1
Todd, G1
Muloiwa, R1
Matjila, M2
Lehloenya, RJ1
Sirirungsi, W1
Traisathit, P1
Mcintosh, K5
Kiweewa, FM1
Bakaki, PM2
McConnell, MS5
Musisi, M1
Namirembe, C1
Nakayiwa, F1
Kusasira, F1
Nakintu, D1
Mubiru, MC1
Chang, TS1
Dollard, SC1
Amin, MM1
Ellington, S2
Okawa, S1
Chirwa, M1
Ishikawa, N2
Kapyata, H1
Msiska, CY1
Syakantu, G1
Miyano, S2
Komada, K1
Jimba, M1
Yasuoka, J1
Vogt, F1
Ferreyra, C2
Bernasconi, A1
Ncube, L1
Taziwa, F1
Marange, W1
Wachi, D1
Becher, H1
Gandhi, M1
Blat, C1
Hagey, J1
Shade, SB1
Vittinghoff, E1
Newmann, SJ1
De Nardo, P1
Gentilotti, E1
Nguhuni, B1
Vairo, F1
Chaula, Z1
Nicastri, E2
Ippolito, G1
Baroncelli, S2
Holgate, S1
Nelson, A1
Wedderburn, C1
Darin, KM1
Nakalema, S1
Back, DJ3
Byakika-Kibwika, P2
Else, LJ2
Dilly Penchala, S1
Buzibye, A1
Cohn, SE1
Merry, C2
Lamorde, M2
Nakanga, W1
Patel, P1
Panjwani, S1
Kennedy, N1
Kawaza, K1
Bolaris, MA1
Keller, MA1
Robbins, BL1
Podany, AT1
Fletcher, CV1
Moodley, T1
Sebitloane, M1
Maharaj, N1
Sartorius, B1
Cha, A1
Elsamadisi, P1
Su, CP1
Phipps, E1
Birnbaum, JM1
Scarcella, P3
Aliyu, MH1
Blevins, M2
Audet, CM1
Kalish, M1
Gebi, UI1
Onwujekwe, O1
Lindegren, ML1
Wester, CW1
Vermund, SH15
Olagunju, A1
Bolaji, O1
Neary, M1
Back, D2
Owen, A1
Dahinten, AP1
Msuya, LJ1
Capretti, MG1
Marsico, C1
Conti, M1
Corvaglia, LT1
Arcuri, S1
Faldella, G1
Re, MC1
Julian, MN1
Stewart, A1
Lehloenya, R1
Boulle, A3
de Waal, R1
Maartens, G1
Cohen, K1
Olana, T1
Bacha, T1
Worku, W1
Tadesse, BT1
Wang, Q2
Wang, L3
Fang, L2
Wang, A1
Jin, X1
Wang, F1
Qiao, Y1
Sullivan, SG1
Rutherford, S1
Zhang, L1
De Sousa Mendes, M1
Lui, G1
Zheng, Y2
Pressiat, C1
Valade, E1
Bouazza, N1
Foissac, F1
Benaboud, S2
Qin, M1
McIntyre, J14
Coletti, AS1
Klingman, KL2
Martinson, FE1
Violari, A3
Theron, GB3
Mlay, P1
Loftis, AJ1
Browning, R1
Purdue, L2
Basar, M1
Tooke, L1
Riemer, L1
Harrison, M1
Turriziani, O1
Russo, G1
Lichtner, M1
Stano, A1
Tsague, G1
Maida, P1
Vullo, V1
Antonelli, G1
Chintu, N8
Cantrell, RA4
Kruse, G2
Mbewe, F4
Sinkala, M27
Smith, PJ1
Stringer, EM10
Stringer, JS25
Onah, HE1
Ibeziako, N1
Nkwo, PO1
Obi, SN1
Nwankwo, TO1
Kasenga, F2
Hurtig, AK2
Emmelin, M2
Prendergast, A1
Mphatswe, W1
Tudor-Williams, G2
Rakgotho, M1
Pillay, V5
Thobakgale, C1
McCarthy, N1
Morris, L12
Walker, BD1
Goulder, P1
Hughes, V1
Lionel, J1
Aleyamma, TK1
Varghese, L1
Buck, J1
Gopalakrishnan, G1
Chaguturu, S1
Cu-Uvin, S1
Mayer, K1
Naniche, D1
Lahuerta, M1
Bardaji, A1
Sigauque, B1
Romagosa, C1
Berenguera, A1
Mandomando, I1
David, C1
Sanz, S1
Aponte, J1
Ordi, J1
Alonso, P1
Bedri, A2
Gudetta, B2
Isehak, A2
Kumbi, S2
Lulseged, S2
Mengistu, Y2
Bhore, AV2
Varadhrajan, V1
Sastry, J6
Tripathy, S4
Mubiru, M6
Onyango, C1
Taylor, A1
Abashawl, A2
Adamu, R2
Antelman, G2
Bright, P1
Chaudhary, MA1
Coberly, J1
Guay, L6
Hassen, E2
Moulton, LH2
Nayak, U4
Omer, SB5
Propper, L1
Ram, M3
Rexroad, V1
Ruff, AJ1
Bae, WH1
Wester, C5
Smeaton, LM3
Shapiro, RL6
Lockman, S11
Onyait, K1
Thior, I5
Draper, B3
Abdullah, F2
Spensley, A1
Turner, AN1
Hoblitzelle, C1
Robinson, J1
Wilfert, C4
van Schalkwyk, JE1
Alimenti, A1
Khoo, D1
Maan, E1
Forbes, JC1
Burdge, DR1
Gilgoff, S1
Money, DM1
Villani, P2
Floridia, M2
Cusato, M2
Pinnetti, C2
Sabbatini, F1
Molinari, A2
Tamburrini, E2
Regazzi, M2
Ekouevi, DK15
Coffie, PA6
Becquet, R8
Tonwe-Gold, B7
Horo, A2
Thiebaut, R2
Leroy, V10
Dabis, F20
Chung, MH4
Kiarie, JN6
Richardson, BA7
Lehman, DA6
Overbaugh, J8
Kinuthia, J2
Njiri, F2
John-Stewart, GC9
Brown, E2
Read, JS5
Sharma, U2
Hoffman, IF2
Pikora, C1
Goldenberg, R3
Rollins, NC1
Basson, AE1
Ntsala, M2
Tlale, E1
Corrigan, GE1
Shao, X1
Gray, G12
Shiri, T1
Welte, A1
Thomas, T1
Capparelli, E4
Zeh, C2
Holland, D1
Masaba, R2
Odhiambo, P1
Weidle, PJ4
Thigpen, MC6
Walter, J2
Semrau, K6
Thea, DM7
Aldrovandi, GM11
Moorthy, A2
Thakar, M2
Kagal, A2
Venkataramani, V1
Balasubramaniam, U1
Ziemniak, C2
Delvaux, T1
Elul, B1
Ndagije, F1
Munyana, E1
Roberfroid, D1
Asiimwe, A1
Mellors, JW4
Chow, JY2
Kondo, W2
Astori, Ade A1
Gomes, Sel-K1
Fernandes, Rde B1
Sasaki, Md2
Sbalqueiro, RL1
Patel, AK1
Patel, KK1
Sharma, R1
Ranjan, RR1
Shukla, RK1
Patel, JA1
Ryan, CT1
McKoy, JM1
Bennett, CL1
Scheetz, MH1
Differding, V1
Chandler, KL1
Yarnold, PR1
Sutton, S1
Palella, F1
Johnson, S1
Obadina, E1
Raisch, DW1
Parada, JP1
Pornprasert, S1
Mary, JY2
Leechanachai, P2
Limtrakul, A1
Rugpao, S1
Sirivatanapa, P1
Gomuthbutra, V1
Matanasaravoot, W1
Barré-Sinoussi, F4
Menu, E2
Martinson, NA6
Johnson, J1
Gray, GE9
Dhlamini, P3
Cohen, S2
Steyn, J2
McIntyre, JA8
Rutta, E1
Gongo, R1
Mwansasu, A1
Mutasingwa, D1
Rwegasira, V1
Kishumbu, S1
Tabayi, J1
Masini, T1
Ramadhani, H1
Han, J1
Jiang, Y1
Zhang, Q1
Yao, J1
Arrivé, E3
Chaix, ML6
Nerrienet, E3
Rouzioux, C7
Kruy Leang, S1
Avit, D2
Srey, VH1
N'Dri-Yoman, T2
Diallo, A1
Dahl, V1
Palmer, S3
Wind-Rotolo, M1
Durand, C1
Cranmer, L1
Reid, A1
Doherty, M1
Jilek, BL1
Kagaayi, J2
Kizza, A1
Laeyendecker, O1
Reynolds, SJ1
Eshleman, SH22
Lau, B1
Ray, SC1
Siliciano, JD1
Quinn, TC1
Siliciano, RF1
Charurat, M1
Datong, P1
Matawal, B1
Ajene, A1
Blattner, W1
Abimiku, A1
Guidozzi, F1
Black, V2
Behets, F2
Mutombo, GM1
Edmonds, A1
Dulli, L1
Belting, MT1
Kapinga, M1
Pantazis, A1
Tomlin, H1
Okitolonda, E1
Foster, C1
Lyall, H1
Olmscheid, B1
Pearce, G1
Zhang, S1
Mabuka, JM1
Ramachandran, S1
Scott, N2
Kasonde, P7
Mwiya, M3
Decker, D1
Ammann, AJ1
Agmon-Levin, N1
Elbirt, D1
Asher, I1
Torten, D1
Cohen, Y1
Gradestein, S1
Werner, B1
Turner, D1
Chowers, M1
Gottesman, G1
Maayan, S1
Risenberg, K1
Levi, I1
Sthoeger, Z1
Church, JD4
Bagenda, D6
Eure, C2
Bakaki, P4
Matovu, F3
McConnell, M2
Megazzini, KM2
Redden, DT2
Krebs, DW2
Simwenda, M1
Tambatamba, B1
Johnson, N2
Palmer, P3
Samuels, LA1
Morgan, O1
Onyonyor, A1
Anderson, M1
Moore, J1
Billings, C1
Harvey, KM2
Mullings, A1
McDonald, D2
Alexander, G2
Smikle, MF3
Williams, EW1
Davis, D1
Christie, CD3
Ouyang, DW2
Lu, M2
Brogly, SB2
French, AL2
Leighty, RM2
Thompson, B2
Tuomala, RE3
Hershow, RC2
Mmiro, FA1
Aizire, J3
Mwatha, AK1
Musoke, PM2
Mwinga, K1
Urassa, W1
Carpenetti, N1
Valentine, M2
Goldenberg, RL12
Kurewa, EN1
Gumbo, FZ5
Munjoma, MW3
Mapingure, MP4
Chirenje, MZ5
Rusakaniko, S5
Stray-Pedersen, B5
Galegov, GA1
Becker, S1
Mlay, R1
Schwandt, HM1
Lyamuya, E1
Ilboudo, D1
Simpore, J3
Sanou, DS1
Karou, D1
Sia, DJ1
Ouermi, D1
Bisseye, C1
Sagna, T1
Odolini, S1
Buelli, F1
Pietra, V3
Pignatelli, S2
Gnoula, C1
Nikiema, JB2
Castelli, F2
Shalekoff, S1
Meddows-Taylor, S2
Schramm, DB3
Coovadia, A1
Sim, MS1
Cumberland, WG1
Duan, N1
Bryson, YJ2
Chantarangsu, S1
Mahasirimongkol, S1
Tawon, Y1
Chantratita, W1
Kumwenda, J1
Cole, SR1
Hoover, DR10
Kafulafula, G3
Li, Q2
Kumwenda, NI4
Mofenson, L9
Hopley, M1
Eklund, M1
Hall, DB2
Robinson, P3
Mayers, D2
Anzidei, G1
Tibaldi, C1
Guaraldi, G1
Guerra, B1
Meloni, AM1
Vimercati, A1
Dalzero, S1
Ravizza, M1
Ellis, GM2
Warrier, R1
Nakamura, K1
Nsibande, D1
Mngoma, D1
Cheng, I1
Kuritzkes, DR1
Mwanza, J1
Bulterys, M6
Ivanovic, J1
Anceschi, MM1
Ascenzi, P1
Signore, F1
Pisani, G1
Vallone, C1
Mattia, E1
Notari, S1
Tempestilli, M1
Pucillo, LP1
Narciso, P3
Lidström, J1
Kumwenda, N7
Ciccacci, C1
Borgiani, P1
Ceffa, S3
Sirianni, E1
Altan, AM1
Paturzo, G2
Bramanti, P1
Novelli, G1
Hudelson, SE6
Piwowar-Manning, E2
Nolan, ML1
Ndirangu, J1
Tanser, F1
Herbst, AJ1
Bland, R1
van Zyl, GU2
Traisaithit, P1
Collins, IJ1
Sukhumanant, T1
Achalapong, J2
Chotivanich, N2
Winiyakul, N1
Ariyadej, S2
Kanjanasing, A1
Ratanakosol, J1
Hemvuttiphan, J1
Kengsakul, K1
Wannapira, W1
Sittipiyasakul, V1
Pornkitprasarn, W1
Liampongsabuddhi, P1
Van Dyke, RB2
Kanchana, S1
Bolu, O2
Anekthananon, T1
Jariyasethpong, T1
Potter, D1
Mutsotso, W1
Borkowf, CB1
Mbori-Ngacha, D1
Muiruri, P1
Ong'ech, JO1
Zulu, I2
Njobvu, L1
Jetsawang, B1
Pathak, S1
Wagner, TA1
Kress, CM1
Techapornroong, M1
Wittayapraparat, P1
Tansuphasawasdikul, S1
Cohen, J3
Delva, W3
Yard, E1
Muigai, E1
Oyier, V1
Conkling, M1
Shutes, EL1
Karita, E2
Chomba, E1
Tichacek, A1
Vwalika, B1
Iwanowski, M1
Allen, SA1
Kurewa, NE4
Kandawasvika, GQ2
Duri, K3
Pazvakavambwa, IE1
Rowley, CF2
Boutwell, CL1
Lee, EJ2
MacLeod, IJ2
Torpey, K2
Dirks, R2
Bweupe, M1
Kabaso, M1
Mandala, J2
Sangiwa, G1
Kuonza, LR1
Tshuma, CD1
Shambira, GN1
Tshimanga, M1
Giganti, MJ2
Putta, NB1
Sadoki, E1
Chasela, CS2
Hudgens, MG2
Tegha, G2
Knight, RJ2
Ahmed, YI1
Kamwendo, DD2
Kacheche, Z2
Soko, A2
Wiener, JB2
Kazembe, P1
Mofolo, IA2
Chigwenembe, M2
Sichali, DS2
van der Horst, CM1
Hughes, MD4
Ogwu, A2
Kitch, D1
Moffat, C4
van Widenfelt, E3
Leidner, J2
Asmelash, A3
Tumbare, E1
Handelsman, E1
Mburu, K1
Jayeoba, O1
Moko, E1
Souda, S1
Lubega, E1
Akhtar, M1
Tuomola, R1
Snowden, W1
Martinez-Tristani, M1
Mazhani, L2
O'Gorman, DA1
Nyirenda, LJ1
Theobald, SJ1
Lawson-Evi, K1
Mouhari-Toure, A1
Tchama, R1
Akakpo, SA1
Atakouma, DY2
Beauvais, L1
Pitche, P1
Kochar, R1
Nevah, MI1
Lukens, FJ1
Fallon, MB1
Machicao, VI1
Okaba-Kayom, V1
Flaherty, JP1
Boffito, M1
Namakula, R1
Ryan, M1
Kouanda, S1
Tougri, H1
Cisse, M1
Doulougou, B1
Ouedraogo, G1
Ouedraogo, CM1
Soudre, R1
Sondo, B1
Coetzee, D2
Creek, TL1
Stinson, K1
Welty, TK2
Wilfert, CM4
Bersoff-Matcha, SJ1
Rourke, D1
Blank, J1
Barigye, H1
Levin, J1
Maher, D1
Tindiwegi, G1
Atuhumuza, E1
Nakibinge, S1
Grosskurth, H1
Gadhamsetty, S1
Dixit, NM1
Farr, SL1
Nelson, JA1
Ng'ombe, TJ1
Johnson, JA3
Tegha, GL1
Eron, JJ1
Banda, HN1
Mpaso, M1
Lipscomb, J1
Matiki, C1
Kristiansen, KI1
Muller, F1
Bancheno, WM1
Mwanyumba, F3
Mareverwa, J1
Aaron, E1
Kempf, MC1
Criniti, S1
Tedaldi, E1
Gracely, E1
Warriner, A1
Kumar, R1
Bachmann, LH1
Nielsen-Saines, K5
Haswell, J2
Magid, NA2
Buonomo, E2
Doro Altan, AM1
Conradie, F2
Sawe, F1
Mohapi, L1
Stringer, E2
Mngqibisa, R1
Siika, A2
Atwine, D1
Hakim, J1
Shaffer, D1
Kanyama, C1
Salata, RA1
Hogg, E1
Alston-Smith, B1
Walawander, A1
Purcelle-Smith, E1
Eshleman, S1
Rooney, J1
Rahim, S1
Schooley, RT1
Palumbo, P1
Lindsey, JC1
Meyers, T1
Kamthunzi, P1
Millar, L1
Petzold, E1
Lurie, MN1
Triche, EW1
De Bruyn, G1
Harwell, JI1
McGarvey, ST1
Rey, E1
Sim, KL1
Tattevin, P1
Arvieux, C1
Courpotin, C1
Ouattara, E1
Moh, R1
Amani-Bosse, C3
Messou, E1
Sissoko, M1
Anglaret, X1
Eholié, SP1
Danel, C1
Mudiope, P2
Kekitiinwa, A1
Matovu, J1
Kayma, S1
Salmond, W1
Maganda, A1
Galla, M1
Byamugisha, J1
Davies, MA1
Moultrie, H1
Eley, B2
Van Cutsem, G1
Giddy, J1
Wood, R3
Technau, K1
Keiser, O1
Egger, M1
Tsague, L1
Tsiouris, FO1
Mugisha, V1
Tene, G2
Nyankesha, E1
Koblavi-Deme, S1
Mugwaneza, P1
Kayirangwa, E1
Sahabo, R1
Huang, S3
Culnane, M4
Kaiser, KA1
Scheuerle, A2
Stanley, K1
Delfraissy, JF5
Rajesh, L1
Ramesh, K1
Hanna, LE1
Narayanan, PR1
Swaminathan, S1
van Luin, M1
Wit, FW2
Smit, C2
Rigter, IM1
Franssen, EJ1
Richter, C1
Kroon, F1
de Wolf, F4
Dorton, BJ1
Mulindwa, J1
Li, MS1
Chintu, NT1
Chibwesha, CJ1
Joshi, S1
Khandekar, M1
Karmarkar, A1
Paranjape, R1
Jamkar, A1
de Vincenzi, I1
Ashworth, R1
Ruff, A1
Van Dyke, R1
Cababasay, MP1
Louw, J1
Smith, E2
Maupin, R2
Li, JF2
Lipscomb, JT1
Wei, X1
Basu, S1
Kumar, A1
Das, BK1
Ciaranello, AL2
Freedberg, KA2
Hughes, M1
Chu, J2
Currier, J1
Holmes, CB1
Pillay, S1
Losina, E1
Walensky, RP2
Pilger, D1
Hauser, A2
Kuecherer, C2
Mugenyi, K4
Kabasinguzi, R1
Somogyi, S1
Azcoaga-Lorenzo, A1
Alvarez, A1
Palma, PP1
Velilla, E1
del Amo, J1
Bolhaar, MG1
Karstaedt, AS1
Sikwane, E1
Majaja, M1
Parham, L1
de Rivera, IL1
Murillo, W1
Naver, L1
Largaespada, N1
Albert, J1
Karlsson, AC1
Kieffer, MP1
Nhlabatsi, B1
Mahdi, M1
Hoffman, HJ1
Kudiabor, K1
Dolgin, E1
Ciampa, PJ1
Burlison, JR1
Moon, TD1
Rothman, RL1
Nathoo, K1
Perez, F2
Maruva, M1
Engelsmann, B1
Keatinge, J1
Mugwagwa, R1
Zimba, I1
Tudor Car, L1
van-Velthoven, MH1
Brusamento, S1
Elmoniry, H1
Car, J1
Majeed, A1
Atun, R2
Joseph, O1
Biodun, O1
Michael, E1
Siegfried, N1
van der Merwe, L2
Brocklehurst, P4
Sint, TT2
Schouten, EJ1
Midiani, D1
Makombe, SD1
Mnthambala, A1
Harries, AD1
van Oosterhout, JJ1
Meguid, T1
Ben-Smith, A1
Zachariah, R1
Lynen, L1
Zolfo, M1
Van Damme, W1
Gilks, CF2
Shawa, M1
Chimbwandira, F1
Wigzell, H1
Falksveden, L1
Wahren, B1
Kanhon, SK1
Touré, H2
Ettiegne-Traoré, V1
Baan, E1
de Ronde, A1
Vyankandondera, J2
Lange, JM1
Pollakis, G1
Paxton, WA1
Mugabo, P1
Els, I1
Smith, J1
Smith, P1
Steyn, W1
Hall, D2
Madsen, R1
Shah, SK1
Dawson, L1
Dixon, DO1
Lie, RK1
von Kleist, M1
Schütte, C1
Antunes, AM1
Novais, DA1
da Silva, JL1
Santos, PP1
Oliveira, MC1
Beland, FA1
Marques, MM1
Cecchini, D1
Urueña, A1
Trinidad, P1
Vesperoni, F1
Mecikovsky, D1
Wang, J1
Shetty, AK3
Kamateeka, M1
Bolton, SG1
Ribaudo, H1
Chen, J1
Parekh, N1
L'homme, R1
Aitken, SC1
Mariki, G1
Van der Ven, AJ1
Dolmans, W1
Britto, P3
Roongpisuthipong, A1
Yuthavisuthi, P1
Prommas, S1
Puthanakit, T1
Rasri, W1
Drake, AL2
Roxby, AC2
Ongecha-Owuor, F2
John-Stewart, G1
Wald, A2
Emery, S2
Farquhar, C4
Taylor, S1
Khoo, SH1
Chetty, V1
Msweli, L1
Kisenge, R1
Lynn, DJ1
Schmidt, NC1
Roman-Pouriet, J1
Fernandez, AD2
Beck-Sagué, CM1
Leonardo-Guerrero, J1
Nicholas, SW1
Elbireer, A1
Nolan, M1
Janoff, EN1
Snijdewind, IJ1
Godfried, MH5
Nellen, JF2
Boer, K5
van der Ende, ME4
Bentley, ME1
Mkhomawanthu, C1
King, CC2
Chitsulo, P1
Tembo, M1
Tohill, B1
Piwoz, EG1
Adair, L1
Mapingure, PM1
Boltz, VF1
Hopley, MJ1
Maldarelli, F2
Coffin, JM1
Sewangi, J1
Mbezi, P2
Dugange, F1
Lau, I1
Ziske, J1
Theuring, S1
Wamalwa, DC1
McCoy, CO1
Matsen, FA1
Langat, A1
Chohan, BH1
Benki-Nugent, S1
Custers-Allen, R1
Bushman, FD1
van Hoog, S1
Nellen, J2
Scherpbier, H1
Carlsson, J1
Jamisse, L2
Adair, LS1
Sikazwe, I1
Moyo, T1
Weaver, M1
Suzuki, C1
Hayashi, C1
Pennings, PS1
Richardson, B1
Matemo, DN1
Veloso, VG2
Joao, EC2
Pilotto, JH2
Santos, B1
Fonseca, R1
Kreitchmann, R1
Pinto, J2
Mussi-Pinhata, MM1
Ceriotto, M1
Machado, D1
Bethel, J2
Morgado, MG1
Dickover, R1
Camarca, M2
Siberry, G1
Grinsztejn, B1
Moreira, RI1
Bastos, FI1
Xu, J2
Moye, J2
Minniear, TD1
Polle, N1
Peters, PJ1
Oyaro, B1
Akoth, B1
Ndivo, R1
Angira, F1
Mills, LA1
Thomas, TK1
Ha, TT1
Anh, NM1
Bao, NH1
Tuan, PL1
Caridha, R1
Gaseitsiwe, S1
Hien, NT1
Cam, PD1
Ehrnst, A1
Kinikar, AA1
Khandave, M1
Shankar, AV1
Bera, E1
Mia, R1
Rossi, S1
Moss, M1
Calmy, A1
Andrieux-Meyer, I1
Hargreaves, S1
Mills, EJ1
Shubber, Z1
McMahon, DK1
Zheng, L1
Halvas, EK1
Bonhomme, J1
Wallis, CL1
Neubert, J1
Pfeffer, M1
Borkhardt, A1
Niehues, T1
Adams, O1
Bolten, M1
Reuter, S1
Stannigel, H1
Laws, HJ1
Mukherjee, S1
Ghosh, S1
Goswami, DN1
Samanta, A1
Sidley, P2
Rekacewicz, C3
Gelber, RD4
Dorenbaum, A5
Bazin, B1
Sullivan, JL7
Achmat, Z1
Baleta, A11
Woods, D1
Volmink, J7
Nachega, J1
Fleming, T9
Mracna, M3
Becker-Pergola, G2
Kreiss, JK1
Klosinski, L1
Hashimoto, H1
Kapiga, SH1
Murata, Y1
Bateman, C4
Annas, GJ1
Moodley, J4
Hofmyer, J1
Nikodem, C1
Gigliotti, M2
Boshoff, L1
Stout, JP4
Chapman, V2
Kumwenda-Phiri, R1
Marseille, E4
Laurence, J1
Boyle, BA2
Knudtson, E1
Para, M1
Boswell, H1
Fan-Havard, P2
Blanchard, S1
Mzyece, E1
Makuka, I1
Kwape, P1
Chilufya, M1
Quaghebeur, A2
Mandaliya, K2
Mudenda, V2
Kumwenda, R2
Pillay, C2
Chezzi, C1
Lupondwana, P1
Levin, L1
Venter, F1
Das, P1
Kironde, S1
Lukwago, J1
Ssenyonga, R1
Rely, K1
Bertozzi, SM1
Avila-Figueroa, C1
Guijarro, MT1
Bruun, JN1
Vermund, S1
Acosta, E1
Beckerman, KP2
Sherman, J2
Ducar, C2
Deseyve, M4
Duefield, C1
Miotti, P2
Bray, D2
Bertolli, J1
Hu, DJ1
Nieburg, P1
Macalalad, A1
Simonds, RJ2
Pittoggi, C1
Sciamanna, I1
Mattei, E1
Beraldi, R1
Lobascio, AM1
Mai, A1
Quaglia, MG1
Lorenzini, R1
Spadafora, C1
Gibbons, A2
Broadhead, RL2
Lema, V2
Liomba, G3
Nkhoma, C2
Miotti, PG2
Kapiriri, L1
Robberstad, B1
Robbestad, B1
Frithjof Norheim, O1
Ayouba, A1
Cunin, P1
Foupouapouognigni, Y1
Kfutwah, A1
Thonnon, J1
Scarlatti, G1
Monny-Lobé, M1
Eteki, N2
Kouanfack, C1
Tardy, M1
Leke, R1
Nkam, M2
Nlend, AE1
Martin, PM1
Rouse, DJ3
Marseille, EA1
Mirochnick, MM1
Katzenstein, DA2
Wells, J2
Maponga, CC1
Jones, SA3
Abdool Karim, SS1
Bassett, MT1
Perez-Then, E1
Peña, R1
Tavarez-Rojas, M1
Peña, C1
Quiñonez, S1
Buttler, M1
Ammann, A1
Hernández, W1
Goyanes, M1
Miguez, MJ1
Shor-Posner, G2
Hudson, CP5
Cooper, E1
Jackson, B2
Gerntholtz, L1
Balasubramanian, R1
Maupin, RT1
Delke, I1
Fiore, S1
Jaspan, HB1
Garry, RF1
Smart, T1
Servais, J1
Lambert, C1
Vanhove, D1
Fischer, A1
Baurith, T1
Schmit, JC1
Schneider, F1
Hemmer, R1
Arendt, V1
Thompson, CA1
Coovadia, AH2
Urban, MF2
Bolton, KD1
Rouet, F5
Inwoley, A1
Viho, I8
Bequet, L5
Chama, CM1
Audu, BM1
Kyari, O1
Urban, M2
Chersich, M1
Stek, AM1
Nachman, SA1
Baker, D1
Gonzalez-Garcia, A1
Provisor, A1
Thorpe, EM2
Paul, ME1
Foca, M2
Gandia, J1
Wei, LJ1
Stevens, LM1
McNamara, J1
Mukotekwa, T1
Miller, A1
Orne-Gliemann, J1
Glenshaw, M1
Chitsike, I2
Kanshana, S1
Thaineua, V1
Bowonwatanuwong, C1
Kantipong, P1
Leenasirimakul, P1
Hammer, S2
Nour, S1
Chen, S8
Check, E3
Fleming, TR1
Sweat, MD1
O'Reilly, KR1
Schmid, GP1
Denison, J1
de Zoysa, I1
LaFraniere, S1
Mutunga, L1
Verhofstede, C1
Covington, DL1
Beckerman, K2
Garcia, P1
Ross, B1
Sacks, S1
Chavers, S1
Tilson, H1
Herzmann, C1
Karcher, H4
Goulder, PJ1
Blanckenberg, N1
Dong, K1
Feinberg, J1
Tempelman, C2
Timmermans, S2
Dieleman, JP1
Kabura, MN1
John, FN1
Nduati, RW1
Mbori-Ngacha, DA2
Mbopi-Keou, FX1
Alemnji, G1
Alemdji, G1
Nkengasong, JN2
Meli, C1
Nana, PN1
Ako, SN1
Tonye, RN1
Leke, RJ1
Lyons, FE1
Coughlan, S1
Byrne, CM1
Hopkins, SM1
Hall, WW1
Mulcahy, FM2
Roehr, B1
Mullings, AA1
Williams, E1
Whorms, S2
Figueroa, JP2
Steel-Duncan, JC1
Pierre, R1
Evans-Gilbert, T1
Rodriquez, B1
Hambleton, I1
Massaquoi, I1
Asiimwe, S1
Kamya, MR1
Arts, EJ1
Whalen, CC1
Sakarovitch, C2
Fassinou, P2
Dequae-Merchadou, L1
Welffens-Ekra, C1
Lallemant, MJ1
Kunkeaw, S1
Lane, HC1
Folkers, GK1
Fauci, AS1
Turner, VF1
Maclean, CC2
Thorne, C2
Kamenga, C1
de Zoysa, IF1
Vwalika, C3
Shutes, E1
Aldrovandi, G1
Couzin, J1
Dreyfuss, ML2
Kigozi, G1
Chen, MZ1
Wabwire-Mangen, F1
Serwadda, D1
Wawer, MJ1
Sewankambo, NK1
Nalugoda, F1
Kiwanuka, N1
Kiddugavu, M1
Gray, RH2
Dieleman, J1
Sprenger, H1
Schneider, ME1
Stephenson, J2
James, JS5
Hammer, SM1
Flys, T1
Nissley, DV1
Claassen, CW1
Jones, D2
Shi, C1
Strathern, JN1
Eshleman, JR1
Taha, T2
Parkin, N2
Bolton, C1
van Niekerk, R1
Stevens, W1
Levy, J2
Degroot, A1
Urassa, P1
Gosling, R1
Pool, R1
Reyburn, H1
Mahlat, U1
Kantor, R2
Zijenah, L2
Sheldon, W1
Mateta, P2
Johnston, E2
Contag, CH1
Bassett, M1
Hilderbrand, K1
Goemaere, E1
Kurowski, M4
Sheriff, M1
van't Hoog, AH1
Marum, LH1
Otieno, JA1
Misore, AO1
Nganga, LW1
Decock, KM1
Joy, S1
Poi, M1
Hughes, L1
Brady, MT1
Koletar, SL1
Para, MF1
Welty, ER1
Ndikintum, G1
Nkuoh, G1
Nkfusai, J1
Clark, R1
Albrecht, S1
Quian, J1
Visconti, A1
Gutiérrez, S1
Galli, A1
Maturo, M1
Galeano, V1
Serra, M1
Lioni, M1
Savadogo, A1
Nadembega, WM1
Yara, J1
Zoungrana, N1
Bakouan, D1
Musumeci, S1
Toni, TD2
Masquelier, B3
Lazaro, E1
Dore-Mbami, M1
Ba-Gomis, FO1
Téa-Diop, Y1
Kouakou, K1
Diby, J1
Sia, E1
Soppi, S1
Essien, S1
Schrive, MH1
Pinson, P1
Chenal, H1
Fleury, HJ2
Calvet, GA1
Menezes, JA1
D'Ippolito, MM1
Cruz, ML1
Salgado, LA1
Matos, HJ1
Anderson, JR1
Peytavin, G2
Menan, H2
Janowitz, B1
Homan, R1
Johnson, L1
Schmitz, T1
Kleinkauf, N1
Klempa, B1
Ringe, H1
Varnholt, V1
Grosch-Wörner, I1
Parsons, T2
Smith, DM1
Koh, MT1
Loubser, S1
Balfe, P1
Oleske, JM1
Lyons, F1
Hopkins, S1
Kelleher, B1
McGeary, A1
Sheehan, G1
Geoghegan, J1
Bergin, C1
McCormick, PA1
Soorapanth, S1
Sansom, S1
Besser, M1
Boltz, V1
Mellors, J1
Coffin, J1
Kouam, L1
Nsangou, I1
Mbanya, D1
Kongnyuy, EJ1
Ngassa, P1
Tebeu, PM1
Elobe, N1
Kamgaing, NG1
Zekeng, L1
Doh, AS1
Geffen, N1
Nattrass, N2
Taiwo, BO1
Homsy, J1
Kalamya, JN1
Obonyo, J1
Ojwang, J1
Mugumya, R1
Opio, C1
Mermin, J1
Kankasa, MP1
Germinario, EA1
Bassani, L1
Dehò, L1
Okong, P1
Flys, TS2
Jones, DC1
Nightingale, S1
Heymann, SJ1
Gilbert, PB1
Stevens, L2
Peter, T1
Kim, S1
Ndase, P2
Arimi, P2
Kebaabetswe, P1
Mazonde, P1
Lee, TH1
Marlink, R1
Lagakos, S2
Poggensee, G1
Gingelmaier, A1
Kästner, R1
Eberle, J1
Mylonas, I1
Belohradsky, BH1
Friese, K1
Grubert, TA1
Germano, P2
Guidotti, G2
Loureiro, S2
da Cruz Gomes, A1
Valls Blazquez, MC1
Perno, CF1
Sagay, AS1
Musa, J1
Adewole, AS1
Imade, GE1
Ekwempu, CC1
Kapiga, S1
Sankale, JL2
Idoko, J2
Kanki, P1
Rexroad, VE1
Hamzeh, FM1
Li, X1
Stamper, PD1
von Hentig, N1
Carlebach, A1
Gute, P1
Knecht, G1
Klauke, S1
Rohrbacher, M1
Stocker, H1
Harder, S1
Staszewski, S1
Haberl, A2
Bhayroo, S1
Thistle, P1
Spitzer, RF1
Glazier, RH1
Pilon, R1
Arbess, G1
Simor, A1
Boyle, E1
Gottesman, M1
Silverman, M1
Gu, SM1
Giaquinto, C1
Rampon, O1
De Rossi, A1
Mayer, A1
Simo, S1
Ali, M1
Salu, OB1
Musa, AZ1
Onyewuche, J1
Funso-Adebayo, EO1
Iroha, EO1
Ezeaka, VC1
Adetifa, IM1
Okoeguale, B1
Idigbe, EO1
Chand, F1
Bedikou, G1
Timite-Konan, M1
Siegfried, NL1
Balkus, J1
Manuel, R1
Djedje, M1
Seoighe, C1
Ketwaroo, F1
Scheffler, K1
Wood, N1
Duffet, R1
Zvelebil, M1
Hide, W1
Westreich, D1
Eron, J1
Horst, Cv1
Van Rie, A1
Natarajan, U1
Pym, A1
McDonald, C1
Velisetty, P1
Edwards, SG2
Hay, P2
Welch, J2
de Ruiter, A2
Taylor, GP3
Anderson, J1
Manosuthi, W1
Athichathanabadi, C1
Uttayamakul, S1
Phoorisri, T1
Sungkanuparph, S1
Lupodwana, P1
Steyn, JG1
Mtonga, V1
Lee, A1
Suksomboon, N1
Poolsup, N1
Ket-Aim, S1
Patel, D1
Cortina-Borja, M1
Alcorn, K1
Kurle, SN1
Gangakhedkar, RR1
Sen, S1
Hayatnagarkar, SS1
Tripathy, SP1
Paranjape, RS1
Perre, PV1
Samuel, NM3
Parameshwari, S1
Dharmarajan, S1
Van Hook, HM1
Jacob, SM1
Junankar, V1
Stoszek, SK1
Rollins, N1
Little, K1
Mzolo, S1
Horwood, C1
Basavraj, A1
Kakrani, A1
Philip, S1
Desai, D1
Manfredi, R1
Calza, L1
Bennetto-Hood, C1
King, JR1
Woodman, K1
Ashouri, N1
Igumbor, OJ1
Pengpid, S1
Obi, CL1
Apornpong, T1
Teeratakulpisarn, S1
Chaithongwongwatthana, S1
Taweepolcharoen, C1
Mangclaviraj, S1
Limpongsanurak, S1
Jadwattanakul, T1
Eiamapichart, P1
Luesomboon, W1
Apisarnthanarak, A1
Kamudhamas, A1
Tangsathapornpong, A1
Vitavasiri, C1
Singhakowinta, N1
Attakornwattana, V1
Kriengsinyot, R1
Methajittiphun, P1
Chunloy, K1
Preetiyathorn, W1
Aumchantr, T1
Toro, P1
El-Sadr, W1
Phanuphak, P1
Donninger, S1
Toure, S1
El-Sadr, WM1
Kassaye, S1
Lee, E1
Winters, M1
Katzenstein, D1
Dao, H1
Ekpini, R1
Barnhart, M1
D'costa, GF1
Khadke, K1
Patil, YV1
Bharucha, KE1
Kulkarni, P1
Phadke, M1
Djadou, KE1
Ocloo, A1
Dokounor, D1
Agbodjan-Djossou, O1
Akakpossa, A1
Safrit, JT1
Shekelle, P1
Maglione, M1
Geotz, MB1
Wagner, G1
Wang, Z1
Hilton, L1
Carter, J1
Tringle, C1
Mojica, W1
Newberry, S1
Tsai, WY1
Ly, N1
Phoung, V1
Min, DC2
Srey, C1
Kruy, LS2
Koum, K1
Chhum, V1
Glaziou, P2
Reynes, JM1
Ojesina, AI1
Mullins, C1
Imade, G1
Samuels, J1
Pam, S1
Sagay, S1
Kanki, PJ1
Downing, R1
Greenberg, AE1
Schlösser, R1
Linde, R1
Dunsch, D1
Reitter, A1
Bauer, K1
Clarisse, AB1
Dandona, L1
Kumar, SG1
Ramesh, YK1
Rao, MC1
Dandona, R1
Eyakuze, C1
Jones, DA1
Starrs, AM1
Sorkin, N1
Dube, S1
Boily, MC1
Mugurungi, O1
Mahomva, A1
Chikhata, F1
Gregson, S1
Carraro, EA1
Prandel, E1
Dias, JM1
Perini, J1
Macedo, RL1
Cornelsen, TC1
Sbalquiero, R1
Rees, H1
Kirere Mathe, M1
Sondag-Thull, D1
Lepage, P1
Aweeka, F1
Stek, A1
Hu, C1
Burchett, SK1
Best, B1
Watts, H1
Nachman, S1
Jimenez, E3
Shearer, WT1
Damming, M1
Prins, JM1
Pérez, H1
Vignoles, M1
Laufer, N1
Gómez, A1
Coll, P1
Lottner, J1
Rolón, M1
Salomón, H1
Cahn, P1
Gomutbutra, V1
Ghosh, M1
Bii, SC1
Otieno-Nyunya, B1
Rotich, JK1
Claassen, M1
Engelbrecht, S1
Laten, JD1
Preiser, W1
Gagnier, P1
Pav, J1
Gwynne, M1
Siminski, S2
Yogev, R1
Elliott, T1
Horton, S1
Dransfield, K2
Pav, JW1
Murarka, A1
Hom, D1
McCarthy, M1
Renault, B1
Birmingham, K2
Lurie, P1
Wolfe, SM1
Campa, AM1
Baum, MK1
Cherry, M4
Temesgen, Z1
Wright, AJ1
Clarke, SM1
Mulcahy, F1
Healy, CM1
Condon, S1
Butler, KM1
Masland, T1
King, P1
Lyall, EG1
Ward, C1
Hayashi, T1
Chen, F1
Pau, AK1
Piscitelli, SC1
Cooper, PA1
Jivkov, BI1
Schorn, MC1
Stinnett, AA1
Clarke, DF1
Akue, JP1
Babaki, P2
Charpak, N2
de Thé, G2
Rea, MF1
Huraux, C2
Ndiaye, B2
Pratomo, H2
Zetterström, R2
Lhotska, L1
Armstrong, H1
McNeeley, DF1
Dovie Akue, JP1
Ferreira Rea, M1
Benson, M1
Shannon, M1
Bowersox, J1
Kasper, T1
Sax, PE1
Lindsay, MK1
MacDougall, DS1
Hankins, C1
Jones, TT2
Cunningham, S2
Smith, AN2
Glenn Fowler, M1
Lugo, M1
Smith, PF1
DiCenzo, R1
Morse, GD1
Larbalestier, N1
Easterbrook, P1
Florence, KJ1
Podzamczer, D1
Fumero, E1
Bonard, D1
Faure, M1
Huët, C1
Caumont, A1
Roques, P1
Salamon, R1
Fleury, H1
Ashraf, H1
Hoover, D1
Mukiibi, J1
Broadhead, R1
Saman, M1
Leng, C1
Huff, B1
Skordis, J1
Zuniga, JM1
Gebbie, KM1
Cullinan, K2
Marzolini, C1
Béguin, A1
Telenti, A1
Schreyer, A1
Buclin, T1
Biollaz, J1
Decosterd, LA1
Cunningham-Schrader, B1

Clinical Trials (64)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
PHPT-5 Second Phase: Perinatal Antiretroviral Intensification for the Prevention of Mother-to-child Transmission of HIV in Thai Women Having Received Less Than 8 Weeks of HAART During Pregnancy[NCT01511237]Phase 3379 participants (Actual)Interventional2011-12-31Completed
A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding[NCT00074412]Phase 32,026 participants (Actual)Interventional2007-01-31Completed
Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study[NCT02140255]Phase 1/Phase 2905 participants (Anticipated)Interventional2015-01-23Recruiting
Short Duration Exclusive Breastfeeding With Abrupt Weaning to Reduce the Risk of Mother-to-Child HIV Transmission[NCT00310726]1,435 participants (Actual)Interventional2001-05-31Completed
Evaluation of Conditional Cash Transfers to Increase Retention in PMTCT Services in Akwa Ibom State, Nigeria[NCT02447159]554 participants (Actual)Interventional2015-08-31Completed
The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance After a Single Dose Nevirapine (VIramune®), Which is Part of ARV Prophylaxis for PMTCT in Moshi, TAnzania, and in Lusaka, Zambia (VITA2 Trial)[NCT01187719]Phase 266 participants (Actual)Interventional2010-05-31Completed
Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women[NCT00993031]Phase 3389 participants (Actual)Interventional2009-12-15Completed
Interactions Between Antiretrovirals and Combined Oral Contraceptive Pills[NCT00829114]Phase 4370 participants (Anticipated)Interventional2009-03-31Completed
PROMISE EBF: Promoting Infant Health and Nutrition in Sub-Saharan Africa: Safety and Efficacy of Exclusive Breastfeeding Promotion in the Era of HIV[NCT00397150]2,579 participants (Actual)Interventional2006-11-30Completed
Maternal and Infant Peripartum Nevirapine, Versus Infant Only Peripartum Nevirapine, or Maternal Lopinavir/Ritonavir in Addition to Standard Zidovudine Prophylaxis for the Prevention of Perinatal HIV in Thailand.[NCT00409591]Phase 3435 participants (Actual)Interventional2008-07-31Terminated (stopped due to Change in National PMTCT guidelines in Thailand)
A Pharmacokinetic Evaluation of Levonorgestrel Implant and Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in HIV-infected Ugandan Women[NCT01789879]Phase 260 participants (Actual)Interventional2014-03-04Completed
Optimizing Integrated PMTCT Services in Rural North-Central Nigeria: A Cluster Randomized Trial[NCT01805752]369 participants (Actual)Interventional2013-03-31Completed
Role of Pharmacogenetics in Efavirenz and Nevirapine Pharmacokinetics, Efficacy and Safety in Mother-infant Pairs During Pregnancy and Lactation[NCT02269462]460 participants (Actual)Observational2012-12-31Completed
Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)[NCT01061151]Phase 33,747 participants (Actual)Interventional2011-03-01Completed
Addition of Single-dose, Maternal Tenofovir and Emtricitabine to Reduce Non-nucleoside Reverse Transcriptase Inhibitor Resistance Mutations in the Setting of Zidovudine and Nevirapine for Prevention of Mother-to-child HIV Transmission[NCT00204308]Phase 2400 participants (Actual)Interventional2005-03-31Completed
Effect of Intermittent Preventive Treatment (IPTp) With Sulfadoxine-Pyrimethamine Plus Insecticide Treated Nets, Delivered Through Antenatal Clinics for the Prevention of Malaria in Mozambican Pregnant Women[NCT00209781]1,028 participants Interventional2003-08-31Active, not recruiting
Prevention of Maternal to Infant HIV Transmission in India[NCT00061321]Phase 3770 participants (Actual)Interventional2002-08-31Completed
Nevirapine (NVP) Use to Prevent Maternal-Infant HIV Transmission: A Randomized Clinical Trial of Two Doses of NVP Compared to Six Weeks of NVP for the Prevention of Maternal-Infant HIV Transmission in the Breastfeeding Infant[NCT00074399]Phase 3775 participants (Actual)Interventional2001-02-28Completed
A Phase III Randomized Clinical Trial of the Standard Two Dose Nevirapine (NVP) Regimen With the Addition of HIV Immune Globulin(HIVIGLOB) or Extended Infant NVP Dosing Compared With the Standard NVP Regimen Alone for the Prevention of Maternal-Infant HIV[NCT00639938]Phase 3722 participants (Actual)Interventional2004-07-31Completed
Presumptive and Definitive Virologic HIV Diagnosis in Hospitalized Malawian Infants[NCT01388452]300 participants (Actual)Interventional2011-06-30Completed
ARVs to Prevent Breastmilk HIV:Viral and Immune Responses[NCT00167674]Phase 258 participants (Actual)Interventional2003-05-31Completed
A Cohort Study To Assess The Impact Of A Breastfeeding Counselling And Support Strategy To Promote Exclusive Breastfeeding On Post-Natal Transmission Of HIV In African Women[NCT01948557]3,465 participants (Actual)Interventional2001-10-31Completed
Phase II Trial, Multicentre, Opened Label Evaluating the Pharmacokinetics and the Safety and Toxicity of the Tenofovir-Emtricitabine Combination in Pregnant Women and Infants in Africa and Asia[NCT00334256]Phase 272 participants (Actual)Interventional2006-10-31Completed
Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)[NCT01066858]1,765 participants (Actual)Observational2011-03-22Completed
Phase III Trial of Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission[NCT00021671]Phase 33,720 participants InterventionalCompleted
HIV Exposure, Disease Acquisition and Progression Among Children: Role of Maternal Immunogenetics, Viral Genetic Diversity, HAART Exposure, Co-morbidities and Psycho-Social Status: (UZ-CHS Birth Cohort)[NCT04087239]1,200 participants (Actual)Observational2016-01-26Active, not recruiting
An Open-label Study Evaluating the Resistance Profile of Single Dose Nevirapine(NVP) When Combined With a 4 or 7 Day Course of Combivir® (ZDV/3TC) Compared to Single Dose Nevirapine for the Prevention of Mother to Child Transmission (pMTCT) of HIV - Treat[NCT00144183]Phase 3407 participants Interventional2003-01-31Completed
Optimizing the Delivery of Maternal and Child Health Services to Strengthen the Primary Health Care System in Rural South Africa[NCT02626351]3,172 participants (Actual)Interventional2015-07-15Completed
A Phase 2, One Arm, Open Label, Feasibility Study Assessing One Month Zidovudine/Didanosine Postpartum Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine to Prevent Mother to Child Transmission of HIV[NCT00142337]Phase 2244 participants (Actual)Interventional2004-12-31Completed
Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand[NCT00433030]2,816 participants (Actual)Observational2007-01-31Completed
HIV Infection and Breastfeeding: Interventions for Maternal and Infant Health[NCT00164736]Phase 32,369 participants (Actual)Interventional2004-03-31Completed
Pharmacokinetics and Safety of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants[NCT04862975]200 participants (Anticipated)Observational2024-01-08Not yet recruiting
Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana[NCT00270296]Phase 2730 participants (Actual)Interventional2006-06-30Completed
Z 1303 - Point-of-Care Virologic Testing to Improve Outcomes of HIV-Infected Children[NCT02682810]4,000 participants (Actual)Interventional2016-02-29Completed
Nevirapine Pharmacodynamics and Resistance Among HIV-Infected Mothers in Lilongwe, Malawi[NCT00164762]126 participants (Actual)Observational2005-06-30Completed
Optimal Combination Therapy After Nevirapine Exposure[NCT00089505]Phase 3745 participants (Actual)Interventional2006-11-30Completed
Phase II, Parallel, Randomized, Clinical Trials Comparing the Responses to Initiation of NNRTI-Based Versus PI-Based Antiretroviral Therapy in HIV Infected Infants Who Have and Have Not Previously Received Single Dose Nevirapine for Prevention of Mother-t[NCT00307151]Phase 2452 participants (Actual)Interventional2005-12-31Completed
A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177]Phase 496 participants (Actual)Interventional2013-01-31Completed
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years[NCT01504841]Phase 1/Phase 226 participants (Actual)Interventional2013-03-14Completed
The Effect of Single Dose Carbamazepine on the Pharmacokinetics of Single Dose Nevirapine (Viramune, NVP) and Development of NVP Resistance, PMTCT Program of Moshi, Tanzania (VITA1)[NCT00294892]Phase 2144 participants (Actual)Interventional2006-02-28Completed
[NCT00398684]Phase 31,792 participants Interventional2001-01-31Completed
Phase II Study of the Pharmacokinetics of Nevirapine and the Incidence of Nevirapine Resistance Mutations in HIV-Infected Women Receiving a Single Intrapartum Dose of Nevirapine With the Concomitant Administration of Zidovudine/Didanosine or Zidovudine/Di[NCT00109590]Phase 2175 participants (Actual)Interventional2006-06-30Completed
HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding[NCT00530777]Phase 2148 participants (Actual)Interventional2008-04-30Completed
Phase III Randomized Trial of the Safety and Efficacy of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV-1 Transmission[NCT00099359]Phase 31,735 participants (Actual)Interventional2004-02-29Completed
A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection[NCT01780831]Phase 152 participants (Actual)Interventional2014-01-28Completed
Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine[NCT00099632]Phase 2484 participants (Actual)Interventional2006-03-31Completed
A Phase III Randomized, Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women[NCT00000869]Phase 32,009 participants InterventionalCompleted
A Phase III Placebo-Controlled Trial to Determine the Efficacy of Oral AZT and the Efficacy of Oral Nevirapine for the Prevention of Vertical Transmission of HIV-1 Infection in Pregnant Ugandan Women and Their Neonates[NCT00006396]Phase 31,500 participants InterventionalCompleted
A Phase III Randomized Trial of the Safety and Antiretroviral Effects of Zidovudine/Lamivudine/Abacavir Versus Zidovudine/Lamivudine/Lopinavir/Ritonavir in the Prevention of Perinatal Transmission of HIV[NCT00086359]Phase 319 participants (Actual)Interventional2004-07-31Completed
Assessment of Safety and Toxicity Among Infants Born to HIV-1-Infected Women Enrolled in Antiretroviral Treatment Protocols in Diverse Areas of the World[NCT00100867]236 participants (Actual)Observational2006-06-30Completed
Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum[NCT00042289]1,578 participants (Actual)Observational2003-06-09Completed
Phase I/II Study to Assess the Safety and Plasma Concentrations of Nevirapine Given Daily, Twice a Week or Weekly as Prophylaxis in Breastfeeding Infants From Birth to 6 Months[NCT00006279]Phase 175 participants InterventionalCompleted
A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women[NCT00001135]Phase 32,009 participants InterventionalCompleted
A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women[NCT00000942]Phase 31,244 participants InterventionalCompleted
Randomized Trial of Protease Inhibitor-Including vs. Protease Inhibitor-Sparing Regimens for Women Who Initiate Therapy of HIV Infection During Pregnancy[NCT00017719]Phase 3440 participants Interventional2002-05-31Completed
An Open-Label, Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Pre-menopausal Women[NCT00961272]6 participants (Actual)Observational2009-07-31Completed
A Phase IV, Open-Label, Single-Sequence Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Women[NCT00774683]1 participants (Actual)Observational2008-08-31Completed
A Phase IV, Open-Label Study to Characterize the First-Dose and Multiple-Dose Pharmacokinetics of Raltegravir in the Gastrointestinal Tract of Healthy Male Volunteers[NCT01325051]Phase 115 participants (Actual)Interventional2011-04-30Completed
A Phase I Study of the Safety, Tolerance, and Pharmacokinetics of Tenofovir Disoproxil Fumarate (TDF) and the Combination of TDF Plus Emtricitabine in HIV-1 Infected Pregnant Women and Their Infants[NCT00076791]Phase 166 participants (Actual)Interventional2004-03-31Completed
"Prevention of Milk-Borne Transmission of HIV-1C in Botswana (Mashi)"[NCT00197587]1,200 participants (Actual)Interventional2002-08-31Completed
ART Readiness in HIV-infected Pregnant Women: From Formative Qualitative Research to Individual Randomized Trial[NCT02459678]454 participants (Actual)Interventional2015-05-31Completed
Pilot Evaluation of Pulmonary Tuberculosis Screening in Antenatal Clinics in Lusaka, Zambia[NCT02053129]5,033 participants (Actual)Interventional2011-11-30Completed
A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers[NCT00000808]Phase 149 participants InterventionalCompleted
Mother-Infant Rapid Intervention at Delivery (MIRIAD)[NCT00046436]7,500 participants ObservationalTerminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Frequency and Severity of Adverse Reactions Among Participating Infants

For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness. (NCT00074412)
Timeframe: 6 weeks through 18 months

,
InterventionNumber of Adverse Events (Number)
DeathLife-ThreateningSevereModerateMild
Nevirapine2687375694832
Placebo3087332677838

HIV Infection in Infants Determined to be HIV Uninfected at 6 Weeks Enrolled in Each Arm of the Study

(NCT00074412)
Timeframe: At Month 6

,
Interventionparticipants (Number)
# of HIV infections at 6 months# of Infants at risk for HIV infection at 6 months
Nevirapine8700
Placebo18699

Infant Survival Rates (Mortality Regardless of HIV Infection) in the Two Arms

(NCT00074412)
Timeframe: At Month 18

,
Interventionparticipants (Number)
# Infant Deaths at 18 months# Infants at risk of death at 18 months
Nevirapine26678
Placebo30684

Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms

(NCT00074412)
Timeframe: At Months 6 and 18

,
Interventionparticipants (Number)
Number of Infants Alive and HIV-free at 6 monthsNumber of Infants Alive and HIV-free at 18 months
Nevirapine689629
Placebo683616

Relative Rates of HIV Infection in the Two Arms

(NCT00074412)
Timeframe: At Month 18

,
Interventionparticipants (Number)
# of infants with HIV infection at 18 months# of infants @ risk for HIV infection at 18 months
Nevirapine16664
Placebo23663

ART Levels in Hair Samples at Delivery

antiretroviral hair concentrations (per doubling) (NCT00993031)
Timeframe: delivery

Interventionantiretroviral hair concentration(ng/mg) (Mean)
Without Protease Inhibitor5.7
With Protease Inhibitor6.6

Change in Maternal CD4 Cell Counts

CD4 cell count recovery efavirenz at delivery (NCT00993031)
Timeframe: Time of randomization to delivery, an average of 20 weeks

InterventionCD4 cell count (Median)
Without Protease Inhibitor-7
With Protease Inhibitor57

Incidence of Pre-eclampsia Defined by Hypertension > 140/90 on Two Occasions Measured > 6 Hours Apart With ≥1+ Proteinuria on Clean Catch Urine Dipstick

Pre-eclampsia Defined by Hypertension > 140/90 on Two Occasions Measured > 6 Hours Apart With ≥1+ Proteinuria on Clean Catch Urine Dipstick (NCT00993031)
Timeframe: Time from randomization until delivery

InterventionParticipants (Count of Participants)
Without Protease Inhibitor0
With Protease Inhibitor0

Maternal Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk After Pregnancy

(NCT00993031)
Timeframe: Number of treatments given for clinical malaria based on postive blood smear from time from delivery until 24 months after delivery or cessation of breastfeeding

Interventiontreatments (Number)
Group A21
Group B13

Maternal Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk During Pregnancy

(NCT00993031)
Timeframe: Number of treatments given for clinical malaria based on postive blood smear from time from randomization until 24 months after delivery or cessation of breastfeeding

Interventiontreatments (Number)
With Protease Inhibitor17
Without Protease Inhibitor17

Number of Participants With Grade 3 or 4 Toxicity in the Two Treatment Groups in Women

(NCT00993031)
Timeframe: Randomization to one month postpartum

InterventionParticipants (Count of Participants)
Without Protease Inhibitor12
With Protease Inhibitor8

Number of Participants With Maternal HIV RNA Suppression of <400 Copies/mL

Virologic suppression was defined as plasma HIV-1 RNA 400 copies/ml or less based on the lower limit of detection of the available test. (NCT00993031)
Timeframe: Time from randomization until delivery, an average of 20 weeks

InterventionParticipants (Count of Participants)
Without Protease Inhibitor166
With Protease Inhibitor153

Number of Participants With Maternal to Child Transmission of HIV, Measured by Infant HIV DNA PCR

HIV tested by DNA PCR (NCT00993031)
Timeframe: Delivery to 48 weeks postpartum

InterventionParticipants (Count of Participants)
Without Protease Inhibitor0
With Protease Inhibitor2

Number of Participants With Severe Maternal Anemia Defined by Hemoglobin < 8g/dl at Any Point During the Trial in Each Treatment Group

Proportion of women with severe maternal Anemia (hemoglobin < 8g/dl by hemacue or CBC) at any point during the trial in Each Treatment Group (NCT00993031)
Timeframe: Time from randomization until one year follow up

InterventionParticipants (Count of Participants)
Without Protease Inhibitor11
With Protease Inhibitor11

Placental Malaria Defined as Positive Placental RDT

Number of participants with positive placental RDT for malaria. Malaria rapid diagnostic tests (RDTs) assist in the diagnosis of malaria by detecting evidence of malaria parasites (antigens) in human blood. RDTs permit a reliable detection of malaria infections particularly in remote areas with limited access to good quality microscopy services. (NCT00993031)
Timeframe: Delivery

Interventionparticipants (Number)
With Protease Inhibitor6
Without Protease Inhibitor7

Placental Malaria Defined Placental Histopathologic Analysis

Number of participants with positive placental histopathology slide for malaria (NCT00993031)
Timeframe: Delivery

Interventionparticipants (Number)
With Protease Inhibitor62
Without Protease Inhibitor47

Prevalence of Composite Clinical Outcome Defined by LBW, Stillbirth(Intrauterine Fetal Demise >20wks GA), Late Spontaneous Abortion(Miscarriage 12-20wks GA), Preterm Delivery(<37wks Gestation), Neonatal Death(Death of Liveborn Infant Within First 28days)

Percent of evaluated participants with composite clinical outcome defined by LBW, stillbirth (intrauterine fetal demise >20wks GA), late spontaneous abortion(miscarriage 12-20wks GA), preterm delivery(<37wks gestation), neonatal death(death of live-born infant within first 28 days) (NCT00993031)
Timeframe: Time from randomization until 24 months postpartum or cessation of breastfeeding

Intervention% of evaluated participants with outcome (Number)
With Protease Inhibitor33.9
Without Protease Inhibitor27.8

Prevalence of Malaria Defined as Positive Placental Blood PCR

Number of participants with positive placental blood PCR for malaria (NCT00993031)
Timeframe: Delivery

Interventionparticipants (Number)
With Protease Inhibitor6
Without Protease Inhibitor7

Prevalence of Malaria Defined as Positive Placental Blood Smear

Number of participants with positive placental blood smear for malaria (NCT00993031)
Timeframe: Delivery

Interventionparticipants (Number)
With Protease Inhibitor5
Without Protease Inhibitor6

Exclusive Breastfeeding Rates in Burkina Faso

The EBF prevalences (24-h recall) at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age

Interventionparticipants (Number)
Intervention310
No Intervention161

Exclusive Breastfeeding Rates in South Africa

The EBF prevalences based on 24-h recall at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age

Interventionparticipants (Number)
Intervention56
No Intervention30

Exclusive Breastfeeding Rates in Uganda

The EBF prevalences (24-h recall) at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age

Interventionparticipants (Number)
Intervention323
No Intervention161

Infant Morbidity, 2 Week Diarrhoea Prevalence

(NCT00397150)
Timeframe: at 3 months of age

Interventionparticipants (Number)
Intervention104
No Intervention101

Antepartum Component: Number of Confirmed Infant HIV Infections

Defined as HIV nucleic acid test (NAT) positivity of the specimen drawn at either the birth (Day 0-5) or Week 1 (Day 6-14) visit, confirmed by HIV NAT positivity of a second specimen collected at a different time point (NCT01061151)
Timeframe: Measured at birth or Week 1 study visit

InterventionParticipants (Count of Participants)
Antepartum Arm A25
Antepartum Arm B7
Antepartum Arm C2

Antepartum Component: Number of Infant HIV Infections

Detected by HIV NAT positivity (NCT01061151)
Timeframe: Measured at the birth (<= 3 days postpartum) visit

InterventionParticipants (Count of Participants)
Antepartum Arm A22
Antepartum Arm B4
Antepartum Arm C2

Maternal Health Component: Incidence of AIDS-defining Illness

"AIDS-defining illness refers to the WHO Clinical Stage 4 illnesses listed in Appendix IV. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

InterventionNew cases per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)0.08
Maternal Health Arm B (Discontinue Triple ARVs)0.25

Maternal Health Component: Incidence of Death

Number of women who died during the maternal health component; that is, who had been randomized to either continue or discontinue ART after risk of HIV vertical transmission through breastfeeding was over. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

InterventionNew cases per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)0.24
Maternal Health Arm B (Discontinue Triple ARVs)0.43

Maternal Health Component: Incidence of HIV/AIDS-related Event or Death

"HIV/AIDS-related event refers to the WHO Clinical Stage 4 illnesses, pulmonary tuberculosis, and other serious bacterial infections listed in Appendix IV of the protocol. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

InterventionNew cases per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)1.30
Maternal Health Arm B (Discontinue Triple ARVs)1.43

Maternal Health Component: Incidence of HIV/AIDS-related Event or World Health Organization (WHO) Clinical Stage 2 or 3 Events

"HIV/AIDS-related event refers to the WHO Clinical Stage 4 illnesses, pulmonary tuberculosis, and other serious bacterial infections listed in Appendix IV of the protocol. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

InterventionNew cases per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)3.47
Maternal Health Arm B (Discontinue Triple ARVs)5.61

Maternal Health Component: Incidence of HIV/AIDS-related Events

"HIV/AIDS-related event refers to the WHO Clinical Stage 4 illnesses, pulmonary tuberculosis, and other serious bacterial infections listed in Appendix IV of the protocol. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

InterventionNew cases per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)1.14
Maternal Health Arm B (Discontinue Triple ARVs)1.24

Maternal Health Component: Incidence of Progression to AIDS-defining Illness or Death

AIDS-defining illness refers to the WHO Clinical Stage 4 illnesses in Appendix IV of the protocol. These events were reviewed and confirmed by an Endpoint review group. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

InterventionNew cases per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)0.24
Maternal Health Arm B (Discontinue Triple ARVs)0.49

Maternal Health Component: Incidence of Tuberculosis

Incidence of tuberculosis. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

InterventionNew cases per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)0.40
Maternal Health Arm B (Discontinue Triple ARVs)0.31

Maternal Health Component: Incidence Rate of Cardiovascular or Other Metabolic Events

"Cardiovascular or metabolic events of particular concern were included in this analysis. A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates.~Metabolic events considered were diabetes mellitus, lipodystrophy, or dyslipidemia. Cardiovascular events considered were hypertension, congestive heart failure, stroke, Transient Ischemia Event (TIA), pulmonary embolism, myocardial infarction (whether acute symptomatic or silent), coronary artery disease, deep vein thrombosis, peripheral vascular disease, or symptomatic HIV-associated cardiomyopathy." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

Interventionevents per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)2.9
Maternal Health Arm B (Discontinue Triple ARVs)5.7

Maternal Health Component: Incidence Rate of Death or Any Condition of Particular Concern

Particular events were targeted as those of particular concern. This outcome considered all such events: death, events defining WHO stages II, III, or IV, targeted cardiovascular adverse events, other targeted adverse events, or cancers which were not AIDS-defining. A complete list can be found in Appendix IV of the Protocol. A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

Interventionevents per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)9.0
Maternal Health Arm B (Discontinue Triple ARVs)14.0

Maternal Health Component: Incidence Rate of Progression to AIDS-defining Illness, Death, or a Serious Non-AIDS Cardiovascular, Hepatic, or Renal Event

"This outcome included AIDS-defining illnesses or cardiovascular, hepatic, or renal adverse events of particular concern which were evaluated as serious. Serious outcomes were both those defined as serious according to the International Conference on Harmonization (ICH) definition, or outcomes with grades equal to or worse than 3 (Severe). A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates. Cardiovascular events considered were hypertension, congestive heart failure, stroke, Transient Ischemia Event (TIA), pulmonary embolism, myocardial infarction (whether acute symptomatic or silent), coronary artery disease, deep vein thrombosis, peripheral vascular disease, or symptomatic HIV-associated cardiomyopathy. Hepatic events considered were cirrhosis and idiopathic sclerosing cholangitis. Renal events considered were renal insufficiency, acute or chronic." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

Interventionevents per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)0.5
Maternal Health Arm B (Discontinue Triple ARVs)0.9

Maternal Health Component: Other Targeted Medical Conditions

Other (non-cardiologic) medical conditions of particular concern were included in this outcome. A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates. Events included were metabolic events, hepatic events, renal events, infections such as pulmonary tuberculosis, malaria, or other serious bacterial infections, and others. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

Interventionevents per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)4.0
Maternal Health Arm B (Discontinue Triple ARVs)4.6

Maternal Health Component: Toxicity: Incidence of Grade 3 or Greater Laboratory Results or Signs and Symptoms and Selected Grade 2 Hematologic, Renal, and Hepatic Laboratory Results

The maternal safety endpoints summarized include grade 2, 3 or 4 hematologies (hemoglobin (Hb), White Blood Cells (WBC), Absolute Neutrophil Count (ANC), platelet count), chemistries (Alanine Aminotransferase (ALT or SGPT), serum creatinine), and grade 3 or 4 signs and symptoms that occurred post-randomization. These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com). (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

InterventionNew cases per 100 person-years (Number)
Maternal Health Arm A (Continue Triple ARVs)15.3
Maternal Health Arm B (Discontinue Triple ARVs)13.9

Postpartum Component: Incidence of Confirmed Infant HIV Infection

Defined as infant HIV NAT positivity of a specimen drawn at any post-randomization visit (i.e., any visit after the Week 1 [Day 6-14] visit), confirmed by HIV NAT positivity of a second specimen drawn at a different time point. Analyses were conducted at the Mother-Infant (M-I) pair level, hence the worst outcome for multiple births was counted as a single event. (NCT01061151)
Timeframe: Measured through site recommended duration of breastfeeding, complete cessation of breastfeeding or 18 months of age, whichever comes first

InterventionNew cases per 100 person-years (Number)
Postpartum Arm A (Maternal Prophylaxis)0.56
Postpartum Arm B (Infant Prophylaxis)0.55

Postpartum Component: Incidence of Grade 3 or Higher Adverse Events and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events

These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com). (NCT01061151)
Timeframe: Measured through site recommended duration of breastfeeding, complete cessation of breastfeeding or 18 months of age, whichever comes first

InterventionNew cases per 100 person-years (Number)
Postpartum Arm A (Maternal Prophylaxis)14.4
Postpartum Arm B (Infant Prophylaxis)14.1

Postpartum Component: Proportion of Mother-Infant Pairs With no Death or HIV Diagnosis Through 24 Months Post-delivery

Defined as infant HIV NAT positivity of a specimen drawn at any post-randomization visit, confirmed by HIV NAT positivity of a second specimen drawn at a different time point, or infant death. Analyses (Kaplan-Meier probabilities) were conducted at the Mother-Infant (M-I) pair level, hence the worst outcome for multiple births was counted as a single event. (NCT01061151)
Timeframe: Measured through 24 months post-delivery

InterventionProbability (Number)
Postpartum Arm A (Maternal Prophylaxis)0.971
Postpartum Arm B (Infant Prophylaxis)0.977

Antepartum Component: Number of Mothers With Adverse Pregnancy Outcomes (e.g.,Stillbirth, Preterm Delivery (< 37 Weeks), Low Birth Weight (< 2,500 Grams), and Congenital Anomalies)

Composite outcome (NCT01061151)
Timeframe: Measured at birth

InterventionParticipants (Count of Participants)
Period 2
Antepartum Arm C111

Antepartum Component: Number of Mothers With Adverse Pregnancy Outcomes (e.g.,Stillbirth, Preterm Delivery (< 37 Weeks), Low Birth Weight (< 2,500 Grams), and Congenital Anomalies)

Composite outcome (NCT01061151)
Timeframe: Measured at birth

,
InterventionParticipants (Count of Participants)
Periods 1 and 2Period 2
Antepartum Arm A38991
Antepartum Arm B563123

Antepartum Component: Number of Mothers With Grade 3 or Higher Toxicities and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events

These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com). (NCT01061151)
Timeframe: Measured through the Week 1 postpartum study visit

InterventionParticipants (Count of Participants)
Period 2
Antepartum Arm C60

Antepartum Component: Number of Mothers With Grade 3 or Higher Toxicities and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events

These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com). (NCT01061151)
Timeframe: Measured through the Week 1 postpartum study visit

,
InterventionParticipants (Count of Participants)
Periods 1 and 2Period 2
Antepartum Arm A26159
Antepartum Arm B31861

Antepartum Component: Number of Mothers With Obstetrical Complications

"Complications included deaths, diagnoses, signs/symptoms, chemistry lab tests, or hematological lab tests, with grades of 3 (Severe) or worse. Obstetrical complications were those classified by the MedDra coding system as Pregnancy, puerperium and perinatal conditions, except if the condition was the death of the fetus: Abortions not specified as induced or spontaneous, Abortions spontaneous, or Stillbirth and foetal death." (NCT01061151)
Timeframe: Measured through the Week 1 postpartum study visit

InterventionParticipants (Count of Participants)
Period 2
Antepartum Arm C23

Antepartum Component: Number of Mothers With Obstetrical Complications

"Complications included deaths, diagnoses, signs/symptoms, chemistry lab tests, or hematological lab tests, with grades of 3 (Severe) or worse. Obstetrical complications were those classified by the MedDra coding system as Pregnancy, puerperium and perinatal conditions, except if the condition was the death of the fetus: Abortions not specified as induced or spontaneous, Abortions spontaneous, or Stillbirth and foetal death." (NCT01061151)
Timeframe: Measured through the Week 1 postpartum study visit

,
InterventionParticipants (Count of Participants)
Periods 1 and 2Period 2
Antepartum Arm A8920
Antepartum Arm B7512

Antepartum Component: Probability of Overall and HIV-free Infant Survival Until 104 Weeks of Age, by Antepartum Arm (in Conjunction With Infants in the Postpartum Component)

For overall survival, failure was defined to be death. For HIV-free survival, failure was defined to be either death or developing HIV. The probability of living, or living without HIV infection, at 104 weeks was calculated by Kaplan-Meier estimation of the survival function. (NCT01061151)
Timeframe: Measured from birth through 104 weeks of age

InterventionProportional probability (Number)
Overall survival, period 2 groupHIV-free survival, period 2 group
Antepartum Arm C0.9420.921

Antepartum Component: Probability of Overall and HIV-free Infant Survival Until 104 Weeks of Age, by Antepartum Arm (in Conjunction With Infants in the Postpartum Component)

For overall survival, failure was defined to be death. For HIV-free survival, failure was defined to be either death or developing HIV. The probability of living, or living without HIV infection, at 104 weeks was calculated by Kaplan-Meier estimation of the survival function. (NCT01061151)
Timeframe: Measured from birth through 104 weeks of age

,
InterventionProportional probability (Number)
Overall survival, Periods 1 & 2 group (arms A & B only)Overall survival, period 2 groupHIV-free survival, Periods 1&2 group (arms A&B only)HIV-free survival, period 2 group
Antepartum Arm A0.9590.9510.9370.936
Antepartum Arm B0.9670.9820.9470.940

Postpartum Component: Proportion of Infants Alive Through 12 and 24 Months Post-delivery

Analyses (Kaplan-Meier probabilities) conducted for all individual infants (rather than M-I pair) (NCT01061151)
Timeframe: Measured at 12 and 24 months post-delivery

,
InterventionProbability (Number)
12 months post delivery24 months post delivery
Postpartum Arm A (Maternal Prophylaxis)0.9880.978
Postpartum Arm B (Infant Prophylaxis)0.9890.987

Antepartum Component: Maternal HIV RNA Less Than 400 Copies/mL at Delivery

Analysis used the principle of intent to treat. (NCT01061151)
Timeframe: Measured at the time of delivery

InterventionParticipants (Count of Participants)Participants (Count of Participants)
Periods 1 and 272329519Periods 1 and 272329520Period 272329520Period 272329519Period 272329521
HIV RNA < 400 copies/mLHIV RNA >= 400 copies/mL
Antepartum Arm A415
Antepartum Arm B1092
Antepartum Arm A929
Antepartum Arm B275
Antepartum Arm A102
Antepartum Arm B259
Antepartum Arm C225
Antepartum Arm A210
Antepartum Arm B62
Antepartum Arm C79

Postpartum Component: Adherence to the Maternal and/or Infant ARV Regimens, as Measured by Maternal Report and Hair Measures

"Adherence is by maternal report; adherence through hair analysis is not included here.~The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome since adherence was not a focus of the study." (NCT01061151)
Timeframe: Week 6 visit (14 days - 9 weeks postpartum); Week 14 visit (10-19 weeks postpartum); Week 26 visit (20 to 31 weeks postpartum); Week 50 visit (44 to 55 weeks postpartum); and Week 74 visit (68 to 80 weeks postpartum).

InterventionParticipants (Count of Participants)
Week 6 visit72329524Week 6 visit72329525Week 14 visit72329524Week 14 visit72329525Week 26 visit72329524Week 26 visit72329525Week 50 visit72329524Week 50 visit72329525Week 74 visit72329524Week 74 visit72329525
Missed dose over 1 month agoNever missed a doseMissed dose 2-4 weeks agoMissed dose within last 2 weeks
Postpartum Arm A (Maternal Prophylaxis)1003
Postpartum Arm B (Infant Prophylaxis)1104
Postpartum Arm A (Maternal Prophylaxis)12
Postpartum Arm A (Maternal Prophylaxis)17
Postpartum Arm B (Infant Prophylaxis)4
Postpartum Arm A (Maternal Prophylaxis)140
Postpartum Arm B (Infant Prophylaxis)74
Postpartum Arm A (Maternal Prophylaxis)956
Postpartum Arm B (Infant Prophylaxis)1081
Postpartum Arm A (Maternal Prophylaxis)20
Postpartum Arm B (Infant Prophylaxis)0
Postpartum Arm A (Maternal Prophylaxis)35
Postpartum Arm A (Maternal Prophylaxis)112
Postpartum Arm B (Infant Prophylaxis)50
Postpartum Arm A (Maternal Prophylaxis)888
Postpartum Arm B (Infant Prophylaxis)1035
Postpartum Arm A (Maternal Prophylaxis)48
Postpartum Arm A (Maternal Prophylaxis)31
Postpartum Arm B (Infant Prophylaxis)8
Postpartum Arm A (Maternal Prophylaxis)103
Postpartum Arm B (Infant Prophylaxis)47
Postpartum Arm A (Maternal Prophylaxis)716
Postpartum Arm B (Infant Prophylaxis)841
Postpartum Arm A (Maternal Prophylaxis)37
Postpartum Arm A (Maternal Prophylaxis)34
Postpartum Arm B (Infant Prophylaxis)7
Postpartum Arm A (Maternal Prophylaxis)64
Postpartum Arm B (Infant Prophylaxis)30
Postpartum Arm A (Maternal Prophylaxis)311
Postpartum Arm B (Infant Prophylaxis)377
Postpartum Arm A (Maternal Prophylaxis)15
Postpartum Arm B (Infant Prophylaxis)2
Postpartum Arm B (Infant Prophylaxis)1
Postpartum Arm B (Infant Prophylaxis)9

Number of HIV+ Infants

Number of infants with HIV-positive status (NCT00270296)
Timeframe: Throughout study, including breastfeeding, assessed up to 24 months

InterventionInfants (Number)
TZV Arm6
Kaletra Arm1
NVP Arm1

Number of Participants With Virologic Suppression

Suppression of the plasma HIV-1 RNA level to less than 400 copies per milliliter (NCT00270296)
Timeframe: Throughout study, including breastfeeding, assessed up to 24 months

InterventionParticipants (Count of Participants)
TZV Arm274
Kaletra Arm256
NVP Arm160

Number of Participants Who Experienced HIV-related Disease Progression or Death

Worsening to WHO stage III/IV (among subjects who had WHO stage I/II at baseline) and death were the composite secondary endpoint. WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents is an approach for use in resource limited settings in studies of progression to symptomatic HIV disease. There are 4 stages of disease staging, 1 being the least severe and 4 being the most severe disease stage based on the HIV related symptoms and diagnoses. Please refer to the following web page for detailed staging criteria: http://www.who.int/docstore/hiv/scaling/anex1.html (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.

Interventionparticipants (Number)
NVP/NVP6
NVP/LPV_r4
NoNVP/NVP19
NoNVP/LPV_r26

Number of Participants Who Experienced Treatment-related Toxicity That Led to Discontinuation of Randomized Regimen.

The outcome is defined as treatment-related toxicity (as evaluated by sites), regardless of grade, that led to discontinuation of randomized regimen. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.

Interventionparticipants (Number)
NVP/NVP15
NVP/LPV_r0
NoNVP/NVP35
NoNVP/LPV_r0

Number of Participants Who Experienced Virologic Failure or Died.

Virologic failure (VF) is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.

Interventionparticipants (Number)
NVP/NVP32
NVP/LPV_r10
NoNVP/NVP42
NoNVP/LPV_r50

Number of Participants Who Received NVP-containing Regimens at Randomization and Experienced NVP-associated Rash or Grade 2+ Liver Lab Abnormality

Any grade of rash or grade 2+ liver lab abnormality events that were claimed to be NVP associated (definitely, probably, or possibly) by site investigators were evaluated. Grade 2+ liver lab abnormality is defined as aspartate aminotransferase (AST)>=2.6 x ULN or alanine aminotransferase (ALT)>=2.6 x ULN. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP arm. Throughout study for NoNVP/NVP arm.

Interventionparticipants (Number)
NVP/NVP20
NoNVP/NVP51

CD4 Count Change From Randomization

Change was calculated as the CD4 count at Week 48 (or at Week 96) minus the baseline CD4 count (last CD4 before/on treatment start date). For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r. Week 48 and 96.

,,,
Interventioncells/mm^3 (Median)
Week 48 CD4 count change from randomizationWeek 96 CD4 count change from randomization
NoNVP/LPV_r172256
NoNVP/NVP172223
NVP/LPV_r201278
NVP/NVP191291

Percent of Participants Who Experienced Virologic Failure or Died

Results report cumulative percent of participants reaching virologic failure (VF) or death by week 48 and week 96 calculated using the Kaplan-Meier method. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.

,,,
InterventionPercent of participants (Number)
week 48 percent of virologic failure or deathweek 96 percent of virologic failure or death
NoNVP/LPV_r1420
NoNVP/NVP1417
NVP/LPV_r412
NVP/NVP2331

Percent of Participants Who Reported to Never Missed Any of the Study Drug Regimen in the Past Month

Self-reported adherence at week 48 and 96 while participants remained on randomized regimen. Adherence interviews for each antiretroviral drug drug the participant is taking was performed by site personnel every 24 weeks. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.

,,,
Interventionpercent of participants (Number)
week 48 percent of full adherence in past monthweek 96 percent of full adherence in past month
NoNVP/LPV_r8687
NoNVP/NVP9093
NVP/LPV_r8895
NVP/NVP8994

Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study Entry

5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) with median follow-up 72 weeks and range from 0 to 144 weeks.

,
Interventionweeks (Number)
5th percentile10th percentile25th percentile
NVP/LPV_r6084NA
NVP/NVP121260

Time From Randomization to Virologic Failure or Death for Participants Without SD NVP Exposure Prior to Study Entry

5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Throughout study with median follow-up 72 weeks and range from 0 to 180 weeks.

,
Interventionweeks (Number)
5th percentile10th percentile25th percentile
NoNVP/LPV_r1236132
NoNVP/NVP2436NA

Change in CD4 Percent From Entry to Week 48

Change was calculated as CD4 percent at week 48 minus entry CD4 percent (last CD4 percent before randomization date). Only subjects who reached 48 weeks of follow-up before DSMB decisions to unblind each Cohort were included in summary. (NCT00307151)
Timeframe: 48 weeks if before date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)

InterventionPercent of CD4 (Mean)
Coh I: NVP13.9
Coh I: LPV/r12.0
Coh II: NVP15.2
Coh II: LPV/r14.3

Number of Participants Developing New NRTI, NNRTI or PI-resistant Virus

Numbers of participants developing new NRTI, NNRTI or PI-resistant virus after reaching a virologic failure endpoint (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)

Interventionparticipants (Number)
Coh I: NVP16
Coh I: LPV/r1
Coh II: NVP10
Coh II: LPV/r4

Percent of Participants Experiencing Virologic Failure

Virologic failure is defined as a confirmed plasma HIV-1 RNA level that is <1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level >400 copies/mL at 24 weeks OR death on or before 24 weeks. Results report percent of participants reaching a virologic failure endpoint by week 24 calculated using the Kaplan-Meier method. (NCT00307151)
Timeframe: Earlier of 24 weeks or date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)

InterventionPercent of participants (Number)
Coh I: NVP27.4
Coh I: LPV/r10.4
Coh II: NVP28.6
Coh II: LPV/r12.9

Percent of Participants With Treatment Failure, Defined as a Confirmed Virologic Failure or Permanent Discontinuation of the Randomized NNRTI or PI Component of Study Treatment

Treatment failure is defined as a confirmed plasma HIV-1 RNA level that is <1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level >400 copies/mL at 24 weeks OR permanent discontinuation of the randomized NNRTI or PI component of study treatment at or prior to 24 weeks of treatment for any reason including death. Results report percent of participants reaching a treatment failure endpoint by week 24 calculated using the Kaplan-Meier method. (NCT00307151)
Timeframe: Earlier of 24 weeks or date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)

InterventionPercent of participants (Number)
Coh I: NVP39.6
Coh I: LPV/r21.7
Coh II: NVP40.8
Coh II: LPV/r19.3

Time From Randomization to Death

Results report 2nd percentile of time from randomization to death (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)

InterventionWeeks (Number)
Coh I: NVP11
Coh I: LPV/r3
Coh II: NVP2
Coh II: LPV/r83

Time From Randomization to HIV-related Disease Progression or Death

HIV-related disease progression was defined as progression in WHO clinical stage from stage at entry or death. For subjects in WHO Stage IV at entry, disease progression was defined as death. (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)

,,,
InterventionWeeks (Number)
5th percentile10th percentile
Coh I: LPV/r24
Coh I: NVP1117
Coh II: LPV/r35132
Coh II: NVP835

Time From Randomization to Treatment Failure, Defined as Virologic Failure or Permanent Discontinuation of the Randomized NNRTI or PI Component of Study Treatment

Treatment failure is defined as a confirmed plasma HIV-1 RNA level that is <1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level >400 copies/mL at 24 weeks OR a confirmed viral rebound >4000 copies/mL after week 24 OR permanent discontinuation of the randomized NNRTI or PI component of study treatment for any reason including death. (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)

,,,
InterventionWeeks (Number)
10th percentile25th percentile
Coh I: LPV/r436
Coh I: NVP1216
Coh II: LPV/r1436
Coh II: NVP416

Time From Randomization to Virologic Failure

Virologic failure is defined as the earlier of a confirmed plasma HIV-1 RNA level that is <1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level >400 copies/mL at 24 weeks OR a confirmed viral rebound >4000 copies/mL after week 24 OR death. (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)

,,,
InterventionWeeks (Number)
5th percentile10th percentile
Coh I: LPV/r1624
Coh I: NVP1212
Coh II: LPV/r1624
Coh II: NVP1216

Time From Start of Study Treatment to First New Grade >=3 Lab Abnormality, Sign or Symptom Occurring on Study Treatment

Safety events include lab abnormalities, signs or symptoms of grade 3 or higher. Events were graded according to the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events, Version 1.0. Events defined as new if first occurrence was after initiation of study treatment or if severity increased from entry and while on the NNRTI or PI component of study treatment. (NCT00307151)
Timeframe: On randomized NNRTI or PI component of study treatment and until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)

,,,
InterventionWeeks (Number)
10th percentile25th percentile
Coh I: LPV/r836
Coh I: NVP424
Coh II: LPV/r412
Coh II: NVP34

Area Under the Plasma Concentration-Time Curve Over 12 Hours of ETR

Geometric Mean (Standard Deviation) of the area under the plasma concentration-time curve over 12 hours (AUC12h) of ETR. (NCT01504841)
Timeframe: Pre-dose, 1, 2, 4, 6, 9, and 12 hours post-dose measured at intensive PK visit (within 7-10 days after last dose of study drug administration)

Interventionng*h/mL (Geometric Mean)
Cohort I: Treatment Experienced, 2 to 6 Years of Age5512.85
Cohort II: Treatment Experienced, 1 to 2 Years of Age4821.76

Decline in Absolute CD4 Percent of Greater Than 5 Percent Any Time After 12 Weeks of Therapy

Number (%) of participants with a >5% decline in absolute CD4 percent from baseline at weeks 12, 24, and 48, by Cohort, including Clopper-Pearson confidence intervals. (NCT01504841)
Timeframe: Measured at baseline and at Weeks 12, 24, and 48

InterventionParticipants (Count of Participants)
Week 1272045667Week 1272045668Week 2472045667Week 2472045668Week 4872045667Week 4872045668
>5% decline in CD4 % from baselineIncrease or <5% decline in CD4 % from baseline
Cohort I: Treatment Experienced, 2 to 6 Years of Age1
Cohort II: Treatment Experienced, 1 to 2 Years of Age2
Cohort I: Treatment Experienced, 2 to 6 Years of Age10
Cohort II: Treatment Experienced, 1 to 2 Years of Age1
Cohort II: Treatment Experienced, 1 to 2 Years of Age3
Cohort I: Treatment Experienced, 2 to 6 Years of Age2
Cohort I: Treatment Experienced, 2 to 6 Years of Age9

HIV-1 RNA Virologic Failure Status at Weeks 24 and 48

Number (%) of participants with confirmed Virologic Failure, defined as: failure to suppress plasma HIV-1 RNA to fewer than 400 copies/ml and failure to achieve at least a 2-log10 reduction (from baseline) in HIV-1 RNA at Weeks 24 or 48, by Cohort, with Clopper-Pearson confidence intervals. The initial HIV-1 RNA results that met the Virologic Failure definition were each confirmed by a second result obtained within 1 to 4 weeks of the initial result obtained at Week 24 and/or 48. (NCT01504841)
Timeframe: Baseline, Week 24, and Week 48

InterventionParticipants (Count of Participants)
Week 2472045667Week 2472045668Week 4872045667Week 4872045668
Virologic FailureNo Virologic Failure
Cohort I: Treatment Experienced, 2 to 6 Years of Age2
Cohort I: Treatment Experienced, 2 to 6 Years of Age9
Cohort I: Treatment Experienced, 2 to 6 Years of Age3
Cohort II: Treatment Experienced, 1 to 2 Years of Age3
Cohort I: Treatment Experienced, 2 to 6 Years of Age8
Cohort II: Treatment Experienced, 1 to 2 Years of Age1

Area Under the Curve Pharmacokinetic Outcome for LPV/r. (AUC ug*hr/mL)

Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum

Interventionug*hr/mL (Median)
Within 72 Hrs Ppm99.7
At Day 30 PpmNA

Four (4) Hour Concentration Pharmacokinetic Outcome for LPV/r (C4hour ug/mL).

Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum

Interventionug/mL (Median)
Within 72 Hrs Ppm10.78
At Day 30 Ppm12.96

Maximum Concentration Pharmacokinetic Outcome for LPV/r (Cmax ug/mL) .

Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum

Interventionug/mL (Median)
Within 72 Hrs Ppm11.2
At Day 30 PpmNA

Median HIV-1 Viral Load at 24 Weeks Postpartum in Women

(NCT00109590)
Timeframe: at 24 weeks postpartum

Interventionlog10 copies/mL (Median)
Arm A : LPV/r x 7d4.3
Arm B : no LPV/r3.9
Arm C: LPV/r x 30d4.0

Number of Women With Grade >=3 Events After Start of Study Treatment

Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading > the Severity of Adult and Pediatric Adverse Events (December 2004). All grade 3 and higher signs, symptoms, and laboratory toxicities (and events of any grade that led to a change in study treatment) were included. (NCT00109590)
Timeframe: After start of study Treatment (postpartum)

Interventionparticipants (Number)
Arm A : LPV/r x 7d2
Arm B : no LPV/r0
Arm C: LPV/r x 30d2

Pre-dose Concentration Pharmacokinetic Outcome for LPV/r (Cpredose ug/mL).

Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum

Interventionug/mL (Median)
Within 72 Hrs Ppm6.08
At Day 30 Ppm9.17

Resistance Mutations in HIV Infected Infants

Resistance mutations as identified by consensus sequencing or OLA (NCT00109590)
Timeframe: 24 weeks postpartum

Interventionparticipants (Number)
Arm B : no LPV/r0
Arm C: LPV/r x 30d0

The Proportion of Women in Each Randomized Arm Who Have One or More New NVP Resistance Mutations as Identified by Consensus Sequencing or Oligonucleotide Ligation Assay (OLA) in Plasma

The incidence of new NVP resistance mutations at day 10 or week 6 postpartum in each randomized arm. Samples with viral load <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: at Day 10 or Week 6 postpartum.

Interventionpercent of participants (Number)
Arm A : LPV/r x 7d3.6
Arm B : no LPV/r7.1
Arm C : LPV/r x 30d5.3

The Proportion of Women in Each Randomized Arm Who Have One or More New NVP Resistance Mutations for the Subgroup of Women With Plasma HIV RNA >= 500 Copies/ml At Entry

The incidence of new NVP resistance mutations at day 10 or week 6 postpartum in each randomized arm. Samples with viral load <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: at Day 10 or Week 6 postpartum.

Interventionpercent of participants (Number)
Arm A: LPV/r x 7d4.9
Arm B: no LPV/r9.5
Arm C : LPV/r x 30d7.0

The Proportion of Women Who Develop One or More New NVP Resistance Mutations as Identified by Consensus Sequencing or Oligonucleotide Ligation Assay in Plasma (Sampling Was Done at Days 10,21,30, and Weeks 5,6, and 8 Postpartum).

The incidence of new NVP resistance mutation in plasma HIV within 8 weeks postpartum in each randomized arm was estimated using an exact binomial confidence interval. If a resistance mutation was detected at any of the timepoints then an endpoint was met. Samples with VL <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml (e.g.missed visit), it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: within 8 weeks postpartum.

Interventionpercent of participants (Number)
Arm A : LPV/r x 7d7.1
Arm B : no LPV/r12.5
Arm C: LPV/r x 30d5.3

Proportion of Women With New NVP Resistance Mutation Within 8 Weeks Postpartum Who Had a NVP Resistance Mutation Detected at 72 Weeks Postpartum.

Resistance mutations as identified by OLA in plasma samples or PBMC at 72 weeks postpartum amongst women who had new NVP resistance mutations within 8 weeks postpatrum. These results were based on the 13 women who developed a new NVP resistance mutation in the first 8 weeks postpartum. For the primary outcome measure 1, one particpant in arm A was unavailable for follow-up after week 5 and was conservatively imputed to have developed resistance mutation. (NCT00109590)
Timeframe: within 72 weeks postpartum

,,
Interventionparticipants (Number)
OLA in plasma samplesOLA in PBMC
Arm A : LPV/r x 7d00
Arm B : no LPV/r00
Arm C: LPV/r x 30d01

The Proportion of Women With Any New ZDV, ddI, or LPV/r Resistance Mutations.

(NCT00109590)
Timeframe: At Week 5 postpartum (ZDV) and at the first timepoint with viral load >=500 copies/ml after treatment discontinuation (ddI and LPV/r).

,,
Interventionpercent of participants (Number)
The proportion of women with new ZDV resistanceThe proportion of women with new ddI resistanceThe proportion of women with new LPV/r resistance
Arm A : LPV/r x 7d000
Arm B : no LPV/r1.7800
Arm C: LPV/r x 30d000

Mean Change in HIV-1 Levels in Plasma Between 34 and 38 Weeks Gestation

Calculated as log10 plasma viral load at 34 weeks gestation - log10 plasma viral load at 38 weeks gestation (NCT00530777)
Timeframe: 4 weeks

Interventionlog10 copies/mL (Mean)
Valacyclovir-0.53
Placebo0.03

Vertical HIV-1 Transmission

Mother-to-child HIV transmission (NCT00530777)
Timeframe: 1 year postpartum

InterventionParticipants (Number)
Valacyclovir6
Placebo4

Infant HIV Infection Status

Intrapartum HIV infection at 3 Months (NCT00099359)
Timeframe: 3 months

Interventionparticipants (Number)
ARM A (ZDV - Standard of Care)24
ARM B (ZDV + NVP)11
ARM C (ZDV +3TC+NFV)12

Infant HIV-1 Infection Status

In utero HIV-1 infection rate (NCT00099359)
Timeframe: birth

Interventionparticipants (Number)
Arm A (ZDV Only)37
ARM B (ZDV + NVP)28
ARM C (ZDV + 3TC + NFV)28

Participant Deaths

(NCT00099359)
Timeframe: through age 6 months

Interventionparticipants (Number)
Arm A (ZDV Only)11
ARM B (ZDV + NVP)15
ARM C (ZDV + 3TC + NFV)17

Participants With Serious Adverse Events

Serious Adverse Events by System Organ Class=Blood and lymphatic system disorders (NCT00099359)
Timeframe: through age 6 months.

Interventionparticipants (Number)
ARM A (ZDV Only)86
ARM B (ZDV + NVP)59
ARM C (ZDV + 3TC/NFV)110

3TC and NFV Pharmacokinetics

Descriptive study of 3TC and NFV pharmacokinetics during first two weeks of life using weight band dosing regimen in a subset of enrolled infants. (NCT00099359)
Timeframe: through age 14 days

Interventionug*h/mL (Median)
(NFV-AUC-12h) 4-7 day(NFV-AUC-12h) 10-14 day(3TC-AUC-12 h) 4-7 day(3TC-AUC-12h) 10-14 day
ARM C (ZDV + 3TC/NFV)20.725.54.07.9

NVP Pharmacokinetics

Descriptive study of NVP pharmacokinetics during first two weeks of life using weight band dosing in a subset of enrolled infants. (NCT00099359)
Timeframe: 14 days

Interventionng/mL (Median)
NVP conc prior to 3rd doseNVP peak conc (Cmax) post 3rd doseNVP conc 3-5 day post 3rd doseNVP conc 7 day post 3rd dose
ARM B (ZDV + NVP)362228645976

Risk Factors for Perinatal HIV-1 Transmission

Risk factors to be assessed include maternal HIV-1 RNA levels at delivery, maternal syphilis and other infections, obstetrical factors such as duration of membrane rupture, and adherence to neonatal medication. (NCT00099359)
Timeframe: through age 3 months

,
Interventionparticipants (Number)
Treatment Arm C (ZDV+3TC/NFV)Treatment Arm B (ZDV+NFV)Treatment Arm A (ZDV only)Illegal Substance Abuse during pregnancy
Infected1211247
Uninfected516523505130

AUC24 for Cohort 1 RAL Dose #1 (Within 48 Hours of Birth)

Area Under the Concentration-time Curve at 24-hour interval (AUC24) based on intensive PK sampling around Cohort 1 RAL dose #1 (within 48 hours of birth) (NCT01780831)
Timeframe: Cohort 1 RAL dose #1 (within 48 hours of birth) intensive PK sampling: within 30 min pre-dose; and 1-2, 4-8, 12 (±1), 24 (±1) hours post-dose.

Interventionmg*h/L (Geometric Mean)
Cohort 1 RAL-naive: 3 mg/kg for First Dose53.88
Cohort 1 RAL-naive: 2 mg/kg for First Dose44.26
Cohort 1 RAL-exposed 1.5 mg/kg37.42

AUC24 for Cohort 2 Initial RAL Dose (Within 48 and 12-60 Hours of Birth for RAL-naive and RAL-exposed Groups, Respectively)

Area Under the Concentration-time Curve at the 24-hour interval (AUC24) for Cohort 2 initial RAL dose (within 48 and between 12-60 hours of birth for RAL-naive and RAL-exposed, respectively). (NCT01780831)
Timeframe: Cohort 2 initial dose (within 48 and between 12-60 hours of birth for RAL-naive and RAL-exposed, respectively) intensive PK sampling: within 1 hour pre-dose; and 1-2, 6-10, 20-24 hours post-dose.

Interventionmg*h/L (Geometric Mean)
Cohort 2 RAL-naive: 1.5 mg/kg Once Daily on Days 1-7 of Life38.2
Cohort 2 RAL-exposed: 1.5mg/kg Once Daily on Days 1-7 of Life42.89

Clast for Cohort 2 Initial RAL Dose (Within 48 and Between 12-60 Hours of Birth for RAL-naïve and RAL-exposed Groups, Respectively)

Last concentration of the drug (Clast) at 24 hour interval post dosing for the Cohort 2 initial RAL dose (within 48 and at 12-60 hours of birth for RAL-naive and RAL-exposed, respectively). This is the plasma RAL concentration from a sample collected at or close to 24 hours post dose. (NCT01780831)
Timeframe: Cohort 2 initial dose (within 48 and between 12-60 hours of birth for RAL-naive and RAL-exposed groups, respectively) intensive PK sampling: within 1 hour pre-dose; and 1-2, 6-10, 20-24 hours post-dose.

Interventionng/mL (Geometric Mean)
Cohort 2 RAL-naive: 1.5 mg/kg Once Daily on Days 1-7 of Life947.90
Cohort 2 RAL-exposed: 1.5 mg/kg Once Daily on Days 1-7 of Life946.24

Cmax for Cohort 1 RAL Dose #1 (Within 48 Hours of Birth)

Maximum concentration (Cmax) for Cohort 1 dose #1 (within 48 hours of birth) (NCT01780831)
Timeframe: Cohort 1 dose #1(within 48 hours of birth) intensive PK sampling: within 30 min pre-dose; and 1-2, 4-8, 12 (±1), 24 (±1) hours post-dose.

Interventionng/mL (Geometric Mean)
Cohort 1 RAL-naive: 3 mg/kg for First Dose3360.89
Cohort 1 RAL-naive: 2 mg/kg for First Dose3405.24
Cohort 1 RAL-exposed: 1.5 mg/kg for First Dose2188.82

Cohort 1 Dose #1 Neonatal RAL Elimination (CL/F) by UGT1A1 Genotype Group

Cohort 1 Dose #1 neonatal RAL elimination was represented by Clearance (CL/F), which is the volume of plasma cleared of the drug per unit time. Genotyping for polymorphisms of UGT1A1 were performed on infants who were eligible for PK sampling and were consented by their mothers/guardians (i.e. genotyping was optional) . (NCT01780831)
Timeframe: Cohort 1 Dose #1 Intensive PK sampling: within 30 min pre-dose; and 1-2, 4-8, 12, 24 hours post-dose. Samples for UGT1A1 genotype testing were collected at study entry.

InterventionL/hr (Median)
(TA)6(TA)60.11
(TA)6(TA)70.06

Cohort 2 Initial Dose Neonatal RAL Elimination (CL/F) by UGT1A1 Genotype Group

Cohort 2 initial dose neonatal RAL elimination was represented by Clearance (CL/F), which is defined as the volume of plasma cleared of the drug per unit time. Genotyping for polymorphisms of UGT1A1 were performed on infants who were eligible for PK sampling and were consented by their mothers/guardians (i.e. genotyping was optional) . (NCT01780831)
Timeframe: Intensive PK sampling for Cohort 2 initial dose: within 1 hour pre-dose; and 1-2, 6-10, 20-24 hours post-dose. Samples for UGT1A1 genotype testing were collected at study entry.

InterventionL/hr (Median)
(TA)6(TA)6 Wildtype0.1
Mutation0.1

Cohort 2 Neonatal RAL Elimination (CL/F) at 15-18 Days of Life by UGT1A1 Genotype Group

Cohort 2 15-18 days of life dose neonatal RAL elimination was represented by Clearance (CL/F), which is defined as the volume of plasma cleared of the drug per unit time at 15-18 days of life when RAL dosing would have been 3 mg/kg twice daily. Genotyping for polymorphisms of UGT1A1 were performed on infants who were eligible for PK sampling and were consented by their mothers/guardians(i.e. genotyping was optional) . (NCT01780831)
Timeframe: Intensive PK sampling for Cohort 2 at 15-18 days of life: within 1 hour pre-dose; and 1-2 hours post-dose, 4-6, 8-12 hours post-dose. Samples for UGT1A1 genotype testing were collected at study entry.

InterventionL/hr (Median)
(TA)6(TA)6 Wildtype0.5
Mutation0.5

Number of Infants Who Died or Had Grade 3/4 Adverse Event Through 24 Weeks of Life

Number of infants who died or had adverse events (AEs) of Grade 3 or 4 as defined in DAIDS AE Grading Table. Events with onset dates prior to first RAL dosing and congenital anomalies assessed as baseline by the study team were considered baseline events and not AEs. (NCT01780831)
Timeframe: From first RAL dose through 24 weeks of life

InterventionParticipants (Count of Participants)
Cohort 1 RAL-naive2
Cohort 1 RAL-exposed2
Cohort 1 Total4
Cohort 2 RAL-naive11
Cohort 2 RAL-exposed4
Cohort 2 Total15

Number of Infants Who Died or Had Grade 3/4 Adverse Event Through 6 Weeks of Life

Number of infants who died or had adverse events (AEs) of Grade 3 or 4 as defined in DAIDS AE Grading Table. Events with onset dates prior to first RAL dosing and congenital anomalies assessed as baseline by the study team were considered baseline events and not AEs. (NCT01780831)
Timeframe: From first dosing of RAL through 6 weeks of life

InterventionParticipants (Count of Participants)
Cohort 1 RAL-naive2
Cohort 1 RAL-exposed2
Cohort 1 Total4
Cohort 2 RAL-naive7
Cohort 2 RAL-exposed4
Cohort 2 Total11

Number of Infants Who Died or Had SADR of Grade 3 or 4 Through 24 Weeks of Life

"Number of infants who died or had Suspected Adverse Drug Reaction (SADR) of Grade 3 or 4 as defined in DAIDS AE Grading Table.~Events with onset dates prior to the first RAL dosing and congenital anomalies assessed as baseline by the study team were considered baseline events and not AEs. SADRs are AEs assessed as definitely related, probably related or possibly related to RAL." (NCT01780831)
Timeframe: From first RAL dose through 24 weeks of life

InterventionParticipants (Count of Participants)
Cohort 1 RAL-naive1
Cohort 1 RAL-exposed0
Cohort 1 Total1
Cohort 2 RAL-naive0
Cohort 2 RAL-exposed0
Cohort 2 Total0

Number of Infants Who Died or Had SADR of Grade 3 or 4 Through 6 Weeks of Life

"Number of infants who died or had Suspected Adverse Drug Reaction (SADR) of Grade 3 or 4 as defined in DAIDS AE Grading Table.~Events with onset dates prior to the first RAL dosing and congenital anomalies assessed as baseline by the study team were considered baseline events and not AEs. SADRs are AEs assessed as definitely related, probably related or possibly related to RAL." (NCT01780831)
Timeframe: From first RAL dose through 6 weeks of life

InterventionParticipants (Count of Participants)
Cohort 1 RAL-naive1
Cohort 1 RAL-exposed0
Cohort 1 Total1
Cohort 2 RAL-naive0
Cohort 2 RAL-exposed0
Cohort 2 Total0

RAL AUC12 for Cohort 2 at 15-18 Days of Life

Area Under the Concentration-time Curve at 12-hour interval (AUC12) of RAL for Cohort 2 at 15-18 days of life. (NCT01780831)
Timeframe: Intensive PK sampling for Cohort 2 at 15-18 days of life: within 1 hour pre-dose; and 1-2, 4-6, 8-12 hours post-dose.

Interventionmg*h/L (Geometric Mean)
Cohort 2 RAL-naive: 3 mg/kg Twice Daily on Days 8-18 of Life14.3
Cohort 2 RAL-exposed: 3 mg/kg Twice Daily on Days 8-28 of Life18.25

RAL C12 for Cohort 2 at 15-18 Days of Life

RAL concentration at 12 hours (C12) for Cohort 2 at 15-18 days of life. (NCT01780831)
Timeframe: Intensive PK sampling for Cohort 2 at 15-18 days of life: within 1 hour pre-dose; and 1-2, 4-6, 8-12 hours post-dose.

Interventionmg*h/L (Geometric Mean)
Cohort 2 RAL-naive: 3 mg/kg Twice Daily on Days 8-28 of Life176.11
Cohort 2 RAL-exposed: 3 mg/kg Twice Daily on Days 8-28 of Life273.59

Number of Participants Who Discontinued Study Treatment Prematurely

participants assigned to 7-day treatment arm and 21-day treatment arm were supposed to stay in study treatment for 7 days and 21 days respectively. (NCT00099632)
Timeframe: From first day of study treatment to last day of study treatment (up to 21 days)

Interventionparticipants (Number)
7-day Lamivudine/Zidovudine (3TC/ZDV)0
21-day Lamivudine/Zidovudine (3TC/ZDV)2
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)0
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)0
7-day Lopinavir/Ritonavir (LPV/r)0
21-day Lopinavir/Ritonavir (LPV/r)5

Number of Participants With New Circulating Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant Variants as Detected by Standard Composite (Bulk) Genotyping

"For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed to the primary endpoint; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed to primary endpoint.~10 participants who did not have resistance samples available were excluded from the primary endpoint analysis." (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment

Interventionparticipants (Number)
7-day Lamivudine/Zidovudine (3TC/ZDV)1
21-day Lamivudine/Zidovudine (3TC/ZDV)0
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)0
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)0
7-day Lopinavir/Ritonavir (LPV/r)3
21-day Lopinavir/Ritonavir (LPV/r)1

Number of Participants With New Circulating NRTI-resistant Variants Detected by Standard Composite (Bulk) Genotyping.

For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed. (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment

Interventionparticipants (Number)
7-day Lamivudine/Zidovudine (3TC/ZDV)0
21-day Lamivudine/Zidovudine (3TC/ZDV)1
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)1
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)1
7-day Lopinavir/Ritonavir (LPV/r)1
21-day Lopinavir/Ritonavir (LPV/r)0

Number of Participants With New PI-resistant Variants as Detected by Standard Composite (Bulk) Genotyping.

For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed. (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment

Interventionparticipants (Number)
7-day Lamivudine/Zidovudine (3TC/ZDV)0
21-day Lamivudine/Zidovudine (3TC/ZDV)0
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)0
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)0
7-day Lopinavir/Ritonavir (LPV/r)0
21-day Lopinavir/Ritonavir (LPV/r)0

Severe (Grade 3) and Higher Adverse Events and Any Grade Adverse Event That Leads to a Treatment Change From First Day of Study Treatment to Week 12

"Grade 3 or higher signs and symptoms, laboratory abnormalities, events that are reported through the EAE system, and any grade event that leads to a treatment change from first day of study treatment to week 12.~Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death" (NCT00099632)
Timeframe: From first day of study treatment to week 12

Interventionparticipants (Number)
7-day Lamivudine/Zidovudine (3TC/ZDV)5
21-day Lamivudine/Zidovudine (3TC/ZDV)1
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)1
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)0
7-day Lopinavir/Ritonavir (LPV/r)2
21-day Lopinavir/Ritonavir (LPV/r)2

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs

Infant plasma concentrations were collected and measured during the first 9 days of life. Half-life is defined as 0.693/k, where k, the elimination rate constant, is the slope of the decline in concentrations. (NCT00042289)
Timeframe: Infant plasma samples at 2-10, 18-28, 36-72 hours and 5-9 days after birth.

Interventionhour (Median)
DTG 50mg q.d.32.8
EVG/COBI 150/150mg q.d.7.6
DRV/COBI 800/150 mg q.d.NA
EFV 600 mg q.d. (Outside THA)65.6

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs

Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.

Interventionunitless (Median)
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.0.15
DTG 50mg q.d.1.25
EVG/COBI 150/150mg q.d.0.91
DRV/COBI 800/150 mg q.d.0.07
ATV/COBI 300/150 mg q.d.0.07
TFV 300mg q.d.0.88

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs

Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. For arms with zero overall participants analyzed, samples were below the limit of quantification and ratios could not be calculated. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.

Interventionunitless (Median)
TAF 10mg q.d. w/COBI0.97
EFV 600 mg q.d. (Outside THA)0.67
EFV 600mg q.d.0.49
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.0.2
RAL 400mg b.i.d.1.5
ETR 200mg b.i.d.0.52
MVC 150 or 300mg b.i.d.0.33
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.0.14
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.0.16
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.0.19
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)0.12
RPV 25mg q.d.0.55
ATV/RTV 300/100mg q.d. or TFV/ATV/RTV 300/300/100mg q.d.0.18
DRV/RTV 800/100mg q.d. or DRV/RTV 600/100mg b.i.d.0.18

Plasma Concentration for Contraceptives

Serum concentrations of the contraceptives. Note that no historical controls were provided by team pharmacologists and thus no comparisons were done for contraceptive concentrations in women using hormonal contraceptives and selected ARV drugs as compared to historical controls not using those ARV drugs. (NCT00042289)
Timeframe: Measured at 6-7 weeks after contraceptive initiation postpartum

Interventionpg/mL (Median)
ATV/RTV/TFV 300/100/300mg q.d. With ENG604
LPV/RTV 400/100 b.i.d. With ENG428
EFV 600mg q.d. With ENG125

Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12h (area-under-the-curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8 and 12 hours post dosing.

Interventionmcg*hr/mL (Median)
Before contraceptive initiationAfter contraceptive initiation
LPV/RTV 400/100 b.i.d. With ENG115.97100.20

Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8, 12, and 24 hours post dosing.

,
Interventionmcg*hr/mL (Median)
Before contraceptive initiationAfter contraceptive initiation
ATV/RTV/TFV 300/100/300mg q.d. With ENG53.9655.25
EFV 600mg q.d. With ENG53.6456.65

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.

,
InterventionParticipants (Count of Participants)
3rd TrimesterPostpartum
EFV 600mg q.d.2021
MVC 150 or 300mg b.i.d.87

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.

,,,,,,,,,,,,,,,,,,,,,,
InterventionParticipants (Count of Participants)
2nd Trimester3rd TrimesterPostpartum
ATV/RTV Arm 1: 300/100mg q.d.11212
DRV/COBI 800/150 mg q.d.3414
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.71622
DRV/RTV 600/100mg b.i.d.71922
DRV/RTV 800/100mg q.d.91922
DTG 50mg q.d.92023
EFV 600 mg q.d. (Outside THA)123334
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.82927
ETR 200mg b.i.d.5137
EVG/COBI 150/150mg q.d.81018
FPV/RTV 700/100mg b.i.d.82622
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)101926
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.93027
ATV/COBI 300/150 mg q.d.125
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA1514
RAL 400mg b.i.d.113330
RPV 25mg q.d.142625
TAF 10mg q.d. w/COBI152322
TAF 25mg q.d.132324
TAF 25mg q.d. w/COBI or RTV Boosting102418
TFV 300mg q.d.22727
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.11112
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.72332

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs

Infant plasma concentrations were collected and measured during the first 9 days of life. (NCT00042289)
Timeframe: Blood samples were collected at 2-10, 18-28, 36-72 hours and 5-9 days after birth.

,,,
Interventionmcg/mL (Median)
2-10 hours after birth18-28 hours after birth36-72 hours after birth5-9 days after birth
DRV/COBI 800/150 mg q.d.0.351.431.871.72
DTG 50mg q.d.1.731.531.000.06
EFV 600 mg q.d. (Outside THA)1.11.00.90.4
EVG/COBI 150/150mg q.d.0.1320.0320.0050.005

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs

Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

Interventionng*hour/mL (Geometric Mean)
2nd Trimester3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.NA27173645

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.55.151.879.6
DRV/RTV 600/100mg b.i.d.45.845.961.7
FPV/RTV 700/100mg b.i.d.43.5032.1551.60
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA34.233.5

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.4.58.35.3
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)14.916.127.1
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.7296133
RAL 400mg b.i.d.6.65.411.6

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24 (area under the curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

,,,,,,,,,,,,,
Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.25.3318.8536.20
ATV/RTV Arm 1: 300/100mg q.d.88.241.957.9
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.30.645.748.8
DRV/COBI 800/150 mg q.d.50.0042.0595.55
DRV/RTV 800/100mg q.d.64.663.5103.9
DTG 50mg q.d.47.649.265.0
EFV 600 mg q.d. (Outside THA)47.3060.0262.70
EVG/COBI 150/150mg q.d.15.314.021.0
TAF 10mg q.d. w/COBI0.1970.2060.216
TAF 25mg q.d.0.1710.2120.271
TAF 25mg q.d. w/COBI or RTV Boosting0.1810.2570.283
TFV 300mg q.d.1.92.43.0
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.14.528.839.6
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.26.237.758.7

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

Interventionmg*hour/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.55.458.3

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.

Interventionmg*hour/L (Median)
2nd Trimester3rd TrimesterPostpartum
RPV 25mg q.d.1.9691.6692.387

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

Interventionmg/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.5.445.10

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,,,,,,,,,,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.2.822.203.90
ATV/RTV Arm 1: 300/100mg q.d.NA3.64.1
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.3.114.514.52
DRV/COBI 800/150 mg q.d.4.593.677.04
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.6.226.558.96
DRV/RTV 600/100mg b.i.d.5.645.537.78
DRV/RTV 800/100mg q.d.6.775.788.11
DTG 50mg q.d.3.623.544.85
EFV 600 mg q.d. (Outside THA)3.875.134.41
FPV/RTV 700/100mg b.i.d.5.615.126.75
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)3.893.625.37
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA5.15.0
TFV 300mg q.d.0.2500.2450.298
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.1.22.54.1
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.2.733.565.43

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.0.701.010.63
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.8.410.714.6
RAL 400mg b.i.d.2.2501.7703.035
RPV 25mg q.d.0.1450.1340.134

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

Interventionng/mL (Median)
3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.448647

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.

,,,
Interventionng/mL (Median)
2nd Trimester3rd TrimesterPostpartum
EVG/COBI 150/150mg q.d.1447.11432.81713.1
TAF 10mg q.d. w/COBI80.491.298.2
TAF 25mg q.d.69.796133
TAF 25mg q.d. w/COBI or RTV Boosting87.8107141

PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

Interventionng/mL (Geometric Mean)
3rd TrimesterPostpartum
MVC 150 or 300mg b.i.d.108128

PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.2.842.524.51
DRV/RTV 600/100mg b.i.d.2.122.222.51
FPV/RTV 700/100mg b.i.d.2.121.642.87
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.NA0.470.52

PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.

,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ETR 200mg b.i.d.0.360.480.38
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)0.130.130.28
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.3.75.17.2
RAL 400mg b.i.d.0.06210.0640.0797

PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs

"Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose.~For the TAF 25 mg q.d., 10 mg q.d. w/COBI, and 25 mg q.d. w/COBI or RTV boosting arms, samples were all below the limit of quantification and statistical analyses were not conducted." (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

,,,,,,,,,,,,,
Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
ATV/COBI 300/150 mg q.d.0.210.210.61
ATV/RTV Arm 1: 300/100mg q.d.2.00.71.2
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.0.490.710.90
DRV/COBI 800/150 mg q.d.0.330.271.43
DRV/RTV 800/100mg q.d.0.991.172.78
DTG 50mg q.d.0.730.931.28
EFV 600 mg q.d. (Outside THA)1.491.481.94
EVG/COBI 150/150mg q.d.0.02580.04870.3771
TAF 10mg q.d. w/COBI0.001950.001950.00195
TAF 25mg q.d.0.001950.001950.00195
TAF 25mg q.d. w/COBI or RTV Boosting0.001950.001950.00195
TFV 300mg q.d.0.0390.0540.061
TFV/ATV/RTV Arm 1: 300/300/100mg q.d.0.30.50.8
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.0.440.571.26

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

Interventionmg/L (Median)
3rd TrimesterPostpartum
EFV 600mg q.d.1.602.05

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.

Interventionmg/L (Median)
2nd Trimester3rd TrimesterPostpartum
RPV 25mg q.d.0.0630.0560.081

Reviews

51 reviews available for nevirapine and Pregnancy

ArticleYear
Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines.
    Journal of the International AIDS Society, 2017, 05-11, Volume: 20, Issue:1

    Topics: Adult; Alkynes; Benzoxazines; Contraception; Contraceptive Agents; Counseling; Cyclopropanes; Drug I

2017
Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs.
    PloS one, 2018, Volume: 13, Issue:6

    Topics: Abnormalities, Drug-Induced; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Congenital Abnormalities

2018
Drug interactions between antiretrovirals and hormonal contraceptives.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:5

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Drug Interactio

2013
HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission.
    Current HIV research, 2013, Volume: 11, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Aptamers, Nucleotide; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; D

2013
Prevention of perinatal HIV I transmission by protease inhibitor based triple drug antiretroviral therapy versus nevirapine as single dose at the time of delivery.
    The Journal of the Association of Physicians of India, 2012, Volume: 60

    Topics: Anti-HIV Agents; Delivery, Obstetric; Drug Therapy, Combination; Female; HIV Infections; HIV Proteas

2012
Antiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi baby.
    Expert review of anti-infective therapy, 2014, Volume: 12, Issue:3

    Topics: Age Factors; Anti-HIV Agents; Clinical Protocols; Female; HIV Infections; Humans; Infant; Infant, Ne

2014
Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Jun-01, Volume: 60 Suppl 3

    Topics: Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Dideoxynucleosides; Drug Combinations; Fem

2015
Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study.
    The lancet. HIV, 2015, Volume: 2, Issue:11

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents; Cyclopropanes; Drug

2015
Efavirenz-based antiretroviral therapy versus nevirapine-including regimens for prevention of mother-to-child transmission of HIV option B plus in resource-limited settings: is there anything missing?
    Expert review of anti-infective therapy, 2016, Volume: 14, Issue:1

    Topics: Adult; Africa South of the Sahara; Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; D

2016
Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.
    Drug safety, 2009, Volume: 32, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur

2009
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
    HIV medicine, 2009, Volume: 10, Issue:7

    Topics: Adenine; Adult; Africa South of the Sahara; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly

2009
Optimal versus suboptimal treatment for HIV-infected pregnant women and HIV-exposed infants in clinical research studies.
    Journal of acquired immune deficiency syndromes (1999), 2009, Aug-15, Volume: 51, Issue:5

    Topics: Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Drug Resistance, Viral; Female; HIV

2009
[Highly efficient chemoprophylaxis of perinatal transmission of HIV 1 infection in HIV-infected pregnant women].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2009, Volume: 54, Issue:3-4

    Topics: Animals; Anti-HIV Agents; Azides; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant,

2009
Integrating prevention of mother-to-child HIV transmission (PMTCT) programmes with other health services for preventing HIV infection and improving HIV outcomes in developing countries.
    The Cochrane database of systematic reviews, 2011, Jun-15, Issue:6

    Topics: Anti-HIV Agents; Developing Countries; Female; HIV Infections; Humans; Infectious Disease Transmissi

2011
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    The Cochrane database of systematic reviews, 2011, Jul-06, Issue:7

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudi

2011
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
    Antiviral therapy, 2011, Volume: 16, Issue:8

    Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fet

2011
Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2012, Oct-08, Volume: 102, Issue:11 Pt 1

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Contraindications; Female; HIV Infections; Humans; Nevirapine

2012
Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis.
    AIDS (London, England), 2013, Apr-24, Volume: 27, Issue:7

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Seropositivity; Humans; Nevirapine; Pregna

2013
Mother to child transmission of HIV.
    Clinical evidence, 2002, Issue:7

    Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Combined Modality Therapy; Female; HIV Infections

2002
Mother to child transmission of HIV.
    Clinical evidence, 2002, Issue:8

    Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Combined Modality Therapy; Female; HIV Infections

2002
HIV: mother to child transmission.
    Clinical evidence, 2003, Issue:9

    Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Drug Therapy, Combination; Female; HIV Infections

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Prevention of mother-to-child transmission of HIV--what next?
    Journal of acquired immune deficiency syndromes (1999), 2003, Volume: 34 Suppl 1

    Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec

2003
Issues in antiretroviral toxicity.
    The AIDS reader, 2003, Volume: 13, Issue:10

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Exanthema; Female; HIV

2003
Nevirapine to prevent mother-to-child transmission of HIV-1 among women of unknown serostatus.
    Lancet (London, England), 2003, Nov-29, Volume: 362, Issue:9398

    Topics: Africa; AIDS Serodiagnosis; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infectious Disea

2003
Preventing neonatal HIV: a review.
    Current HIV research, 2003, Volume: 1, Issue:3

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious

2003
The safety of antiretroviral drugs in pregnancy.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and

2005
The safety of antiretroviral drugs in pregnancy.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and

2005
The safety of antiretroviral drugs in pregnancy.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and

2005
The safety of antiretroviral drugs in pregnancy.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and

2005
Nevirapine toxicity--implications for management of South African patients.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2005, Volume: 95, Issue:4

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; HIV-1; Humans; Infectious Disease

2005
Preventing mother-to-child transmission of HIV: successes and challenges.
    BJOG : an international journal of obstetrics and gynaecology, 2005, Volume: 112, Issue:9

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Drug Resistance, Viral; Fema

2005
HIV: mother to child transmission.
    Clinical evidence, 2005, Issue:13

    Topics: Administration, Intravaginal; Anti-HIV Agents; Breast Feeding; Cesarean Section; Female; HIV Infecti

2005
Sex differences in antiretroviral therapy-associated intolerance and adverse events.
    Drug safety, 2005, Volume: 28, Issue:12

    Topics: Acidosis, Lactic; Anti-Retroviral Agents; Didanosine; Exanthema; Female; HIV Infections; Humans; Liv

2005
Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:6

    Topics: Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Dis

2006
Nevirapine toxicity.
    International journal of STD & AIDS, 2006, Volume: 17, Issue:6

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Liver; Nevirapine; Pregnancy; Pregnancy Complicatio

2006
Evidence behind the WHO guidelines: hospital care for children: what antiretroviral agents and regimens are effective in the prevention of mother-to-child transmission of HIV?
    Journal of tropical pediatrics, 2006, Volume: 52, Issue:4

    Topics: Anti-HIV Agents; Breast Feeding; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; I

2006
Antiretroviral therapy for prevention of mother-to-child HIV transmission : focus on single-dose nevirapine.
    Clinical drug investigation, 2006, Volume: 26, Issue:11

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant, Newborn; Infectious

2006
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    The Cochrane database of systematic reviews, 2007, Jan-24, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi

2007
Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.
    Journal of clinical pharmacy and therapeutics, 2007, Volume: 32, Issue:3

    Topics: Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Child; Female; HIV Infectio

2007
Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.
    International journal of epidemiology, 2007, Volume: 36, Issue:5

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1

2007
International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update.
    American journal of obstetrics and gynecology, 2007, Volume: 197, Issue:3 Suppl

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Breast Feeding; Clinical Trials as Topic; Drug Administrati

2007
Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter?
    American journal of obstetrics and gynecology, 2007, Volume: 197, Issue:3 Suppl

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Drug Resistance; Female; HIV Infections; Humans; Infectious

2007
Antiretroviral (ARV) drug resistance in the developing world.
    Evidence report/technology assessment, 2007, Issue:156

    Topics: Africa; Anti-HIV Agents; Asia; Child; Developing Countries; Drug Resistance, Viral; Female; HIV; HIV

2007
Antiretrovirals.
    Mayo Clinic proceedings, 1999, Volume: 74, Issue:12

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; D

1999
[New therapy reduces AIDS passed to fetuses and costs less].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2000, Volume: 120, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Developing Countries; Female; Health Care Costs

2000
Update on preventing vertical transmission of HIV type 1.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2000, Sep-01, Volume: 57, Issue:17

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female;

2000
Nevirapine: pharmacokinetic considerations in children and pregnant women.
    Clinical pharmacokinetics, 2000, Volume: 39, Issue:4

    Topics: Adult; Area Under Curve; Child; Drug Administration Schedule; Drug Interactions; Female; Half-Life;

2000
Management of the infant born to a mother infected with human immunodeficiency virus type 1 (HIV-1): current concepts.
    American journal of perinatology, 2000, Volume: 17, Issue:8

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Female; HIV In

2000
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.
    Clinical pharmacokinetics, 2001, Volume: 40, Issue:12

    Topics: Alkynes; Benzoxazines; Biological Availability; Cyclopropanes; Delavirdine; Drug Interactions; Femal

2001
Prevention of mother-to-child transmission of HIV: challenges for the current decade.
    Bulletin of the World Health Organization, 2001, Volume: 79, Issue:12

    Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Drug Resistance, Microbial; Female; Health Resour

2001
The role of nevirapine in the treatment of HIV-1 disease.
    Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:12

    Topics: Anti-HIV Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Interac

2001
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    The Cochrane database of systematic reviews, 2002, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi

2002
HIV-1 drug resistance and mother-to-child transmission.
    SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging, 2001, Volume: 56, Issue:12

    Topics: Anti-HIV Agents; Developing Countries; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans

2001
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    The Cochrane database of systematic reviews, 2002, Issue:2

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi

2002

Trials

136 trials available for nevirapine and Pregnancy

ArticleYear
Lower Insulin Sensitivity in Newborns With In Utero HIV and Antiretroviral Exposure Who Are Uninfected in Botswana.
    The Journal of infectious diseases, 2022, 11-28, Volume: 226, Issue:11

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Botswana; Female; HIV Infections; Humans; Infant; Infant, N

2022
Maternal Humoral Immune Responses Do Not Predict Postnatal HIV-1 Transmission Risk in Antiretroviral-Treated Mothers from the IMPAACT PROMISE Study.
    mSphere, 2019, 10-23, Volume: 4, Issue:5

    Topics: Adolescent; Adult; Anti-Retroviral Agents; Antibody-Dependent Cell Cytotoxicity; Breast Feeding; Coh

2019
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
    AIDS (London, England), 2019, 12-01, Volume: 33, Issue:15

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination;

2019
A mobile health-facilitated behavioural intervention for community health workers improves exclusive breastfeeding and early infant HIV diagnosis in India: a cluster randomized trial.
    Journal of the International AIDS Society, 2020, Volume: 23, Issue:7

    Topics: Adult; Anti-HIV Agents; Behavior Therapy; Breast Feeding; Cluster Analysis; Community Health Workers

2020
Maternal HBV Viremia and Association With Adverse Infant Outcomes in Women Living With HIV and HBV.
    The Pediatric infectious disease journal, 2021, 02-01, Volume: 40, Issue:2

    Topics: Anti-HIV Agents; Birth Weight; Coinfection; Double-Blind Method; Female; Hepatitis B; Hepatitis B vi

2021
Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.
    The lancet. HIV, 2021, Volume: 8, Issue:3

    Topics: Anti-HIV Agents; Female; Gestational Age; HIV Infections; Humans; Infant; Infant, Newborn; Infectiou

2021
Efficacy of Mobile phone use on adherence to Nevirapine prophylaxis and retention in care among the HIV-exposed infants in prevention of mother to child transmission of HIV: a randomized controlled trial.
    BMC pediatrics, 2021, 04-20, Volume: 21, Issue:1

    Topics: Anti-HIV Agents; Cell Phone Use; Child; Female; HIV Infections; Humans; Infant; Infectious Disease T

2021
Association of Maternal Viral Load and CD4 Count With Perinatal HIV-1 Transmission Risk During Breastfeeding in the PROMISE Postpartum Component.
    Journal of acquired immune deficiency syndromes (1999), 2021, 10-01, Volume: 88, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Female; HIV Infections; HIV Seropositivity; H

2021
Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates.
    Journal of acquired immune deficiency syndromes (1999), 2017, 08-15, Volume: 75, Issue:5

    Topics: Anti-HIV Agents; Breast Feeding; Chemoprevention; Clinical Protocols; Dose-Response Relationship, Dr

2017
Conditional cash transfers to prevent mother-to-child transmission in low facility-delivery settings: evidence from a randomised controlled trial in Nigeria.
    BMC pregnancy and childbirth, 2019, Jan-16, Volume: 19, Issue:1

    Topics: Adult; Delivery, Obstetric; Female; HIV Infections; Hospitals, Public; Humans; Infant, Newborn; Infa

2019
Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns.
    Journal of clinical pharmacology, 2013, Volume: 53, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Dise

2013
Cluster randomised trial of the uptake of a take-home infant dose of nevirapine in Kenya.
    East African medical journal, 2010, Volume: 87, Issue:7

    Topics: Adolescent; Adult; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission,

2010
Short communication: effect of short-course antenatal zidovudine and single-dose nevirapine on the BED capture enzyme immunoassay levels in HIV type 1 subtype C infection.
    AIDS research and human retroviruses, 2013, Volume: 29, Issue:6

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Female; HIV Antibodies; HIV Infections; HIV-1;

2013
Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.
    The Journal of infectious diseases, 2013, Aug-15, Volume: 208, Issue:4

    Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Chemoprevention; Cytochrome P-450 CYP2B6; Fem

2013
Health outcomes of HIV-exposed uninfected African infants.
    AIDS (London, England), 2013, Mar-13, Volume: 27, Issue:5

    Topics: Anti-Retroviral Agents; Antiviral Agents; Breast Feeding; Cause of Death; Drug Therapy, Combination;

2013
HIV disease progression in the first year after delivery among African women followed in the HPTN 046 clinical trial.
    Journal of acquired immune deficiency syndromes (1999), 2013, Nov-01, Volume: 64, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Disease Progression; Doubl

2013
Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:11

    Topics: Adult; Anti-HIV Agents; Anticonvulsants; Drug Interactions; Drug Resistance, Viral; Female; Half-Lif

2013
WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity.
    Journal of acquired immune deficiency syndromes (1999), 2013, Mar-01, Volume: 62, Issue:3

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte Count; Cohort S

2013
Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
    International health, 2013, Volume: 5, Issue:2

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyc

2013
Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness.
    AIDS (London, England), 2013, Volume: 27 Suppl 1

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Contraceptives, Oral; Dru

2013
Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival.
    Journal of acquired immune deficiency syndromes (1999), 2013, Dec-15, Volume: 64, Issue:5

    Topics: Anthropometry; Anti-HIV Agents; Body Height; Body Weight; Chemoprevention; Child, Preschool; Female;

2013
Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three African countries.
    BMC infectious diseases, 2013, Nov-06, Volume: 13

    Topics: Adult; Africa South of the Sahara; Anemia; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; I

2013
Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women.
    BMC research notes, 2014, Jan-21, Volume: 7

    Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4

2014
Hypothesis testing for an extended cox model with time-varying coefficients.
    Biometrics, 2014, Volume: 70, Issue:3

    Topics: Algorithms; Biometry; Computer Simulation; Data Interpretation, Statistical; Female; HIV Infections;

2014
Evaluation of adherence measures of antiretroviral prophylaxis in HIV exposed infants in the first 6 weeks of life.
    BMC pediatrics, 2015, Mar-19, Volume: 15

    Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Infant,

2015
Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand.
    AIDS (London, England), 2015, Nov-28, Volume: 29, Issue:18

    Topics: Adult; Anti-HIV Agents; Chemoprevention; DNA, Viral; Double-Blind Method; Female; HIV Infections; Hu

2015
Cytomegalovirus IgG Level and Avidity in Breastfeeding Infants of HIV-Infected Mothers in Malawi.
    Clinical and vaccine immunology : CVI, 2015, Volume: 22, Issue:12

    Topics: Anti-HIV Agents; Antibodies, Viral; Antibody Affinity; Breast Feeding; Cytomegalovirus; Cytomegalovi

2015
Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Mar-15, Volume: 62, Issue:6

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Co

2016
Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural north-central Nigeria: a cluster-randomised controlled trial.
    The lancet. HIV, 2016, Volume: 3, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delive

2016
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.
    The New England journal of medicine, 2016, 11-03, Volume: 375, Issue:18

    Topics: Adult; Anti-Retroviral Agents; Black or African American; CD4 Lymphocyte Count; Drug Therapy, Combin

2016
Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission.
    Journal of acquired immune deficiency syndromes (1999), 2008, Jun-01, Volume: 48, Issue:2

    Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine

2008
Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    AIDS (London, England), 2008, Jul-11, Volume: 22, Issue:11

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dru

2008
Mother-to-child transmission of HIV-1: association with malaria prevention, anaemia and placental malaria.
    HIV medicine, 2008, Volume: 9, Issue:9

    Topics: Adult; Anemia; Anti-HIV Agents; Antimalarials; CD4 Lymphocyte Count; Drug Combinations; Female; HIV

2008
Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants.
    AIDS (London, England), 2008, Aug-20, Volume: 22, Issue:13

    Topics: Alanine Transaminase; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active

2008
Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
    Antiviral therapy, 2008, Volume: 13, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Seroposit

2008
Determining an optimal testing strategy for infants at risk for mother-to-child transmission of HIV-1 during the late postnatal period.
    AIDS (London, England), 2008, Nov-12, Volume: 22, Issue:17

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Developing Countries; Female; HIV Infections; H

2008
Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
    PloS one, 2009, Volume: 4, Issue:1

    Topics: Anti-HIV Agents; Breast Feeding; Drug Resistance, Viral; Female; Genotype; HIV; HIV Infections; Huma

2009
Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China.
    International journal of STD & AIDS, 2009, Volume: 20, Issue:4

    Topics: Adult; CD4 Lymphocyte Count; China; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combinatio

2009
Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
    AIDS (London, England), 2009, Apr-27, Volume: 23, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Cambodia; Cote d'Ivoire; Deoxycytidine; Drug Administration Schedul

2009
Timing and determinants of mother-to-child transmission of HIV in Nigeria.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2009, Volume: 106, Issue:1

    Topics: Adult; Anti-HIV Agents; Birth Weight; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Hum

2009
Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.
    Journal of acquired immune deficiency syndromes (1999), 2009, Aug-15, Volume: 51, Issue:5

    Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Base Sequence; DNA

2009
Predictors of rapid HIV testing acceptance and successful nevirapine administration in Zambian labor wards.
    Journal of acquired immune deficiency syndromes (1999), 2009, Oct-01, Volume: 52, Issue:2

    Topics: Anti-HIV Agents; Chemoprevention; Clinical Laboratory Techniques; Female; HIV Infections; Humans; In

2009
Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda.
    Journal of acquired immune deficiency syndromes (1999), 2009, Sep-01, Volume: 52, Issue:1

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious

2009
Selected hematologic and biochemical measurements in African HIV-infected and uninfected pregnant women and their infants: the HIV Prevention Trials Network 024 protocol.
    BMC pediatrics, 2009, Aug-07, Volume: 9

    Topics: Adult; Anti-HIV Agents; Blood Cell Count; Double-Blind Method; Female; Follow-Up Studies; Gestationa

2009
Comparing couples' and individual voluntary counseling and testing for HIV at antenatal clinics in Tanzania: a randomized trial.
    AIDS and behavior, 2010, Volume: 14, Issue:3

    Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Counseling; Family Characteristics; Female; HIV Infectio

2010
Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.
    The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:6

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressu

2009
Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
    The Journal of infectious diseases, 2009, Nov-15, Volume: 200, Issue:10

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte

2009
Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.
    PLoS medicine, 2009, Volume: 6, Issue:10

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Fem

2009
Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:11

    Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Sched

2009
A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia.
    AIDS (London, England), 2010, Jan-28, Volume: 24, Issue:3

    Topics: Adult; Anti-HIV Agents; Female; Fetal Blood; Health Services Accessibility; HIV Infections; Humans;

2010
Is single-dose NVP relevant in the era of more efficacious PMTCT regimens? Lessons from Zambia.
    AIDS care, 2010, Volume: 22, Issue:2

    Topics: Anti-HIV Agents; Clinical Protocols; Developing Countries; Disease Transmission, Infectious; Drug Re

2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The

2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The

2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The

2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The

2010
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U

2010
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U

2010
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U

2010
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
    The New England journal of medicine, 2010, Jun-17, Volume: 362, Issue:24

    Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U

2010
Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges.
    Contemporary clinical trials, 2011, Volume: 32, Issue:1

    Topics: Africa, Eastern; Africa, Southern; Africa, Western; Anti-Retroviral Agents; Breast Feeding; Child, P

2011
Antiretroviral therapies in women after single-dose nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug T

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Antiretroviral treatment for children with peripartum nevirapine exposure.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In

2010
Growth of infants born to HIV-infected women in South Africa according to maternal and infant characteristics.
    Tropical medicine & international health : TM & IH, 2010, Volume: 15, Issue:11

    Topics: Adult; Anti-HIV Agents; Body Height; Body Weight; CD4 Lymphocyte Count; Epidemiologic Methods; Femal

2010
Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:1

    Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Infan

2011
Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication.
    Journal of perinatal medicine, 2011, Volume: 39, Issue:2

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Congenital Abnormalities; Double-Blind Method; Female; Heart

2011
CD4+ cell count and risk for antiretroviral drug resistance among women using peripartum nevirapine for perinatal HIV prevention.
    BJOG : an international journal of obstetrics and gynaecology, 2011, Volume: 118, Issue:4

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV Seroposit

2011
Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus.
    The Journal of infectious diseases, 2011, Feb-01, Volume: 203, Issue:3

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis

2011
Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
    The Lancet. Infectious diseases, 2011, Volume: 11, Issue:3

    Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Thera

2011
Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.
    AIDS research and human retroviruses, 2011, Volume: 27, Issue:8

    Topics: Base Sequence; Breast Feeding; Child; Drug Administration Schedule; Drug Resistance, Viral; Ethiopia

2011
Rapid intrapartum or postpartum HIV testing at a midwife obstetric unit and a district hospital in South Africa.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2011, Volume: 113, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Cluster Analysis; Feasibility Studies; Female; HIV Infections; H

2011
Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count.
    AIDS (London, England), 2011, Mar-27, Volume: 25, Issue:6

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female

2011
Improved detection of incident HIV infection and uptake of PMTCT services in labor and delivery in a high HIV prevalence setting.
    Journal of acquired immune deficiency syndromes (1999), 2011, Aug-01, Volume: 57, Issue:4

    Topics: Anti-HIV Agents; Eswatini; Female; Fetal Blood; HIV Antibodies; HIV Infections; Humans; Incidence; I

2011
Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY).
    Journal of acquired immune deficiency syndromes (1999), 2011, Dec-01, Volume: 58, Issue:4

    Topics: Adolescent; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Immunoglobulins, Intravenous; In

2011
Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated.
    AIDS (London, England), 2012, Jan-28, Volume: 26, Issue:3

    Topics: Adult; Anemia; Anti-HIV Agents; Blotting, Western; Breast Feeding; Drug Administration Schedule; Dru

2012
Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention.
    Journal of acquired immune deficiency syndromes (1999), 2012, Mar-01, Volume: 59, Issue:3

    Topics: Adolescent; Adult; Carbamazepine; CD4 Lymphocyte Count; Chi-Square Distribution; Drug Interactions;

2012
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-15, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI

2012
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-15, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI

2012
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-15, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI

2012
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-15, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI

2012
Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.
    The Journal of infectious diseases, 2012, Feb-01, Volume: 205, Issue:3

    Topics: Acyclovir; Adolescent; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; HIV-1; H

2012
Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2012, Jan-21, Volume: 379, Issue:9812

    Topics: Administration, Oral; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Hi

2012
A lipid-based nutrient supplement mitigates weight loss among HIV-infected women in a factorial randomized trial to prevent mother-to-child transmission during exclusive breastfeeding.
    The American journal of clinical nutrition, 2012, Volume: 95, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; Dietary Supplements; Female; HIV Infections; HIV-1; H

2012
Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women.
    Antiviral therapy, 2012, Volume: 17, Issue:2

    Topics: Anti-HIV Agents; Drug Combinations; Drug Resistance, Viral; Female; Genotype; HIV Infections; Humans

2012
Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial.
    Lancet (London, England), 2012, Jun-30, Volume: 379, Issue:9835

    Topics: Adult; Anti-Retroviral Agents; Breast Feeding; Female; Follow-Up Studies; HIV Infections; HIV-1; Hum

2012
Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.
    PloS one, 2012, Volume: 7, Issue:6

    Topics: Acyclovir; Antiviral Agents; Biomarkers; CD4 Antigens; Disease Progression; Female; Herpes Genitalis

2012
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
    The New England journal of medicine, 2012, Jun-21, Volume: 366, Issue:25

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2012
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
    The New England journal of medicine, 2012, Jun-21, Volume: 366, Issue:25

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2012
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
    The New England journal of medicine, 2012, Jun-21, Volume: 366, Issue:25

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2012
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
    The New England journal of medicine, 2012, Jun-21, Volume: 366, Issue:25

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2012
Growth patterns among HIV-exposed infants receiving nevirapine prophylaxis in Pune, India.
    BMC infectious diseases, 2012, Oct-31, Volume: 12

    Topics: Adult; Anthropometry; Female; HIV Infections; HIV Seropositivity; Humans; India; Infant; Infant, New

2012
Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.
    Antiviral therapy, 2013, Volume: 18, Issue:4

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Botswana; Breast Feeding; Dideoxynucl

2013
Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:7

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV;

2013
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
    The Journal of infectious diseases, 2002, Jul-15, Volume: 186, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female;

2002
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
    The Journal of infectious diseases, 2002, Jul-15, Volume: 186, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female;

2002
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
    The Journal of infectious diseases, 2002, Jul-15, Volume: 186, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female;

2002
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
    The Journal of infectious diseases, 2002, Jul-15, Volume: 186, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female;

2002
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
    The Journal of infectious diseases, 2002, Jul-15, Volume: 186, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female;

2002
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
    The Journal of infectious diseases, 2002, Jul-15, Volume: 186, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female;

2002
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
    The Journal of infectious diseases, 2002, Jul-15, Volume: 186, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female;

2002
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
    The Journal of infectious diseases, 2002, Jul-15, Volume: 186, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female;

2002
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
    The Journal of infectious diseases, 2002, Jul-15, Volume: 186, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female;

2002
Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya.
    AIDS (London, England), 2003, Jan-03, Volume: 17, Issue:1

    Topics: Adult; Anti-HIV Agents; Female; Focus Groups; Follow-Up Studies; Health Knowledge, Attitudes, Practi

2003
A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
    The Journal of infectious diseases, 2003, Mar-01, Volume: 187, Issue:5

    Topics: Adult; Anti-HIV Agents; Delivery, Obstetric; Drug Therapy, Combination; Female; HIV Infections; HIV-

2003
Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings.
    Journal of acquired immune deficiency syndromes (1999), 2003, Apr-15, Volume: 32, Issue:5

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; N

2003
Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose.
    Journal of acquired immune deficiency syndromes (1999), 2003, Jun-01, Volume: 33, Issue:2

    Topics: Adult; Anti-HIV Agents; Bahamas; Brazil; Double-Blind Method; Europe; Female; Fetal Blood; HIV Infec

2003
Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine.
    AIDS (London, England), 2003, Jul-25, Volume: 17, Issue:11

    Topics: Adolescent; Adult; Breast Feeding; Drug Administration Schedule; Female; HIV Infections; HIV Seropos

2003
Feeding risk cut for HIV-infected women.
    Lancet (London, England), 2003, Jul-26, Volume: 362, Issue:9380

    Topics: Anti-HIV Agents; Breast Feeding; Didanosine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn;

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll

2003
Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial.
    Lancet (London, England), 2003, Oct-11, Volume: 362, Issue:9391

    Topics: Anti-HIV Agents; Female; Follow-Up Studies; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infan

2003
Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaoundé, Cameroon.
    Journal of acquired immune deficiency syndromes (1999), 2003, Nov-01, Volume: 34, Issue:3

    Topics: Anti-HIV Agents; Cameroon; Female; HIV Infections; HIV-1; Humans; Immunoenzyme Techniques; Infant; I

2003
Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months.
    Journal of acquired immune deficiency syndromes (1999), 2003, Dec-15, Volume: 34, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Epidemiologi

2003
Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.
    Journal of acquired immune deficiency syndromes (1999), 2004, Jul-01, Volume: 36, Issue:3

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Inf

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination;

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B

2004
Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial.
    JAMA, 2004, Jul-14, Volume: 292, Issue:2

    Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Delivery, Obstetric; Drug Therapy, Combination; Female;

2004
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission,

2005
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission,

2005
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission,

2005
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2005, Mar-01, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission,

2005
A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers.
    AIDS (London, England), 2005, Aug-12, Volume: 19, Issue:12

    Topics: Anti-HIV Agents; Bottle Feeding; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Infa

2005
Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine.
    AIDS (London, England), 2005, Sep-02, Volume: 19, Issue:13

    Topics: Adult; Anti-HIV Agents; DNA, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant

2005
Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine.
    The Journal of infectious diseases, 2005, Oct-01, Volume: 192, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infectious Disease T

2005
Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024.
    AIDS (London, England), 2005, Nov-04, Volume: 19, Issue:16

    Topics: Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; Humans;

2005
Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns.
    AIDS (London, England), 2005, Dec-02, Volume: 19, Issue:18

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newb

2005
Reduction of mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso.
    Journal of medical virology, 2006, Volume: 78, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Burkina Faso; Drug Administratio

2006
Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-1 transmission.
    American journal of obstetrics and gynecology, 2006, Volume: 194, Issue:1

    Topics: Acute Disease; Adult; Anti-HIV Agents; Chorioamnionitis; Chronic Disease; Female; Fetal Blood; HIV I

2006
Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission.
    AIDS (London, England), 2006, Jan-09, Volume: 20, Issue:2

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Female; Fetal Blood; HIV Infections; HIV-1; Hu

2006
Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:1

    Topics: Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV-1; Humans; Infant; Infant, Newborn

2006
Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.
    JAMA, 2006, Aug-16, Volume: 296, Issue:7

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Botswana; Breast Feeding; Disease-Free Survi

2006
A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jan-01, Volume: 44, Issue:1

    Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-

2007
Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program.
    Journal of acquired immune deficiency syndromes (1999), 2007, Mar-01, Volume: 44, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infectio

2007
Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:3

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Human

2007
Intrapartum transmission after mucosal exposure to HIV was not observed with single-dose nevirapine for mother and child.
    Journal of acquired immune deficiency syndromes (1999), 2007, Apr-15, Volume: 44, Issue:5

    Topics: Adult; Anti-HIV Agents; Cervix Uteri; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn

2007
Response to antiretroviral therapy after a single, peripartum dose of nevirapine.
    The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2

    Topics: Adult; Anti-Retroviral Agents; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combinatio

2007
Two-year morbidity-mortality and alternatives to prolonged breast-feeding among children born to HIV-infected mothers in Côte d'Ivoire.
    PLoS medicine, 2007, Volume: 4, Issue:1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Cohort Studies; Cote d'Ivoir

2007
Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
    Journal of acquired immune deficiency syndromes (1999), 2007, Apr-01, Volume: 44, Issue:4

    Topics: Adult; Alanine Transaminase; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asparta

2007
Safety of nevirapine in pregnancy.
    HIV medicine, 2007, Volume: 8, Issue:1

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Exanthema

2007
Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire.
    Journal of acquired immune deficiency syndromes (1999), 2007, Jun-01, Volume: 45, Issue:2

    Topics: Adult; Anti-HIV Agents; Cote d'Ivoire; Drug Administration Schedule; Female; HIV Infections; Humans;

2007
Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jul-15, Volume: 45, Issue:2

    Topics: Age Distribution; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Humans; Inci

2007
Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jul-15, Volume: 45, Issue:2

    Topics: Age Distribution; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Humans; Inci

2007
Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jul-15, Volume: 45, Issue:2

    Topics: Age Distribution; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Humans; Inci

2007
Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jul-15, Volume: 45, Issue:2

    Topics: Age Distribution; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Humans; Inci

2007
HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:6

    Topics: Africa; Anti-HIV Agents; Black People; DNA Mutational Analysis; Drug Administration Schedule; Drug R

2007
Pathology of placenta in HIV infection.
    Indian journal of pathology & microbiology, 2007, Volume: 50, Issue:3

    Topics: Anti-HIV Agents; Chorioamnionitis; Female; Fetal Death; HIV Infections; Humans; Hyperplasia; Infant,

2007
Mother-to-child transmission of HIV among women who chose not to exclusively breastfeed their infants in Pune, India.
    The Indian journal of medical research, 2007, Volume: 126, Issue:2

    Topics: Adult; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Cohort Studies; Drug Administration Schedule

2007
Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.
    Lancet (London, England), 2007, Nov-17, Volume: 370, Issue:9600

    Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV

2007
Independent effects of nevirapine prophylaxis and HIV-1 RNA suppression in breast milk on early perinatal HIV-1 transmission.
    Journal of acquired immune deficiency syndromes (1999), 2007, Dec-01, Volume: 46, Issue:4

    Topics: Adult; Anti-HIV Agents; DNA, Viral; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transm

2007
High uptake of exclusive breastfeeding and reduced early post-natal HIV transmission.
    PloS one, 2007, Dec-26, Volume: 2, Issue:12

    Topics: Breast Feeding; Female; HIV Infections; Humans; Infant; Infant Food; Infant, Newborn; Infectious Dis

2007
Temporal and lateral dynamics of HIV shedding and elevated sodium in breast milk among HIV-positive mothers during the first 4 months of breast-feeding.
    Journal of acquired immune deficiency syndromes (1999), 2008, Mar-01, Volume: 47, Issue:3

    Topics: Breast Feeding; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn

2008
Nevirapine concentrations in newborns receiving an extended prophylactic regimen.
    Journal of acquired immune deficiency syndromes (1999), 2008, Mar-01, Volume: 47, Issue:3

    Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; HIV

2008
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team.
    The Journal of infectious diseases, 1998, Volume: 178, Issue:2

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; In

1998
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).
    AIDS (London, England), 1999, Mar-11, Volume: 13, Issue:4

    Topics: Anti-HIV Agents; Consumer Product Safety; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Inf

1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
    Lancet (London, England), 1999, Sep-04, Volume: 354, Issue:9181

    Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H

1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
    Lancet (London, England), 1999, Sep-04, Volume: 354, Issue:9181

    Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H

1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
    Lancet (London, England), 1999, Sep-04, Volume: 354, Issue:9181

    Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H

1999
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
    Lancet (London, England), 1999, Sep-04, Volume: 354, Issue:9181

    Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H

1999
[Encouraging study results. HIV from birth on--virostatic drugs can decrease the risk].
    MMW Fortschritte der Medizin, 1999, Aug-26, Volume: 141, Issue:34

    Topics: Anti-HIV Agents; Female; Follow-Up Studies; HIV Infections; Humans; Infant, Newborn; Infectious Dise

1999
South Africa's Medicines Control Council contradicts Health Minister.
    Lancet (London, England), 2000, Apr-15, Volume: 355, Issue:9212

    Topics: Adverse Drug Reaction Reporting Systems; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Inf

2000
Nevirapine and perinatal transmission.
    AIDS patient care and STDs, 2000, Volume: 14, Issue:4

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infe

2000
Major advance in protecting newborns: one Nevirapine dose cuts infection in half.
    AIDS treatment news, 1999, Jul-16, Issue:No 323

    Topics: Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Dis

1999
Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).
    The Journal of infectious diseases, 2001, Oct-01, Volume: 184, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Microbial; Female; HIV Infections; HIV-1; Humans; Infant; Infectio

2001
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    AIDS (London, England), 2001, Oct-19, Volume: 15, Issue:15

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H

2001
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    AIDS (London, England), 2001, Oct-19, Volume: 15, Issue:15

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H

2001
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    AIDS (London, England), 2001, Oct-19, Volume: 15, Issue:15

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H

2001
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    AIDS (London, England), 2001, Oct-19, Volume: 15, Issue:15

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H

2001
Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure.
    The Pediatric infectious disease journal, 2001, Volume: 20, Issue:8

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease T

2001
Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants.
    AIDS (London, England), 2002, Apr-12, Volume: 16, Issue:6

    Topics: Alanine Transaminase; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newb

2002
Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.
    JAMA, 2002, Jul-10, Volume: 288, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cesarean Section; Drug

2002

Other Studies

480 other studies available for nevirapine and Pregnancy

ArticleYear
Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Adult; Amniotic Fluid; Anti-HIV Agents; Cytochrome P-450 CYP3A;

2009
Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 06-10, Volume: 74, Issue:11

    Topics: Anti-HIV Agents; Breast Feeding; Case-Control Studies; Drug Resistance; Female; HIV; HIV Infections;

2022
HIV Encephalopathy in ART-Naïve, Hospitalized Infants in Mozambique.
    Journal of tropical pediatrics, 2021, 12-08, Volume: 67, Issue:6

    Topics: AIDS Dementia Complex; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infant; Infectious Di

2021
Improved Hematologic Outcomes in HIV1-Exposed Infants Receiving Nevirapine Compared With Zidovudine for Postnatal Prophylaxis in a High Resource Setting.
    The Pediatric infectious disease journal, 2022, 05-01, Volume: 41, Issue:5

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical;

2022
Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child prevention program in Maputo city, Mozambique.
    PloS one, 2022, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Combinations; Female; Hair; HI

2022
Contraceptive implant use duration is not associated with breakthrough pregnancy among women living with HIV and using efavirenz: a retrospective, longitudinal analysis.
    Journal of the International AIDS Society, 2022, Volume: 25, Issue:9

    Topics: Adolescent; Adult; Alkynes; Benzoxazines; Contraceptive Agents; Cyclopropanes; Female; HIV Infection

2022
Twenty years of Prevention of Mother to Child HIV Transmission: research to implementation at a national referral hospital in Uganda.
    African health sciences, 2022, Volume: 22, Issue:Spec Issue

    Topics: Anti-HIV Agents; Child; Female; HIV Infections; Hospitals; Humans; Infant, Newborn; Infectious Disea

2022
Antiretroviral postnatal prophylaxis to prevent HIV vertical transmission: present and future strategies.
    Journal of the International AIDS Society, 2023, Volume: 26, Issue:2

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Inf

2023
Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa.
    BMC infectious diseases, 2019, Sep-16, Volume: 19, Issue:Suppl 1

    Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Female; Follow-Up Studi

2019
Extended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants.
    Journal of acquired immune deficiency syndromes (1999), 2019, 12-01, Volume: 82, Issue:4

    Topics: Anti-HIV Agents; Child Development; Female; Growth; HIV Infections; Humans; Infant; Infectious Disea

2019
Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital.
    Journal of tropical pediatrics, 2020, 08-01, Volume: 66, Issue:4

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Ch

2020
Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before Delivery.
    Journal of acquired immune deficiency syndromes (1999), 2020, 07-01, Volume: 84, Issue:3

    Topics: Adult; Anti-HIV Agents; Bayes Theorem; Drug Combinations; Female; HIV Infections; Humans; Infant, Ne

2020
Barriers and enablers of adherence to infant nevirapine prophylaxis against HIV 1 transmission among 6-week-old HIV exposed infants: A prospective cohort study in Northern Uganda.
    PloS one, 2020, Volume: 15, Issue:10

    Topics: Adult; Age Factors; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Disea

2020
Advancing knowledge in perinatal HIV treatment.
    The lancet. HIV, 2021, Volume: 8, Issue:3

    Topics: Anti-Retroviral Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis

2021
Association of SNPs in HLA-C and ZNRD1 Genes With HIV-1 Mother-to-Child Transmission in Zambia Population.
    Journal of acquired immune deficiency syndromes (1999), 2021, 04-01, Volume: 86, Issue:4

    Topics: Adult; Anti-HIV Agents; DNA-Binding Proteins; Female; Genetic Predisposition to Disease; Genotype; H

2021
Mother-to-Child HIV Transmission among Pregnant Women in a City with the Highest Rates of HIV in Brazil.
    American journal of perinatology, 2022, Volume: 39, Issue:13

    Topics: Brazil; Child; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmiss

2022
HIV-free survival among breastfed infants born to HIV-positive women in northern Uganda: a facility-based retrospective study.
    The Pan African medical journal, 2020, Volume: 37

    Topics: Anti-HIV Agents; Breast Feeding; Cohort Studies; Female; HIV Infections; Humans; Infant; Infant, New

2020
Effects of the Pratt pouch model of dispensing nevirapine prophylaxis on HIV exposed infant completion of 6 weeks of prophylaxis in Uganda.
    PloS one, 2021, Volume: 16, Issue:3

    Topics: Adult; Anti-HIV Agents; Drug Implants; Drug Packaging; Female; HIV Infections; Humans; Infant; Infan

2021
Nevirapine Pharmacokinetics in Neonates Between 25 and 32 Weeks Gestational Age for the Prevention of Mother-to-Child Transmission of HIV.
    The Pediatric infectious disease journal, 2021, 04-01, Volume: 40, Issue:4

    Topics: Administration, Oral; Anti-HIV Agents; Female; Gestational Age; HIV Infections; HIV-1; Humans; Infan

2021
Uptake and performance of prevention of mother-to-child transmission and early infant diagnosis in pregnant HIV-infected women and their exposed infants at seven health centres in Addis Ababa, Ethiopia.
    Tropical medicine & international health : TM & IH, 2017, Volume: 22, Issue:6

    Topics: Adolescent; Adult; Anti-HIV Agents; Ethiopia; Female; Follow-Up Studies; Guideline Adherence; Health

2017
Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
    The Journal of antimicrobial chemotherapy, 2017, 07-01, Volume: 72, Issue:7

    Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Breast Feeding; Case-Control Studies; Drug Therapy, C

2017
Maternal Syphilis: An Independent Risk Factor for Mother to Infant Human Immunodeficiency Virus Transmission.
    Sexually transmitted diseases, 2017, Volume: 44, Issue:6

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cost-Benefit Anal

2017
Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
    BMC infectious diseases, 2017, 06-27, Volume: 17, Issue:1

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Co

2017
Mother-to-child transmission of HIV in Kenya: A cross-sectional analysis of the national database over nine years.
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Databases, Factual;

2017
A Bayesian Analysis of Prenatal Maternal Factors Predicting Nonadherence to Infant HIV Medication in South Africa.
    AIDS and behavior, 2018, Volume: 22, Issue:9

    Topics: Adolescent; Adult; Anti-HIV Agents; Bayes Theorem; Depression; Depression, Postpartum; Disclosure; F

2018
Maternal age, infant age, feeding options, single/multiple pregnancy, type of twin sets and mother-to-child transmission of HIV.
    Journal of tropical pediatrics, 2019, 06-01, Volume: 65, Issue:3

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Cameroon; Female; HIV

2019
Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy.
    AIDS research and human retroviruses, 2018, Volume: 34, Issue:11

    Topics: Adult; Anti-HIV Agents; Antimalarials; Cross-Sectional Studies; Drug Interactions; Female; Fetal Blo

2018
Mother-baby dyads enrolled in PMTCT care in western Kenya: characteristics and implications for ART programmes.
    African journal of AIDS research : AJAR, 2018, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infant; Infectious Diseas

2018
Rates of HBV, HCV, HDV and HIV type 1 among pregnant women and HIV type 1 drug resistance-associated mutations in breastfeeding women on antiretroviral therapy.
    BMC pregnancy and childbirth, 2018, Dec-22, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Cameroon; Coinfection; Drug Resistance, Viral; F

2018
Programmes for the prevention of mother-to-child HIV infection transmission have made progress in Yunnan Province, China, from 2006 to 2015: a cost effective and cost-benefit evaluation.
    BMC infectious diseases, 2019, Jan-17, Volume: 19, Issue:1

    Topics: Adult; China; Cost-Benefit Analysis; Delivery of Health Care; Female; Health Expenditures; HIV; HIV

2019
Incidence, prevalence and associated factors of mother-to-child transmission of HIV, among children exposed to maternal HIV, in Belgaum district, Karnataka, India.
    BMC public health, 2019, Apr-06, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Age Factors; Anti-HIV Agents; Breast Feeding; Child, Preschool; Female; HIV; HIV

2019
Retention of HIV exposed infants in care at Arua regional referral hospital, Uganda: a retrospective cohort study.
    BMC public health, 2019, Apr-25, Volume: 19, Issue:1

    Topics: Adult; Anti-HIV Agents; Chi-Square Distribution; Female; HIV; HIV Infections; Humans; Infant, Newbor

2019
HIV diagnostic challenges in breast-fed infants of mothers on antiretroviral therapy.
    AIDS (London, England), 2019, 09-01, Volume: 33, Issue:11

    Topics: Anti-HIV Agents; Breast Feeding; Early Diagnosis; Female; HIV Infections; HIV Seronegativity; Humans

2019
Increasing body mass index or weight does not appear to influence the association between efavirenz-based antiretroviral therapy and implant effectiveness among HIV-positive women in western Kenya.
    Contraception, 2019, Volume: 100, Issue:4

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; Body Weight; Cohort Stud

2019
Effect of highly active antiretroviral treatment (HAART) during pregnancy on pregnancy outcomes: experiences from a PMTCT program in western India.
    AIDS patient care and STDs, 2013, Volume: 27, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Fem

2013
Scaling up prevention of mother-to-child HIV transmission programs in sub-Saharan African countries: a multilevel assessment of site-, program- and country-level determinants of performance.
    BMC public health, 2013, Apr-01, Volume: 13

    Topics: Africa South of the Sahara; Anti-HIV Agents; Female; Follow-Up Studies; HIV Infections; Humans; Infe

2013
Economic evaluation of 3-drug antiretroviral regimens for the prevention of mother-to-child HIV transmission in Thailand.
    Asia-Pacific journal of public health, 2015, Volume: 27, Issue:2

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cost-Benefit Analysis; Cyclopro

2015
Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis.
    Retrovirology, 2013, Aug-14, Volume: 10

    Topics: Anti-HIV Agents; Chemoprevention; Cluster Analysis; Drug Resistance, Viral; Female; Genotype; HIV In

2013
Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007 - 2012.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2013, Volume: 103, Issue:5

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Female; HIV Infections; Humans; Logistic Models; Nevir

2013
HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants.
    The Journal of nutrition, 2014, Volume: 144, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Black People; Female; Growth Disorders; HIV; HIV Infections; HIV

2014
Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies.
    AIDS (London, England), 2014, Mar-13, Volume: 28, Issue:5

    Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Contraceptive Agents, Female; Cycl

2014
Preliminary study of quinine pharmacokinetics in pregnant women with malaria-HIV co-infection.
    The American journal of tropical medicine and hygiene, 2014, Volume: 90, Issue:3

    Topics: Adult; Anti-HIV Agents; Antimalarials; Antiretroviral Therapy, Highly Active; Coinfection; Drug Inte

2014
Toxicology and Carcinogenesis Studies of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in u
    National Toxicology Program genetically modified model report, 2013, Issue:16

    Topics: Animals; Animals, Genetically Modified; Animals, Newborn; Anti-HIV Agents; Body Weight; Chemistry, P

2013
Progress in the prevention of mother to child transmission of HIV in three regions of Tanzania: a retrospective analysis.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dried Blood Spot Testing; Female; HIV Infect

2014
Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxis in South Africa.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:10

    Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active

2014
Transmission of nevirapine-resistant HIV type 1 via breast milk to infants after single-dose nevirapine in Beira, Mozambique.
    The Journal of infectious diseases, 2014, Aug-15, Volume: 210, Issue:4

    Topics: Anti-HIV Agents; Breast Feeding; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infe

2014
Reduction of nevirapine-driven HIV mutations by carbamazepine is modulated by CYP3A activity.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:7

    Topics: Anti-HIV Agents; Carbamazepine; Chemoprevention; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Indu

2014
The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV.
    Bulletin of the World Health Organization, 2014, Mar-01, Volume: 92, Issue:3

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Cohort Studies; Cost-

2014
The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.
    BMC infectious diseases, 2014, Apr-04, Volume: 14

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; Hepatitis B; He

2014
Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study.
    Sexually transmitted infections, 2014, Volume: 90, Issue:4

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemo

2014
HIV status, breastfeeding modality at 5 months and postpartum maternal weight changes over 24 months in rural South Africa.
    Tropical medicine & international health : TM & IH, 2014, Volume: 19, Issue:7

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Female; Follow-Up Studies; HIV Infections; Humans; Infant; I

2014
Evaluating the benefits of incorporating traditional birth attendants in HIV prevention of mother to child transmission service delivery in Lilongwe, Malawi.
    African journal of reproductive health, 2014, Volume: 18, Issue:1

    Topics: Adult; Anti-HIV Agents; Feasibility Studies; Female; Focus Groups; HIV Infections; Humans; Infant, N

2014
Foetal loss and enhanced fertility observed in mice treated with Zidovudine or Nevirapine.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Animals; Anti-HIV Agents; Female; Fertility; Fetal Death; Male; Mice; Nevirapine; Pregnancy; Sex Rat

2014
Variable and suboptimal nevirapine levels in infants given single-dose nevirapine at birth without maternal prophylaxis.
    AIDS (London, England), 2014, Oct-23, Volume: 28, Issue:16

    Topics: Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Infant, Newborn; Nevirapine; Plasma

2014
HIV testing in pregnancy.
    Sexually transmitted infections, 2014, Volume: 90, Issue:8

    Topics: Adenine; Anti-HIV Agents; Benzoxazines; Female; HIV Infections; Humans; Infectious Disease Transmiss

2014
[Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy].
    Enfermedades infecciosas y microbiologia clinica, 2016, Volume: 34, Issue:1

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cross-Sectional Studies; Female; HIV Infect

2016
Genetic Analyses of HIV-1 Strains Transmitted from Mother to Child in Northern Vietnam.
    AIDS research and human retroviruses, 2015, Volume: 31, Issue:8

    Topics: Anti-HIV Agents; Cluster Analysis; Drug Resistance, Viral; Female; Follow-Up Studies; Genetic Variat

2015
A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
    Journal of medical virology, 2015, Volume: 87, Issue:10

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Deoxycytidine; Drug Administra

2015
Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Anemia; Anti-HIV Agents; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Infecti

2015
Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:10

    Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female;

2015
Lower Preprandial Insulin and Altered Fuel Use in HIV/Antiretroviral-Exposed Infants in Cameroon.
    The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:9

    Topics: Amino Acids, Branched-Chain; Anti-Retroviral Agents; Cameroon; Energy Metabolism; Female; HIV Infect

2015
Missed Opportunities along the Prevention of Mother-to-Child Transmission Services Cascade in South Africa: Uptake, Determinants, and Attributable Risk (the SAPMTCTE).
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Adolescent; Adult; AIDS Serodiagnosis; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studie

2015
Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Anti-HIV Agents; Female; Fetus; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy Outcome; St

2015
A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study".
    BMC public health, 2015, Sep-29, Volume: 15

    Topics: Adult; Cross-Sectional Studies; Disclosure; Fear; Female; HIV Infections; HIV-1; Humans; Mass Screen

2015
Longitudinal adherence to antiretroviral drugs for preventing mother-to-child transmission of HIV in Zambia.
    BMC pregnancy and childbirth, 2015, Oct-12, Volume: 15

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis

2015
Tracing defaulters in HIV prevention of mother-to-child transmission programmes through community health workers: results from a rural setting in Zimbabwe.
    Journal of the International AIDS Society, 2015, Volume: 18

    Topics: Adult; Cohort Studies; Community Health Workers; Female; HIV Infections; Humans; Infant, Newborn; In

2015
Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children.
    Infectious diseases (London, England), 2016, Volume: 48, Issue:4

    Topics: Adult; Anti-HIV Agents; Bacterial Capsules; Child, Preschool; Female; HIV Infections; Humans; Immuno

2016
The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants.
    Journal of the International AIDS Society, 2015, Volume: 18, Issue:Suppl 6

    Topics: Female; HIV Infections; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature

2015
Supra-treatment threshold neonatal jaundice: Incidence in HIV-exposed compared to non-exposed neonates at Queen Elizabeth Central Hospital in Blantyre, Malawi.
    Malawi medical journal : the journal of Medical Association of Malawi, 2015, Volume: 27, Issue:3

    Topics: Anti-HIV Agents; Bilirubin; Breast Feeding; Comorbidity; Female; Gestational Age; HIV Infections; Hu

2015
Nevirapine Plasma Concentrations in Human Immunodeficiency Virus-Exposed Neonates Receiving High-Dose Nevirapine Prophylaxis as Part of 3-Drug Regimen.
    Journal of the Pediatric Infectious Diseases Society, 2017, Mar-01, Volume: 6, Issue:1

    Topics: Adult; Anti-Retroviral Agents; Drug Therapy, Combination; False Positive Reactions; Female; HIV; HIV

2017
Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa.
    BMC pregnancy and childbirth, 2016, Feb-11, Volume: 16

    Topics: Adolescent; Adult; Anti-Retroviral Agents; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate D

2016
Prevention of perinatal transmission of zidovudine- and nevirapine-resistant HIV.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, Apr-01, Volume: 73, Issue:7

    Topics: Adolescent; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infectio

2016
Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.
    AIDS research and human retroviruses, 2016, Volume: 32, Issue:8

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance

2016
Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study.
    Pharmacogenetics and genomics, 2016, Volume: 26, Issue:8

    Topics: Adult; Anti-HIV Agents; Biomarkers; Constitutive Androstane Receptor; Cytochrome P-450 CYP2B6; Femal

2016
Providing Safe and Effective Preventative Antiretroviral Prophylaxis to HIV-exposed Newborns via a Novel Drug Delivery System in Tanzania.
    The Pediatric infectious disease journal, 2016, Volume: 35, Issue:9

    Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Dried Blood Spot Testing; Drug Delivery Systems; Female; HI

2016
Nevirapine prophylaxis to prevent HIV-1 mother-to-child transmission: pharmacokinetic considerations in preterm infants.
    The new microbiologica, 2016, Volume: 39, Issue:4

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infant, Premature; Infectio

2016
HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission.
    Journal of acquired immune deficiency syndromes (1999), 2016, Dec-01, Volume: 73, Issue:4

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infec

2016
Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis.
    Pharmacoepidemiology and drug safety, 2016, Volume: 25, Issue:11

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Drug Eruptions; Drug Therapy, Combination; Female; HIV

2016
Early infant diagnosis of HIV infection using DNA-PCR at a referral center: an 8 years retrospective analysis.
    AIDS research and therapy, 2016, Volume: 13, Issue:1

    Topics: Anti-HIV Agents; DNA, Viral; Early Diagnosis; Ethiopia; Female; HIV; HIV Infections; Humans; Infant;

2016
Timely antiretroviral prophylaxis during pregnancy effectively reduces HIV mother-to-child transmission in eight counties in China: a prospective study during 2004-2011.
    Scientific reports, 2016, 10-10, Volume: 6

    Topics: Adult; Anti-HIV Agents; China; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmissio

2016
A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.
    Clinical pharmacokinetics, 2017, Volume: 56, Issue:5

    Topics: Cytochrome P-450 Enzyme System; Female; Fetus; Forecasting; Humans; Male; Models, Biological; Nevira

2017
Antiretrovirals causing severe pre-eclampsia.
    Pregnancy hypertension, 2016, Volume: 6, Issue:4

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Delivery, Obstetric; F

2016
Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:6

    Topics: Adult; Anti-HIV Agents; Cameroon; Child; Child, Preschool; Cohort Studies; Drug Resistance, Multiple

2008
Voluntary counselling and testing (VCT) uptake, nevirapine use and infant feeding options at the University of Nigeria Teaching Hospital.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2008, Volume: 28, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS Serodiagnosis; Ambulatory Care; Breast F

2008
HIV-positive women's experiences of a PMTCT programme in rural Malawi.
    Midwifery, 2010, Volume: 26, Issue:1

    Topics: Anti-HIV Agents; Choice Behavior; Disclosure; Female; Health Knowledge, Attitudes, Practice; Health

2010
Extra drugs and slower weaning lowers HIV risk for newborns.
    Nature medicine, 2008, Volume: 14, Issue:7

    Topics: Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; Case-Control Studies; Female; HIV Infec

2008
HIV and obstetric complications and fetal outcomes in Vellore, India.
    Tropical doctor, 2008, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; HIV Seronegativity; Humans; India; Infan

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
    Lancet (London, England), 2008, Jul-26, Volume: 372, Issue:9635

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio

2008
A review of the prevention of mother-to-child transmission programme of the Western Cape provincial government, 2003 - 2004.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2008, Volume: 98, Issue:6

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infectious Disease Transmissi

2008
Preventing mother-to-child transmission of HIV in resource-limited settings: the Elizabeth Glaser Pediatric AIDS Foundation experience.
    American journal of public health, 2009, Volume: 99, Issue:4

    Topics: Anti-HIV Agents; Counseling; Developing Countries; Female; Foundations; Health Education; HIV Infect

2009
Serious toxicity associated with continuous nevirapine-based HAART in pregnancy.
    BJOG : an international journal of obstetrics and gynaecology, 2008, Volume: 115, Issue:10

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Multivariate

2008
Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
    Therapeutic drug monitoring, 2008, Volume: 30, Issue:5

    Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Therapy, Combination;

2008
Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
    AIDS (London, England), 2008, Sep-12, Volume: 22, Issue:14

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire;

2008
Infant feeding, HIV transmission and mortality at 18 months: the need for appropriate choices by mothers and prioritization within programmes.
    AIDS (London, England), 2008, Nov-12, Volume: 22, Issue:17

    Topics: Adolescent; Adult; AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Choice

2008
Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2008, Dec-15, Volume: 49, Issue:5

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV Infecti

2008
Transient antiretroviral therapy selecting for common HIV-1 mutations substantially accelerates the appearance of rare mutations.
    Theoretical biology & medical modelling, 2008, Nov-14, Volume: 5

    Topics: Antiviral Agents; Female; Genome; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Ve

2008
Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood; Breast Feeding; Cl

2009
Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study.
    BMC infectious diseases, 2008, Dec-30, Volume: 8

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV; HIV Infections; Humans; I

2008
Determinants of nonadherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Rwanda.
    Journal of acquired immune deficiency syndromes (1999), 2009, Feb-01, Volume: 50, Issue:2

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Female; HIV Infections; HIV-1; Humans; Infant, Newborn

2009
Single-dose nevirapine to prevent mother-to-child transmission of HIV type 1: balancing the benefits and risks.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Feb-15, Volume: 48, Issue:4

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infectious Disease Transmis

2009
[Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital].
    Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 2008, Volume: 30, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Brazil; Female; HIV Infections; Hospitals, University; Humans; N

2008
Prevention of mother-to-child HIV transmission using 3-drug combination antiretroviral treatment: observational cohort in clinical practice setting in India.
    Journal of acquired immune deficiency syndromes (1999), 2009, Feb-01, Volume: 50, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; HIV

2009
Which ART regimen is best after receipt of single-dose nevirapine?
    AIDS clinical care, 2009, Volume: 21, Issue:1

    Topics: Disease Transmission, Infectious; Female; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy C

2009
Higher placental anti-inflammatory IL-10 cytokine expression in HIV-1 infected women receiving longer zidovudine prophylaxis associated with nevirapine.
    Current HIV research, 2009, Volume: 7, Issue:2

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Interleukin-10; Nevirapine; Placenta;

2009
Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance.
    AIDS (London, England), 2009, Apr-27, Volume: 23, Issue:7

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV

2009
Prevention of mother-to-child transmission of HIV in a refugee camp setting in Tanzania.
    Global public health, 2008, Volume: 3, Issue:1

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV Seropositivity; Humans; Infant, Newborn; Infecti

2008
Establishment of drug-resistant HIV-1 in latent reservoirs.
    The Journal of infectious diseases, 2009, May-01, Volume: 199, Issue:9

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Breast Feeding; Developing Countries; Disease R

2009
Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1.
    The Journal of infectious diseases, 2009, May-01, Volume: 199, Issue:9

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Reservoirs; Drug Resistance, Viral; Female; HIV Infec

2009
The obstetric face and challenge of HIV/AIDS.
    Clinical obstetrics and gynecology, 2009, Volume: 52, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Inf

2009
Reducing vertical HIV transmission in Kinshasa, Democratic Republic of Congo: trends in HIV prevalence and service delivery.
    AIDS care, 2009, Volume: 21, Issue:5

    Topics: Anti-HIV Agents; Delivery of Health Care; Democratic Republic of the Congo; Female; HIV Infections;

2009
Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia.
    Journal of acquired immune deficiency syndromes (1999), 2009, Sep-01, Volume: 52, Issue:1

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Hu

2009
Prevention of human immunodeficiency virus mother-to-child transmission in Israel.
    International journal of STD & AIDS, 2009, Volume: 20, Issue:7

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Emigrants and Immigrants;

2009
In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:7

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Administration Schedule; Drug

2009
Evolving care of HIV-infected pregnant women in Jamaica--from nevirapine to HAART.
    The West Indian medical journal, 2008, Volume: 57, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; H

2008
Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.
    AIDS (London, England), 2009, Nov-27, Volume: 23, Issue:18

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Female; HIV Infecti

2009
Effect of maternal HIV status on infant mortality: evidence from a 9-month follow-up of mothers and their infants in Zimbabwe.
    Journal of perinatology : official journal of the California Perinatal Association, 2010, Volume: 30, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; Drug Administration Schedule; Female; Foll

2010
Mother-to-child HIV and HHV-8 transmission in neonates at Saint Camille Medical Centre in Burkina Faso.
    Pakistan journal of biological sciences : PJBS, 2009, Jun-15, Volume: 12, Issue:12

    Topics: Adult; Anti-HIV Agents; Burkina Faso; CD4 Lymphocyte Count; DNA, Viral; Female; Herpesviridae Infect

2009
Single-dose nevirapine exposure affects T cell response and cytokine levels in HIV type 1-infected women.
    AIDS research and human retroviruses, 2009, Volume: 25, Issue:10

    Topics: Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Cytokines; Female; HIV Infections; Humans; Infa

2009
Modeling vertical transmission of HIV: imperfect vaccines can be of benefit.
    Vaccine, 2009, Nov-23, Volume: 27, Issue:50

    Topics: AIDS Vaccines; Anti-HIV Agents; Antibodies, Monoclonal; Breast Feeding; Child, Preschool; Female; HI

2009
Antiretroviral strategies to prevent mother-to-child transmission of HIV: striking a balance between efficacy, feasibility, and resistance.
    PLoS medicine, 2009, Volume: 6, Issue:10

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV Infectio

2009
Plasma lipid profile in pregnant women with HIV receiving nevirapine.
    AIDS patient care and STDs, 2009, Volume: 23, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Cholesterol; Drug Therapy, Combination; Female; HIV Infections;

2009
Improving the coverage of the PMTCT programme through a participatory quality improvement intervention in South Africa.
    BMC public health, 2009, Nov-05, Volume: 9

    Topics: Anti-HIV Agents; Continuity of Patient Care; Female; HIV Infections; Humans; Infant, Newborn; Infect

2009
Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.
    AIDS (London, England), 2010, Jan-02, Volume: 24, Issue:1

    Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Inf

2010
Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.
    AIDS (London, England), 2010, Jan-02, Volume: 24, Issue:1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Indu

2010
Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.
    Current HIV research, 2009, Volume: 7, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Atazanavir Sulfate; Birt

2009
Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero.
    AIDS (London, England), 2010, Jan-28, Volume: 24, Issue:3

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infectious D

2010
Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.
    Pharmacogenomics, 2010, Volume: 11, Issue:1

    Topics: Alleles; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily

2010
Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration.
    AIDS (London, England), 2010, Feb-20, Volume: 24, Issue:4

    Topics: Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Chromatography, Liquid; Drug Resistanc

2010
Decline in early life mortality in a high HIV prevalence rural area of South Africa: evidence of HIV prevention or treatment impact?
    AIDS (London, England), 2010, Feb-20, Volume: 24, Issue:4

    Topics: Adult; Anti-HIV Agents; Child, Preschool; Cohort Studies; Female; HIV Infections; Humans; Infant; In

2010
Another milestone in minimizing risks to mothers exposed to single-dose nevirapine for prevention of vertical transmission of HIV-1 to infants: what next?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Mar-15, Volume: 50, Issue:6

    Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant;

2010
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Mar-15, Volume: 50, Issue:6

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Viral; Female; HIV Infect

2010
Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study.
    PLoS medicine, 2010, Feb-16, Volume: 7, Issue:2

    Topics: Adult; Cohort Studies; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Ke

2010
Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.
    Journal of clinical microbiology, 2010, Volume: 48, Issue:5

    Topics: Adult; Anti-HIV Agents; Chemoprevention; DNA Primers; DNA, Viral; Drug Resistance, Viral; Female; HI

2010
17th Conference on Retroviruses and Opportunistic Infections, 16-19 February, San Francisco, CA. Limits of success.
    Science (New York, N.Y.), 2010, Mar-05, Volume: 327, Issue:5970

    Topics: Anti-HIV Agents; Developing Countries; Female; HIV Infections; Humans; Infant; Infectious Disease Tr

2010
A Safe Motherhood project in Kenya: assessment of antenatal attendance, service provision and implications for PMTCT.
    Tropical medicine & international health : TM & IH, 2010, Volume: 15, Issue:5

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; Health Knowledge, Attitudes, Practice; HIV Infect

2010
Couples' voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals: a prospective cohort study.
    Journal of the International AIDS Society, 2010, Mar-15, Volume: 13

    Topics: Adult; Cohort Studies; Counseling; Family Characteristics; Female; HIV Infections; Humans; Infectiou

2010
Rising mother-to-child HIV transmission in a resource-limited breastfeeding population.
    Tropical doctor, 2010, Volume: 40, Issue:2

    Topics: Adult; Breast Feeding; Cohort Studies; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Inf

2010
Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.
    AIDS research and human retroviruses, 2010, Volume: 26, Issue:3

    Topics: Botswana; Drug Resistance, Viral; Female; Gene Frequency; Genetic Variation; HIV Infections; HIV-1;

2010
Non-adherence to the single dose nevirapine regimen for the prevention of mother-to-child transmission of HIV in Bindura town, Zimbabwe: a cross-sectional analytic study.
    BMC public health, 2010, Apr-28, Volume: 10

    Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Delivery, Obstetric; Educational Status; Female; He

2010
Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2010, Volume: 48, Issue:3

    Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Drug Re

2010
Peripartum nevirapine exposure and subsequent clinical outcomes among HIV-infected women receiving antiretroviral therapy for at least 12 months.
    Tropical medicine & international health : TM & IH, 2010, Volume: 15, Issue:7

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Epidemi

2010
Prevention of mother-to-child transmission of HIV infection: views and perceptions about swallowing nevirapine in rural Lilongwe, Malawi.
    BMC public health, 2010, Jun-21, Volume: 10

    Topics: Administration, Oral; Adult; Aged; Anti-HIV Agents; Attitude to Health; Female; Focus Groups; Health

2010
[Fate of children born to HIV positive mothers followed in the context of preventing mother-to-child transmission of HIV in Togo. Study of 1042 infants].
    Bulletin de la Societe de pathologie exotique (1990), 2010, Volume: 103, Issue:4

    Topics: Anti-HIV Agents; Breast Feeding; Delivery, Obstetric; Female; HIV Infections; HIV Seropositivity; Hu

2010
Vanishing bile duct syndrome in human immunodeficiency virus: nevirapine hepatotoxicity revisited.
    World journal of gastroenterology, 2010, Jul-14, Volume: 16, Issue:26

    Topics: Adult; Anti-HIV Agents; Bile Duct Diseases; Bile Ducts, Intrahepatic; Cholestasis, Intrahepatic; Fem

2010
Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 55, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Longitudinal Studies; Nev

2010
Impact of maternal HAART on the prevention of mother-to-child transmission of HIV: results of an 18-month follow-up study in Ouagadougou, Burkina Faso.
    AIDS care, 2010, Volume: 22, Issue:7

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Burkina Faso; Cohort Stud

2010
Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries.
    JAMA, 2010, Jul-21, Volume: 304, Issue:3

    Topics: Adult; Africa; Anti-HIV Agents; Cross-Sectional Studies; Female; Fetal Blood; HIV Infections; Humans

2010
Evaluation of the safety of nevirapine therapy during pregnancy.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 54, Issue:5

    Topics: Adult; Anti-HIV Agents; Chemoprevention; Drug-Related Side Effects and Adverse Reactions; Female; HI

2010
Operational evaluation of a service for prevention of mother-to-child transmission of HIV in rural Uganda: barriers to uptake of single-dose nevirapine and the role of birth reporting.
    Tropical medicine & international health : TM & IH, 2010, Volume: 15, Issue:10

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Infant, Newborn; Infectious

2010
Estimating frequencies of minority nevirapine-resistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model.
    Journal of virology, 2010, Volume: 84, Issue:19

    Topics: Drug Resistance, Viral; Evolution, Molecular; Female; Genome, Viral; HIV Infections; HIV-1; Humans;

2010
Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 54, Issue:5

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1;

2010
Antenatal HIV-1 RNA load and timing of mother to child transmission; a nested case-control study in a resource poor setting.
    Virology journal, 2010, Aug-02, Volume: 7

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Cohort Studies; Female; HIV Infections; HIV-1; Humans;

2010
Outcomes and challenges of scaling up comprehensive PMTCT services in rural Swaziland, Southern Africa.
    AIDS care, 2010, Volume: 22, Issue:9

    Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Eswatini; Female; HIV Infections; Humans; Infant; Infant

2010
Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.
    PloS one, 2010, Sep-07, Volume: 5, Issue:9

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Follow-Up Studies; HIV Infecti

2010
Extended antenatal antiretroviral use correlates with improved infant outcomes throughout the first year of life.
    AIDS (London, England), 2010, Nov-27, Volume: 24, Issue:18

    Topics: Adult; Breast Feeding; CD4 Lymphocyte Count; Cohort Studies; Drug Administration Schedule; Female; H

2010
Preventing mother-to-child transmission of HIV—protecting this generation and the next.
    The New England journal of medicine, 2010, Oct-14, Volume: 363, Issue:16

    Topics: Anti-HIV Agents; Anti-Retroviral Agents; Female; HIV Infections; Humans; Infectious Disease Transmis

2010
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
    The New England journal of medicine, 2010, 11-11, Volume: 363, Issue:20

    Topics: Anti-Retroviral Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infe

2010
Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire.
    Journal of acquired immune deficiency syndromes (1999), 2011, Feb-01, Volume: 56, Issue:2

    Topics: Abortion, Induced; Abortion, Spontaneous; Adult; Africa, Western; Alkynes; Anti-HIV Agents; Benzoxaz

2011
The impact of maternal highly active antiretroviral therapy and short-course combination antiretrovirals for prevention of mother-to-child transmission on early infant infection rates at the Mulago national referral hospital in Kampala, Uganda, January 20
    Journal of acquired immune deficiency syndromes (1999), 2011, Jan-01, Volume: 56, Issue:1

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Confidence Intervals; Female; HIV Inf

2011
Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.
    Journal of acquired immune deficiency syndromes (1999), 2011, Mar-01, Volume: 56, Issue:3

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschoo

2011
Comparing two service delivery models for the prevention of mother-to-child transmission (PMTCT) of HIV during transition from single-dose nevirapine to multi-drug antiretroviral regimens.
    BMC public health, 2010, Dec-06, Volume: 10

    Topics: Adolescent; Adult; Africa South of the Sahara; Anti-Retroviral Agents; CD4 Lymphocyte Count; Clinica

2010
Easier said than done: World Health Organization recommendations for prevention of mother-to-child transmission of HIV-areas of concern.
    AIDS research and human retroviruses, 2011, Volume: 27, Issue:8

    Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte C

2011
Emergence of drug resistant mutations after single dose nevirapine exposure in HIV-1 infected pregnant women in south India.
    The Indian journal of medical research, 2010, Volume: 132

    Topics: Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; India

2010
Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands.
    Therapeutic drug monitoring, 2011, Volume: 33, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Monitoring; Drug Ther

2011
Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections.
    The Journal of infectious diseases, 2011, Mar-15, Volume: 203, Issue:6

    Topics: Anti-HIV Agents; Disease Transmission, Infectious; DNA Primers; Female; HIV Infections; HIV-1; Human

2011
Perinatal tuberculosis: two unusual cases.
    Annals of tropical paediatrics, 2011, Volume: 31, Issue:1

    Topics: Anti-HIV Agents; Anti-Inflammatory Agents; Antimalarials; Drug Therapy, Combination; Endometritis; F

2011
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.
    AIDS (London, England), 2011, Feb-20, Volume: 25, Issue:4

    Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Female; HIV Infections; Humans; Infant, Newborn; Infe

2011
Minor drug-resistant HIV type-1 variants in breast milk and plasma of HIV type-1-infected Ugandan women after nevirapine single-dose prophylaxis.
    Antiviral therapy, 2011, Volume: 16, Issue:1

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; Genetic Variation; HIV Infec

2011
Study leads to revision in WHO guidelines for HIV women.
    AIDS policy & law, 2010, Volume: 26, Issue:1

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Practice Guid

2010
Effectiveness of a PMTCT programme in rural Western Kenya.
    AIDS care, 2011, Volume: 23, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Epidemiologic Methods; Fe

2011
Efavirenz-based combination antiretroviral therapy after peripartum single-dose nevirapine.
    International journal of STD & AIDS, 2011, Volume: 22, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes;

2011
Factors associated with short-course antiretroviral prophylaxis (dual therapy) adherence for PMTCT in Nkangala district, South Africa.
    Acta paediatrica (Oslo, Norway : 1992), 2011, Volume: 100, Issue:9

    Topics: Anti-HIV Agents; Chi-Square Distribution; Depression, Postpartum; Directive Counseling; Female; Heal

2011
Short communication: high prevalence of drug resistance in HIV type 1-infected children born in Honduras and Belize 2001 to 2004.
    AIDS research and human retroviruses, 2011, Volume: 27, Issue:10

    Topics: Anti-HIV Agents; Base Sequence; Belize; Cohort Studies; Drug Resistance, Multiple, Viral; Female; HI

2011
Trial in youngest group points to HIV treatment overhaul.
    Nature medicine, 2011, Volume: 17, Issue:4

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; HIV Protease Inhibitors; Humans;

2011
Improving retention in the early infant diagnosis of HIV program in rural Mozambique by better service integration.
    Journal of acquired immune deficiency syndromes (1999), 2011, Sep-01, Volume: 58, Issue:1

    Topics: Adult; Anti-HIV Agents; Delivery of Health Care; Drug Therapy, Combination; Female; HIV Infections;

2011
Reduced HIV transmission at subsequent pregnancy in a resource-poor setting.
    Tropical doctor, 2011, Volume: 41, Issue:3

    Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Female; HIV Infections; HIV-1; Humans; Infant, Newb

2011
WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers.
    PloS one, 2011, Volume: 6, Issue:6

    Topics: Anti-HIV Agents; Breast Feeding; Child; Female; HIV Infections; Humans; Infant, Newborn; Infectious

2011
Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes.
    AIDS (London, England), 2011, Aug-24, Volume: 25, Issue:13

    Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Lo

2011
Pregnancy outcome among HIV positive women receiving antenatal HAART versus untreated maternal HIV infection.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2011, Volume: 21, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Cesarean Section; Chi-Sq

2011
Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach.
    Lancet (London, England), 2011, Jul-16, Volume: 378, Issue:9787

    Topics: Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Administration Schedule; Drug The

2011
Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.
    Journal of acquired immune deficiency syndromes (1999), 2011, Nov-01, Volume: 58, Issue:3

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV; HIV Inf

2011
Nevirapine for the prevention of mother-to-child transmission of HIV: a nation-wide coverage survey in Côte d'Ivoire.
    Journal of acquired immune deficiency syndromes (1999), 2011, Jul-01, Volume: 57 Suppl 1

    Topics: Adult; Cote d'Ivoire; Disease Transmission, Infectious; Female; HIV Infections; Humans; Multivariate

2011
HIV type 1 mother-to-child transmission facilitated by distinctive glycosylation sites in the gp120 envelope glycoprotein.
    AIDS research and human retroviruses, 2012, Volume: 28, Issue:7

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Cohort Studies; Female; Glycosylation; HIV Envelope Protein

2012
Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2011, Sep-05, Volume: 101, Issue:9

    Topics: Anti-HIV Agents; Female; HIV-1; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea

2011
Should sponsors and DSMBs share interim results across trials?
    Journal of acquired immune deficiency syndromes (1999), 2011, Dec-15, Volume: 58, Issue:5

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Confidentiali

2011
Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:12

    Topics: Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Female; HIV Infections; HIV-1; Humans; Infant,

2011
Synthesis and oxidation of 2-hydroxynevirapine, a metabolite of the HIV reverse transcriptase inhibitor nevirapine.
    Organic & biomolecular chemistry, 2011, Oct-26, Volume: 9, Issue:22

    Topics: Anti-HIV Agents; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Revers

2011
HIV and pregnancy: maternal and neonatal evolution.
    Medicina, 2011, Volume: 71, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Argentina; Female; Follow-Up Studies;

2011
Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes.
    AIDS (London, England), 2012, Jan-02, Volume: 26, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; N

2012
Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2012, Volume: 116, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis

2012
Kinetics of nevirapine and its impact on HIV-1 RNA levels in maternal plasma and breast milk over time after perinatal single-dose nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2012, Aug-15, Volume: 60, Issue:5

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious D

2012
Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
    The Journal of infection, 2012, Volume: 64, Issue:4

    Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cohort Studies; Coinfection; Drug Th

2012
Predictors of attrition among children born in a PMTCT programme in Zimbabwe followed up over 5 years.
    Journal of tropical pediatrics, 2012, Volume: 58, Issue:5

    Topics: Adult; Anti-HIV Agents; Child; Child, Preschool; Female; Follow-Up Studies; Forecasting; HIV Infecti

2012
Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission.
    PloS one, 2012, Volume: 7, Issue:2

    Topics: Adult; Alleles; Anti-Retroviral Agents; Drug Resistance, Viral; Female; Genetic Variation; HIV Infec

2012
Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment.
    Journal of acquired immune deficiency syndromes (1999), 2012, Jul-01, Volume: 60, Issue:3

    Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; D

2012
Transplacental passage of nevirapine, nelfinavir and lopinavir.
    The Netherlands journal of medicine, 2012, Volume: 70, Issue:2

    Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Female; Fetal Blood; HIV Infections; Humans;

2012
Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine.
    The Journal of infectious diseases, 2012, Jun-15, Volume: 205, Issue:12

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Human

2012
Policy. 3 steps can drastically reduce mother-to-child transmission.
    AIDS policy & law, 2012, Volume: 27, Issue:4

    Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi

2012
Nevirapine prophylaxis during breastfeeding.
    Lancet (London, England), 2012, May-12, Volume: 379, Issue:9828

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmiss

2012
Use of service data to inform pediatric HIV-free survival following prevention of mother-to-child transmission programs in rural Malawi.
    BMC public health, 2012, Jun-06, Volume: 12

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Disease-Free Survival; Female; Follow-Up Studies; Health Ser

2012
Standing genetic variation and the evolution of drug resistance in HIV.
    PLoS computational biology, 2012, Volume: 8, Issue:6

    Topics: Anti-HIV Agents; Computational Biology; Computer Simulation; Drug Resistance, Viral; Evolution, Mole

2012
Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission.
    The Pediatric infectious disease journal, 2012, Volume: 31, Issue:11

    Topics: Adult; Aging, Premature; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Eruptions; Fe

2012
HIV-1 mother-to-child transmission, post-test counselling, and antiretroviral prophylaxis in Northern Viet Nam: a prospective observational study.
    Scandinavian journal of infectious diseases, 2012, Volume: 44, Issue:11

    Topics: Anti-Retroviral Agents; Antibiotic Prophylaxis; Counseling; Delivery, Obstetric; Drug Resistance, Vi

2012
Risk adapted transmission prophylaxis to prevent vertical HIV-1 transmission: effectiveness and safety of an abbreviated regimen of postnatal oral zidovudine.
    BMC pregnancy and childbirth, 2013, Jan-24, Volume: 13

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HI

2013
Infant feeding and transmission of human immunodeficiency virus in the United States.
    Pediatrics, 2013, Volume: 131, Issue:2

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Cooperative Behavior; Developin

2013
Toxicology and carcinogenesis studies of mixtures of 3'-azido-3'-deoxythymidine (AZT), lamivudine (3TC), nevirapine (NVP), and nelfinavir mesylate (NFV) (Cas Nos. 30516-87-1, 134678-17-4, 129618-40-2, 159989-65-8) in B6C3F1 Mice (transplacental exposure s
    National Toxicology Program technical report series, 2013, Issue:569

    Topics: Administration, Oral; Animals; Anti-Retroviral Agents; DNA; Drug Therapy, Combination; Escherichia c

2013
Performance evaluation of PPTCT (Prevention of parent to child transmission of HIV) programme: an experience from West Bengal.
    The Indian journal of medical research, 2012, Volume: 136, Issue:6

    Topics: Adult; Female; Focus Groups; HIV Infections; Humans; India; Infant; Infectious Disease Transmission,

2012
South African government forced to give mothers antiretroviral drug.
    BMJ (Clinical research ed.), 2002, Jul-20, Volume: 325, Issue:7356

    Topics: Anti-HIV Agents; Female; HIV Seropositivity; Humans; Legislation, Drug; Nevirapine; Pregnancy; Rever

2002
South Africans win MTCT court case.
    WORLD (Oakland, Calif. : 1993), 2002, Issue:129

    Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi

2002
South Africa shifts position on antiretroviral drugs.
    The Lancet. Infectious diseases, 2002, Volume: 2, Issue:6

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infant, Newborn; Infectious Disease

2002
An interim plan to reduce mother-to-child HIV infection in South Africa.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2002, Volume: 92, Issue:6

    Topics: Anti-HIV Agents; Breast Feeding; Chemoprevention; Female; Health Promotion; HIV Infections; Humans;

2002
Nevirapine warning on post-exposure prophylaxis.
    AIDS treatment news, 2001, Jan-12, Issue:358

    Topics: Centers for Disease Control and Prevention, U.S.; Female; HIV Infections; Humans; Infectious Disease

2001
Antiretroviral treatment in developing countries.
    The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 2002, Volume: 14, Issue:5

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Developing Countries; Fe

2002
Two drugs reduce transmission.
    AIDS patient care and STDs, 2002, Volume: 16, Issue:9

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2002
Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012).
    Journal of acquired immune deficiency syndromes (1999), 2002, Nov-01, Volume: 31, Issue:3

    Topics: Cohort Studies; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmis

2002
Hope emerges for controlling perinatal HIV transmission.
    Positive living (Los Angeles, Calif.), 1999, Volume: 8, Issue:7

    Topics: Developing Countries; Drug Costs; Female; HIV Infections; Humans; Infant, Newborn; Infectious Diseas

1999
Mass treatment with nevirapine to prevent mother-to-child transmission of HIV/AIDS in sub-Saharan African countries.
    The journal of obstetrics and gynaecology research, 2002, Volume: 28, Issue:6

    Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Counseling; Female; HIV Infections; Humans; Infa

2002
Nevirapine all set to succeed in Gauteng.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2002, Volume: 92, Issue:12

    Topics: Anti-HIV Agents; Counseling; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tra

2002
The right to health and the nevirapine case in South Africa.
    The New England journal of medicine, 2003, Feb-20, Volume: 348, Issue:8

    Topics: Anti-HIV Agents; Child Advocacy; Female; Health Care Costs; Health Policy; Health Services Accessibi

2003
A saga in international HIV policy modeling: preventing mother-to-child HIV transmission.
    Journal of policy analysis and management : [the journal of the Association for Public Policy Analysis and Management], 2002,Summer, Volume: 21, Issue:3

    Topics: Africa; Antiretroviral Therapy, Highly Active; Female; Fetus; Health Policy; HIV Infections; Humans;

2002
Preventing mother-to-infant transmission of HIV in the developing world.
    The AIDS reader, 1999, Volume: 9, Issue:7

    Topics: Anti-HIV Agents; Developing Countries; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infe

1999
More good news on reducing the incidence of maternal-fetal transmission of HIV and simplifying HAART.
    The AIDS reader, 1999, Volume: 9, Issue:7

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Developing Countri

1999
Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus.
    Obstetrics and gynecology, 2003, Volume: 101, Issue:5 Pt 2

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur

2003
Resistant HIV in breast milk.
    AIDS patient care and STDs, 2003, Volume: 17, Issue:4

    Topics: Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Milk, Human; Nevirapine; Pregnancy

2003
Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia.
    AIDS (London, England), 2003, Jun-13, Volume: 17, Issue:9

    Topics: Antiviral Agents; Cost-Benefit Analysis; Counseling; Developing Countries; Drug Costs; Female; HIV I

2003
Mother-to-child HIV transmission in resource poor settings: how to improve coverage?
    AIDS (London, England), 2003, May-23, Volume: 17, Issue:8

    Topics: Anti-HIV Agents; Counseling; Developing Countries; Female; HIV Infections; Humans; Infant, Newborn;

2003
Nevirapine: an option for preventing as well as treating paediatric HIV infection.
    African health sciences, 2001, Volume: 1, Issue:1

    Topics: Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease

2001
Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine.
    AIDS (London, England), 2003, Jul-25, Volume: 17, Issue:11

    Topics: Adult; Developing Countries; Drug Resistance, Viral; Female; Gene Frequency; HIV Infections; HIV-1;

2003
South African government to withdraw antiretrovirals for pregnant mothers.
    BMJ (Clinical research ed.), 2003, Aug-09, Volume: 327, Issue:7410

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Approval; Female; Humans; Nevirapine; Preg

2003
Scaling the frontier--should traditional birth attendants also be used to provide nevirapine for PMTCT in Uganda?
    African health sciences, 2003, Volume: 3, Issue:2

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infectious Disease Transmission, Ver

2003
Cost-effectiveness of strategies to reduce mother-to-child HIV transmission in Mexico, a low-prevalence setting.
    Health policy and planning, 2003, Volume: 18, Issue:3

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Cesarean Section; Cost of Illness; Cost-Benefit

2003
South African government threatens to ban nevirapine. Move would take away option for treating vertical HIV transmission.
    Lancet (London, England), 2003, Aug-09, Volume: 362, Issue:9382

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Disease Outbreaks; Dr

2003
[Antiviral agents for reduction of mother-to-child transmission of HIV infection].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2003, Aug-14, Volume: 123, Issue:15

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Evidence-Based Medicine; Female; HIV Infecti

2003
Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1.
    Lancet (London, England), 2003, Aug-23, Volume: 362, Issue:9384

    Topics: Anti-HIV Agents; Antibodies, Viral; Child; Developed Countries; Female; Fetal Blood; HIV Infections;

2003
Long-term findings of HIVNET 012: the next steps.
    Lancet (London, England), 2003, Sep-13, Volume: 362, Issue:9387

    Topics: Anti-HIV Agents; Clinical Protocols; Disease Outbreaks; Disease-Free Survival; Drug Administration S

2003
Decision analysis to guide choice of interventions to reduce mother-to-child transmission of HIV.
    AIDS (London, England), 2003, Sep-26, Volume: 17, Issue:14

    Topics: Anti-Retroviral Agents; Breast Feeding; Child, Preschool; Decision Support Techniques; Decision Tree

2003
Role of endogenous reverse transcriptase in murine early embryo development.
    Molecular reproduction and development, 2003, Volume: 66, Issue:3

    Topics: Animals; Antibodies; Cell-Free System; Embryonic and Fetal Development; Embryonic Development; Femal

2003
The relationship between prevention of mother to child transmission of HIV and stakeholder decision making in Uganda: implications for health policy.
    Health policy (Amsterdam, Netherlands), 2003, Volume: 66, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Attitude to Health; Cost-Benefit Analysis; E

2003
Preventing mother-to-child HIV transmission in a developing country: the Dominican Republic experience.
    Journal of acquired immune deficiency syndromes (1999), 2003, Dec-15, Volume: 34, Issue:5

    Topics: Bottle Feeding; Delivery, Obstetric; Developing Countries; Dominican Republic; Female; HIV Infection

2003
Nevirapine reduced mother-to-child transmission better than AZT--at 70 times less the cost.
    AIDS treatment news, 2003, Sep-12, Issue:394

    Topics: Drug Costs; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertic

2003
HIVNET 012 and Petra.
    Lancet (London, England), 2004, Jan-17, Volume: 363, Issue:9404

    Topics: Anti-HIV Agents; Counseling; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant, Newbo

2004
HIVNET 012 and Petra.
    Lancet (London, England), 2004, Jan-17, Volume: 363, Issue:9404

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; I

2004
HIVNET 012 and Petra.
    Lancet (London, England), 2004, Jan-17, Volume: 363, Issue:9404

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Follow-Up Studies; Genetic Variation; HIV Infection

2004
HIVNET 012 and Petra.
    Lancet (London, England), 2004, Jan-17, Volume: 363, Issue:9404

    Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newborn;

2004
Nurses in Zambia gain access to antiretroviral treatment.
    International nursing review, 2004, Volume: 51, Issue:1

    Topics: Anti-HIV Agents; Female; Health Policy; Health Services Accessibility; HIV Infections; Humans; Mater

2004
Preventing mother-to-child transmission: landmark decision by South African court.
    Canadian HIV/AIDS policy & law review, 2002, Volume: 6, Issue:3

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr

2002
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
    American journal of obstetrics and gynecology, 2004, Volume: 190, Issue:2

    Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In

2004
Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings.
    AIDS (London, England), 2004, Apr-09, Volume: 18, Issue:6

    Topics: Adult; Anti-HIV Agents; Developing Countries; Directly Observed Therapy; Female; HIV Infections; Hum

2004
Mother-to-child transmission. How will AZT and nevirapine use for MTCT affect future treatment? Two studies provide clues.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 2004,Winter, Volume: 16, Issue:2

    Topics: CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmissi

2004
HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda.
    AIDS research and human retroviruses, 2004, Volume: 20, Issue:3

    Topics: Drug Resistance, Viral; Female; Genes, pol; HIV Infections; HIV Protease; HIV Reverse Transcriptase;

2004
Retrovirus conferees discuss new strategies.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004, Apr-01, Volume: 61, Issue:7

    Topics: Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant, Newborn;

2004
PMTCT from research to reality--results from a routine service.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:4

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease

2004
Nevirapine warning.
    AIDS patient care and STDs, 2004, Volume: 18, Issue:4

    Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; HIV Infections; Humans; Nevirapine;

2004
Nevirapine may promote resistance.
    AIDS patient care and STDs, 2004, Volume: 18, Issue:4

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infectious Disease Transmis

2004
Immune status and uptake of antiretroviral interventions to prevent mother-to-child transmission of HIV-1 in Africa.
    Journal of acquired immune deficiency syndromes (1999), 2004, Jun-01, Volume: 36, Issue:2

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Female; HIV Infections; HIV-1; Humans;

2004
Prevention of mother-to-child transmission of HIV at Maiduguri, Nigeria.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2004, Volume: 24, Issue:3

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease

2004
Risk of archived resistance after intrapartum nevirapine.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:5

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; Humans;

2004
Nevirapine-induced resistance is a problem.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:5

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; Humans;

2004
Acceptability and utilisation of voluntary HIV testing and nevirapine to reduce mother-to-child transmission of HIV-1 integrated into routine clinical care.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:5

    Topics: Anti-HIV Agents; Diagnostic Tests, Routine; Female; HIV Infections; HIV-1; Humans; Infant Welfare; I

2004
Implementing a rural programme of prevention of mother-to-child transmission of HIV in Zimbabwe: first 18 months of experience.
    Tropical medicine & international health : TM & IH, 2004, Volume: 9, Issue:7

    Topics: Adolescent; Adult; Anti-HIV Agents; Attitude to Health; Female; HIV Infections; Humans; Infectious D

2004
Antiretroviral agents--how best to protect infants from HIV and save their mothers from AIDS.
    The New England journal of medicine, 2004, Jul-15, Volume: 351, Issue:3

    Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Developing Countries; Drug Resistance

2004
Health minister ignites row over drugs for HIV mothers.
    Nature, 2004, Jul-22, Volume: 430, Issue:6998

    Topics: Congresses as Topic; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Infant, Newborn; I

2004
Some design issues in trials of microbicides for the prevention of HIV infection.
    The Journal of infectious diseases, 2004, Aug-15, Volume: 190, Issue:4

    Topics: Anti-HIV Agents; Anti-Infective Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase I

2004
Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries.
    AIDS (London, England), 2004, Aug-20, Volume: 18, Issue:12

    Topics: Adult; Anti-HIV Agents; Botswana; Cost-Benefit Analysis; Cote d'Ivoire; Female; HIV Infections; Huma

2004
South Africa rejects use of AIDS drug for women.
    The New York times on the Web, 2004, Jul-14

    Topics: Acquired Immunodeficiency Syndrome; Female; Health Policy; HIV Infections; Humans; Infectious Diseas

2004
Low efficacy of nevirapine (HIVNET012) in preventing perinatal HIV-1 transmission in a real-life situation.
    AIDS (London, England), 2004, Sep-03, Volume: 18, Issue:13

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Nevirapine; Pregnancy; Pregnancy Complicatio

2004
Mutations correlated to NVP concentrations.
    AIDS patient care and STDs, 2004, Volume: 18, Issue:8

    Topics: Drug Resistance, Viral; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis

2004
Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy.
    American journal of obstetrics and gynecology, 2004, Volume: 191, Issue:3

    Topics: Abnormalities, Drug-Induced; Anti-Retroviral Agents; Female; Gestational Age; Humans; Lamivudine; Ma

2004
Perinatal HIV research unit clarifies nevirapine resistance and transmission issues.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:9

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; H

2004
Decreased likelihood [correction of likelyhood] of infants contracting HIV when taking nevirapine.
    Expert review of anti-infective therapy, 2003, Volume: 1, Issue:3

    Topics: Female; HIV Infections; Humans; Infant; Infant, Newborn; Nevirapine; Pregnancy

2003
Nevirapine plus zidovudine to prevent mother-to-child transmission of HIV.
    The New England journal of medicine, 2004, Nov-04, Volume: 351, Issue:19

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2004
Nevirapine plus zidovudine to prevent mother-to-child transmission of HIV.
    The New England journal of medicine, 2004, Nov-04, Volume: 351, Issue:19

    Topics: Anti-Retroviral Agents; DNA, Viral; Female; HIV; HIV Infections; Humans; Infant, Newborn; Infectious

2004
The efficacy-effectiveness gap in PMTCT.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:10

    Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease

2004
Meeting report from the XV International AIDS Conference. Perinatal transmission.
    AIDS clinical care, 2004, Volume: 16, Issue:9

    Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi

2004
[Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].
    Nederlands tijdschrift voor geneeskunde, 2004, Oct-09, Volume: 148, Issue:41

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; F

2004
Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission.
    Journal of acquired immune deficiency syndromes (1999), 2004, Dec-15, Volume: 37, Issue:5

    Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Condoms; Contact Tracing; Counseling; Fa

2004
Reduction of materno-fetal transmission of HIV by improved delivery techniques combined with nevirapine treatment in women attending two family planning clinics in Yaounde, Cameroon.
    International journal of STD & AIDS, 2004, Volume: 15, Issue:12

    Topics: Adolescent; Adult; Anti-HIV Agents; Cameroon; Delivery, Obstetric; Family Planning Services; Female;

2004
Activists and researchers rally behind AIDS drug for mothers.
    Nature, 2004, Dec-23, Volume: 432, Issue:7020

    Topics: Acquired Immunodeficiency Syndrome; Africa; Clinical Trials as Topic; Female; Humans; Infant, Newbor

2004
HIV transmission. Allegations raise fears of backlash against AIDS prevention strategy.
    Science (New York, N.Y.), 2004, Dec-24, Volume: 306, Issue:5705

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant; Infant, Newborn;

2004
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
    AIDS (London, England), 2005, Jan-03, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther

2005
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
    AIDS (London, England), 2005, Jan-03, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther

2005
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
    AIDS (London, England), 2005, Jan-03, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther

2005
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
    AIDS (London, England), 2005, Jan-03, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther

2005
Articles criticising nevirapine trial may endanger babies' lives.
    BMJ (Clinical research ed.), 2005, Jan-08, Volume: 330, Issue:7482

    Topics: Anti-HIV Agents; Controlled Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newbor

2005
HIV seroprevalence, uptake of interventions to reduce mother-to-child transmission and birth outcomes in greater Kingston, Jamaica.
    The West Indian medical journal, 2004, Volume: 53, Issue:5

    Topics: Adolescent; Adult; Female; HIV Infections; HIV Seropositivity; HIV Seroprevalence; Humans; Infectiou

2004
Uptake of interventions, outcomes and challenges in caring for HIV-exposed infants in Kingston, Jamaica.
    The West Indian medical journal, 2004, Volume: 53, Issue:5

    Topics: Antibiotic Prophylaxis; Female; HIV Infections; Humans; Infant; Infant Care; Infant, Newborn; Infect

2004
Zidovudine monotherapy and the prevention of mother-to-child HIV-1 transmission.
    The Lancet. Infectious diseases, 2005, Volume: 5, Issue:2

    Topics: Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis

2005
Recent advances in prevention of mother to child (PMTCT) of HIV.
    African health sciences, 2004, Volume: 4, Issue:3

    Topics: Africa; Anti-HIV Agents; Breast Feeding; Disease Outbreaks; Female; HIV Infections; Humans; Infant,

2004
Effectiveness of nevirapine and zidovudine in a pilot program for the prevention of mother-to-child transmission of HIV-1 in Uganda.
    African health sciences, 2004, Volume: 4, Issue:3

    Topics: Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Disease Outbreaks; Female; HIV Infections;

2004
Top stories of 2004. Perinatal transmission interventions: the benefits come with resistance.
    AIDS clinical care, 2005, Volume: 17, Issue:1

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr

2005
Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission.
    AIDS (London, England), 2005, Feb-18, Volume: 19, Issue:3

    Topics: Adult; Anti-HIV Agents; Cote d'Ivoire; Developing Countries; Drug Therapy, Combination; Female; HIV

2005
Activists angry at fallout from AIDS drug trial allegations.
    Nature medicine, 2005, Volume: 11, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Female; Humans; Infan

2005
Reports on nevirapine threaten public health.
    Nature medicine, 2005, Volume: 11, Issue:3

    Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Female; Government Publications as Topic; HIV Infe

2005
HIV drug remains unproven without placebo trial.
    Nature, 2005, Mar-10, Volume: 434, Issue:7030

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi

2005
FDA advisory on nevirapine.
    AIDS treatment news, 2005, Jan-28, Issue:409

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Nevirapine; Pregnan

2005
Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding.
    Journal of acquired immune deficiency syndromes (1999), 2005, Apr-15, Volume: 38, Issue:5

    Topics: Anti-HIV Agents; Breast Feeding; Costs and Cost Analysis; Female; HIV Infections; HIV Seroprevalence

2005
Should nevirapine be used to prevent mother-to-child transmission of HIV among women of unknown serostatus?
    Bulletin of the World Health Organization, 2005, Volume: 83, Issue:3

    Topics: Anti-HIV Agents; Female; Health Status; HIV Infections; HIV Seropositivity; Humans; Infectious Disea

2005
Routine provision of nevirapine to women of unknown serostatus: at best a temporary solution to prevent MTCT.
    Bulletin of the World Health Organization, 2005, Volume: 83, Issue:3

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infe

2005
Women in couples antenatal HIV counseling and testing are not more likely to report adverse social events.
    AIDS (London, England), 2005, Mar-24, Volume: 19, Issue:6

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Cohort Studies; Counseling; Disclosure; Divorce; Domestic Vi

2005
AIDS research. IOM panel clears HIV prevention study.
    Science (New York, N.Y.), 2005, Apr-15, Volume: 308, Issue:5720

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectio

2005
Nevirapine-related death draws attention.
    AIDS patient care and STDs, 2005, Volume: 19, Issue:3

    Topics: Clinical Trials as Topic; Fatal Outcome; Female; HIV Infections; Humans; Liver Failure; National Ins

2005
Resistance with short-course nevirapine.
    AIDS patient care and STDs, 2005, Volume: 19, Issue:3

    Topics: Clinical Trials as Topic; Drug Resistance, Viral; Female; HIV Infections; Humans; Nevirapine; Pregna

2005
Averting drug resistance while preventing MTCT.
    The AIDS reader, 2005, Volume: 15, Issue:4

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; Human

2005
Maternal self-medication and provision of nevirapine to newborns by women in Rakai, Uganda.
    Journal of acquired immune deficiency syndromes (1999), 2005, May-01, Volume: 39, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2005
A drug is effective if better than a harmless control.
    Nature, 2005, Apr-28, Volume: 434, Issue:7037

    Topics: Controlled Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Dis

2005
Nelfinavir and nevirapine side effects during pregnancy.
    AIDS (London, England), 2005, May-20, Volume: 19, Issue:8

    Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymp

2005
Reducing HIV vertical transmission scrutinized.
    JAMA, 2005, May-04, Volume: 293, Issue:17

    Topics: Anti-HIV Agents; Developing Countries; Drug Resistance, Viral; Female; HIV Infections; Humans; Infan

2005
Nevirapine misinformation: will it kill?
    IAPAC monthly, 2004, Volume: 10, Issue:12

    Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi

2004
IOM: nevirapine study is reliable.
    AIDS treatment news, 2005, Mar-25, Issue:411

    Topics: Clinical Trials as Topic; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, V

2005
Single-dose nevirapine and drug resistance: the more you look, the more you find.
    The Journal of infectious diseases, 2005, Jul-01, Volume: 192, Issue:1

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; Human

2005
Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.
    The Journal of infectious diseases, 2005, Jul-01, Volume: 192, Issue:1

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1

2005
Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.
    The Journal of infectious diseases, 2005, 07-01, Volume: 192, Issue:1

    Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV Infecti

2005
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.
    The Journal of infectious diseases, 2005, Jul-01, Volume: 192, Issue:1

    Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV

2005
Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine.
    AIDS research and human retroviruses, 2005, Volume: 21, Issue:4

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Protea

2005
Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012.
    Journal of acquired immune deficiency syndromes (1999), 2005, Aug-15, Volume: 39, Issue:5

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Female; Genotype; HIV Infections; HIV-1; Humans; Infectious D

2005
Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia.
    AIDS (London, England), 2005, Aug-12, Volume: 19, Issue:12

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; Fetal Blood; HIV Infections; Humans; Infant, Newb

2005
Roundtable. Revisiting the role of single-dose nevirapine for preventing perinatal HIV transmission.
    AIDS clinical care, 2005, Volume: 17, Issue:7

    Topics: Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tr

2005
Attitudes to voluntary counselling and testing prior to the offer of Nevirapine to prevent vertical transmission of HIV in northern Tanzania.
    AIDS care, 2005, Volume: 17, Issue:7

    Topics: Adolescent; Adult; Anti-HIV Agents; Attitude to Health; Counseling; Female; Focus Groups; HIV Infect

2005
Addressing the paediatric HIV epidemic: a perspective from the Western Cape Region of South Africa.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, Volume: 100, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Disease Outbreaks; Female; HIV Infections; Humans; Infant

2006
Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa.
    Bulletin of the World Health Organization, 2005, Volume: 83, Issue:7

    Topics: Adult; Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Female; HIV Infections; Humans; Inf

2005
Nevirapine concentration in cervicovaginal and oropharyngeal secretions after single-dose administration to the mother.
    Antiviral therapy, 2005, Volume: 10, Issue:6

    Topics: Anti-HIV Agents; Cervix Uteri; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Di

2005
Preventing mother-to-child transmission of HIV in Western Kenya: operational issues.
    Journal of acquired immune deficiency syndromes (1999), 2005, Nov-01, Volume: 40, Issue:3

    Topics: Anti-HIV Agents; Counseling; Developing Countries; Female; HIV Infections; Hospitals, General; Hospi

2005
Third-trimester maternal toxicity with nevirapine use in pregnancy.
    Obstetrics and gynecology, 2005, Volume: 106, Issue:5 Pt 1

    Topics: Adolescent; Adult; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Nevirapine; Pregnanc

2005
Integrating prevention of mother-to-child HIV transmission into routine antenatal care: the key to program expansion in Cameroon.
    Journal of acquired immune deficiency syndromes (1999), 2005, Dec-01, Volume: 40, Issue:4

    Topics: Adolescent; Adult; Age Factors; Anti-HIV Agents; Cameroon; Counseling; Female; HIV Infections; Human

2005
Predictors of nonadherence to single-dose nevirapine therapy for the prevention of mother-to-child HIV transmission.
    Journal of acquired immune deficiency syndromes (1999), 2006, Jan-01, Volume: 41, Issue:1

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Home Childbirth; Humans; Infant, Low Birth Wei

2006
[Detection of HIV infection in pregnant women by rapid testing: a successful strategy to reduce its vertical transmission].
    Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia, 2005, Volume: 22, Issue:4

    Topics: Adolescent; Adult; Anti-HIV Agents; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Female; HI

2005
Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.
    AIDS research and human retroviruses, 2005, Volume: 21, Issue:12

    Topics: Adult; Anti-HIV Agents; Chemoprevention; Cote d'Ivoire; DNA, Viral; Drug Resistance, Viral; Female;

2005
Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
    American journal of obstetrics and gynecology, 2006, Volume: 194, Issue:1

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholestasis; Cohort Studies; Female; Hepatitis B; Hepa

2006
HIV and pregnancy at the 12 CROI.
    The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 2005, Volume: 17, Issue:2

    Topics: AIDS Serodiagnosis; Diabetes, Gestational; Drug Resistance, Viral; Female; HIV Infections; HIV Prote

2005
Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1.
    The Journal of infectious diseases, 2006, Feb-15, Volume: 193, Issue:4

    Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H

2006
Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire.
    The Journal of infectious diseases, 2006, Feb-15, Volume: 193, Issue:4

    Topics: Cote d'Ivoire; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hum

2006
The value of contraception to prevent perinatal HIV transmission.
    Sexually transmitted diseases, 2006, Volume: 33, Issue:6

    Topics: Adolescent; Adult; Africa South of the Sahara; Anti-HIV Agents; Contraception; Cost-Benefit Analysis

2006
Transmission of human immunodeficiency virus type 1 nevirapine resistance mutation K103N from a treatment-naive mother to her child.
    The Pediatric infectious disease journal, 2006, Volume: 25, Issue:3

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Fatal Outcome; Female; HIV Infections; HIV-1; Humans; Infan

2006
The controversies of nevirapine for preventing mother-to-child HIV transmission.
    AIDS (London, England), 2006, Jan-09, Volume: 20, Issue:2

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2006
Unrecognized near-fatal hyperlactatemia in an HIV-infected infant exposed to nucleoside reverse transcriptase inhibitors.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2007, Volume: 11, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Lactates; Lamivudine; Male; Mitoch

2007
Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.
    AIDS (London, England), 2006, Apr-24, Volume: 20, Issue:7

    Topics: Anti-HIV Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Female; Gene Freq

2006
This is no time to stop use of nevarapine to prevent mother-to-child transmission of HIV.
    AIDS (London, England), 2006, Apr-24, Volume: 20, Issue:7

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant, Newborn; Infectious

2006
Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy.
    HIV medicine, 2006, Volume: 7, Issue:4

    Topics: Adolescent; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Chemical and Drug

2006
Cost-effectiveness of HIV rescreening during late pregnancy to prevent mother-to-child HIV transmission in South Africa and other resource-limited settings.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:2

    Topics: Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Female; HIV Infection

2006
Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.
    Proceedings of the National Academy of Sciences of the United States of America, 2006, May-02, Volume: 103, Issue:18

    Topics: Adult; Alleles; Anti-HIV Agents; Child; Drug Resistance, Microbial; Female; Genotype; HIV Infections

2006
Prevention of mother-to-child transmission of HIV in Cameroon: experiences from the University Teaching Hospital in Yaounde (Cameroon).
    Zentralblatt fur Gynakologie, 2006, Volume: 128, Issue:2

    Topics: Administration, Oral; Anti-HIV Agents; Cameroon; Developing Countries; Female; Follow-Up Studies; HI

2006
HIV denialists ignore large gap in the study they cite.
    Nature, 2006, May-25, Volume: 441, Issue:7092

    Topics: Clinical Trials as Topic; Denial, Psychological; Female; History, 20th Century; HIV Infections; HIV

2006
Routine intrapartum HIV counseling and testing for prevention of mother-to-child transmission of HIV in a rural Ugandan hospital.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:2

    Topics: Anti-HIV Agents; Counseling; Feasibility Studies; Female; HIV Infections; HIV Seropositivity; Humans

2006
Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:2

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Revers

2006
Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D.
    Journal of acquired immune deficiency syndromes (1999), 2006, Aug-15, Volume: 42, Issue:5

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections;

2006
Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D.
    Journal of acquired immune deficiency syndromes (1999), 2006, Aug-01, Volume: 42, Issue:4

    Topics: Black People; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vert

2006
In vivo effects of HIV-1 exposure in the presence and absence of single-dose nevirapine on cellular plasma activation markers of infants born to HIV-1-seropositive mothers.
    Journal of acquired immune deficiency syndromes (1999), 2006, Aug-15, Volume: 42, Issue:5

    Topics: Adult; Anti-HIV Agents; beta 2-Microglobulin; Biomarkers; Blood Chemical Analysis; Female; Fetal Blo

2006
Outcome of different nevirapine administration strategies in preventing mother-to-child transmission (PMTCT) programs in Tanzania and Uganda.
    MedGenMed : Medscape general medicine, 2006, Apr-12, Volume: 8, Issue:2

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; N

2006
Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.
    AIDS (London, England), 2006, Aug-22, Volume: 20, Issue:13

    Topics: Amniotic Fluid; Antiretroviral Therapy, Highly Active; Drug Combinations; Drug Interactions; Female;

2006
Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women.
    HIV medicine, 2006, Volume: 7, Issue:5

    Topics: Adult; Antiretroviral Therapy, Highly Active; Black People; CD4 Lymphocyte Count; Cohort Studies; Fe

2006
Rapid HIV testing and counselling in labour in a northern Nigerian setting.
    African journal of reproductive health, 2006, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Counseling; Cross-Sectional Studies; Female; HIV Infections; HIV

2006
Stability of nevirapine suspension in prefilled oral syringes used for reduction of mother-to-child HIV transmission.
    Journal of acquired immune deficiency syndromes (1999), 2006, Nov-01, Volume: 43, Issue:3

    Topics: Administration, Oral; Anti-HIV Agents; Drug Packaging; Drug Stability; Drug Storage; Female; HIV Inf

2006
Implementation of single-dose nevirapine for prevention of MTCT of HIV--lessons from Cape Town.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2006, Volume: 96, Issue:8

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Guideline Adherence; Health Planning; HIV Inf

2006
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.
    British journal of clinical pharmacology, 2006, Volume: 62, Issue:5

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Pregnancy; Pr

2006
Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine.
    Journal of acquired immune deficiency syndromes (1999), 2007, Feb-01, Volume: 44, Issue:2

    Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV; HIV Infections

2007
The ethics of placebo-controlled studies on perinatal HIV transmission and its treatment in the developing world.
    Penn bioethics journal, 2006,Spring, Volume: 2, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; Control Groups; Controlled Clinical Trials as Topic; Developing Cou

2006
Estimation of the rate of mother to child transmission of HIV in Nigeria.
    African journal of medicine and medical sciences, 2006, Volume: 35, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Female; HIV Infecti

2006
A model of directional selection applied to the evolution of drug resistance in HIV-1.
    Molecular biology and evolution, 2007, Volume: 24, Issue:4

    Topics: Anti-HIV Agents; Codon; Computer Simulation; Drug Resistance, Viral; Evolution, Molecular; Female; G

2007
Survival in women exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV: a stochastic model.
    The Journal of infectious diseases, 2007, Mar-15, Volume: 195, Issue:6

    Topics: Africa South of the Sahara; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infect

2007
Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
    BMC infectious diseases, 2007, Mar-12, Volume: 7

    Topics: Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dru

2007
Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine.
    AIDS (London, England), 2007, May-11, Volume: 21, Issue:8

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Administra

2007
Expanded services for the prevention of mother-to-child HIV transmission: field acceptability of a pilot program in Lusaka, Zambia.
    Journal of acquired immune deficiency syndromes (1999), 2007, May-01, Volume: 45, Issue:1

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cities; Drug Therapy, Combination; Female; HIV Infections; Hu

2007
Home deliveries: implications for adherence to nevirapine in a PMTCT programme in rural Malawi.
    AIDS care, 2007, Volume: 19, Issue:5

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Delivery, Obstetric; Female; HIV Infections; Home Childbi

2007
Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jun-15, Volume: 44, Issue:12

    Topics: Adolescent; Adult; Africa, Western; Antiretroviral Therapy, Highly Active; Europe; Female; HIV Infec

2007
Delaying maternal NVP-based ART more effective.
    IAPAC monthly, 2007, Volume: 13, Issue:1

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr

2007
Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:5

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Feasibility Studies; Fema

2007
Safety of HIV-1 Perinatal Transmission Prophylaxis With Zidovudine and Nevirapine in Rural South India.
    Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 2007, Volume: 6, Issue:2

    Topics: Anti-HIV Agents; Cohort Studies; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmiss

2007
Surveillance of mother-to-child transmission prevention programmes at immunization clinics: the case for universal screening.
    AIDS (London, England), 2007, Jun-19, Volume: 21, Issue:10

    Topics: Adolescent; Adult; Ambulatory Care Facilities; Anti-HIV Agents; Drug Administration Schedule; Female

2007
Safety issues about nevirapine administration in HIV-infected pregnant women.
    Journal of acquired immune deficiency syndromes (1999), 2007, Jul-01, Volume: 45, Issue:3

    Topics: Adult; Anti-HIV Agents; Bilirubin; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Con

2007
Persistence of nevirapine in breast milk after discontinuation of treatment.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Aug-01, Volume: 45, Issue:3

    Topics: Anti-HIV Agents; Female; Functional Laterality; HIV Infections; Humans; Milk, Human; Nevirapine; Pre

2007
Effect of exposure to clinic-based health education interventions on behavioural intention to prevent mother-to-child transmission of HIV infection.
    SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance, 2006, Volume: 3, Issue:1

    Topics: Adolescent; Adult; Catchment Area, Health; Condoms; Cross-Sectional Studies; Female; Health Behavior

2006
Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
    HIV medicine, 2007, Volume: 8, Issue:6

    Topics: Antiretroviral Therapy, Highly Active; Drug Eruptions; Female; HIV Infections; Humans; Infectious Di

2007
African infants' CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine.
    AIDS (London, England), 2007, Aug-20, Volume: 21, Issue:13

    Topics: Adult; Anti-HIV Agents; Case-Control Studies; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Chemok

2007
Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
    PLoS medicine, 2007, Volume: 4, Issue:8

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Cohort

2007
Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:8

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; M

2007
Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine.
    AIDS (London, England), 2007, Oct-01, Volume: 21, Issue:15

    Topics: Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infectious Disease

2007
[Treatment of children born of AIDS mothers in Tsevie hospital regional center, Togo].
    Bulletin de la Societe de pathologie exotique (1990), 2007, Volume: 100, Issue:4

    Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Breast Feeding; Child Health Services; Femal

2007
Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine.
    Lancet (London, England), 2007, Nov-17, Volume: 370, Issue:9600

    Topics: Anti-HIV Agents; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; I

2007
Dandy-Walker variant in an infant prenatally exposed to antiretroviral medication.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2007, Volume: 97, Issue:10

    Topics: Adult; Anti-Retroviral Agents; Dandy-Walker Syndrome; Female; Heart Ventricles; HIV Infections; Huma

2007
Reverse transcriptase mutations in Cambodian CRF01_AE isolates after antiretroviral prophylaxis against HIV Type 1 perinatal transmission.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:12

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cambodia; Female; HIV Infections; HIV Revers

2007
Characterization of HIV type 1 reverse transcriptase mutations in infants infected by mothers who received peripartum nevirapine prophylaxis in Jos, Nigeria.
    AIDS research and human retroviruses, 2007, Volume: 23, Issue:12

    Topics: Amino Acid Sequence; Anti-HIV Agents; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Huma

2007
Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda.
    Journal of acquired immune deficiency syndromes (1999), 2007, Nov-01, Volume: 46, Issue:3

    Topics: Anti-HIV Agents; Cohort Studies; DNA, Viral; Female; Follow-Up Studies; HIV; HIV Infections; Humans;

2007
[Side effects of antiretroviral treatment for transmission prophylaxis in preterm and near-term infants].
    Zeitschrift fur Geburtshilfe und Neonatologie, 2007, Volume: 211, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cesarean Section; Female; Gestational Age; HIV

2007
Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Feb-15, Volume: 46, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Drug Resistance, Viral; Female; HIV Inf

2008
Outputs, cost and efficiency of public sector centres for prevention of mother to child transmission of HIV in Andhra Pradesh, India.
    BMC health services research, 2008, Jan-31, Volume: 8

    Topics: Abortion, Induced; AIDS Serodiagnosis; Anti-HIV Agents; Costs and Cost Analysis; Counseling; Deliver

2008
A grave delay for South Africa's mothers and infants.
    Lancet (London, England), 2008, Feb-02, Volume: 371, Issue:9610

    Topics: Female; Health Policy; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine

2008
From PMTCT to a more comprehensive AIDS response for women: a much-needed shift.
    Developing world bioethics, 2008, Volume: 8, Issue:1

    Topics: Abortion, Induced; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Developing Countries;

2008
Estimating vertically acquired HIV infections and the impact of the prevention of mother-to-child transmission program in Zimbabwe: insights from decision analysis models.
    Journal of acquired immune deficiency syndromes (1999), 2008, May-01, Volume: 48, Issue:1

    Topics: Decision Support Techniques; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tra

2008
Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2007, Volume: 11, Issue:6

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Drug Eruptions

2007
Incidence of nevirapine-associated hepatitis in an antenatal clinic.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2008, Volume: 98, Issue:2

    Topics: Adult; Alanine Transaminase; Ambulatory Care Facilities; Chemical and Drug Induced Liver Injury; Fem

2008
Feasibility of prevention of perinatal HIV infection by nevirapine in rural areas of the northeast Democratic Republic of Congo, 2002-2004.
    Journal of medical virology, 2008, Volume: 80, Issue:5

    Topics: Chemoprevention; Democratic Republic of the Congo; Female; HIV Infections; Humans; Infant, Newborn;

2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy;

2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy;

2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy;

2008
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy;

2008
Steady-state nevirapine plasma concentrations are influenced by pregnancy.
    HIV medicine, 2008, Volume: 9, Issue:4

    Topics: Adult; Africa; Case-Control Studies; Female; HIV Infections; HIV-1; Humans; Infectious Disease Trans

2008
Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
    Antiviral therapy, 2008, Volume: 13, Issue:1

    Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Multiple, Viral;

2008
Characteristics of pregnancy with human immuno-deficiency virus (HIV) and perinatal transmission in Nakornping Hospital.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2008, Volume: 91, Issue:2

    Topics: Adolescent; Adult; Anti-Retroviral Agents; Female; HIV Infections; Humans; Incidence; Infant, Newbor

2008
Self-reported adherence to single dose nevirapine in the prevention of mother to child transmission of HIV at Kitale District Hospital.
    East African medical journal, 2007, Volume: 84, Issue:12

    Topics: Adolescent; Adult; Anti-HIV Agents; Child; Child Welfare; Cross-Sectional Studies; Female; Health Su

2007
Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa.
    Journal of medical virology, 2008, Volume: 80, Issue:6

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H

2008
[Nevirapine: a new principle of action against HIV].
    Deutsche medizinische Wochenschrift (1946), 1996, Dec-06, Volume: 121, Issue:49

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Do

1996
Low-cost drug cuts perinatal HIV-transmission rate.
    Lancet (London, England), 1999, Jul-24, Volume: 354, Issue:9175

    Topics: Anti-HIV Agents; Drug Costs; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tra

1999
Uganda gives lessons in stemming the AIDS epidemic.
    Nature medicine, 1999, Volume: 5, Issue:9

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Disease Outbreaks; Female; Government; Health P

1999
Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
    Lancet (London, England), 1999, Sep-04, Volume: 354, Issue:9181

    Topics: Africa South of the Sahara; Anti-HIV Agents; Cost-Benefit Analysis; Drug Administration Schedule; Fe

1999
Call to buy nevirapine for developing countries.
    Nature medicine, 1999, Volume: 5, Issue:10

    Topics: Africa; Congresses as Topic; Developing Countries; Female; HIV Infections; Humans; India; Infectious

1999
Perinatal HIV prevention.
    JAMA, 1999, Aug-18, Volume: 282, Issue:7

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

1999
AIDS drug trials in Thailand and Uganda.
    Nature medicine, 1999, Volume: 5, Issue:11

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectio

1999
HIVNET nevirapine trials.
    Lancet (London, England), 1999, Nov-20, Volume: 354, Issue:9192

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Infant, Newbor

1999
HIVNET nevirapine trials.
    Lancet (London, England), 1999, Nov-20, Volume: 354, Issue:9192

    Topics: Anti-HIV Agents; Cost-Benefit Analysis; Counseling; Developing Countries; Female; HIV Infections; HI

1999
HIVNET nevirapine trials.
    Lancet (London, England), 1999, Nov-20, Volume: 354, Issue:9192

    Topics: Anti-HIV Agents; Counseling; Ethics, Medical; Female; HIV Infections; HIV-1; Humans; Infectious Dise

1999
Concern at cheap AIDS drug fears.
    Nature, 1999, Nov-25, Volume: 402, Issue:6760

    Topics: Acquired Immunodeficiency Syndrome; Africa, Southern; Anti-HIV Agents; Costs and Cost Analysis; Fema

1999
The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome.
    International journal of STD & AIDS, 2000, Volume: 11, Issue:4

    Topics: Adolescent; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease

2000
Deaths bring South African HIV drug trials to a premature halt.
    Nature, 2000, Apr-13, Volume: 404, Issue:6779

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Drug T

2000
Flirting with strange ideas. Mbeki reaches out to a controversial AIDS researcher.
    Newsweek, 2000, Apr-17, Volume: 135, Issue:16

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Biochemistry; Clinical Trials as Topic;

2000
Beanie Baby profits support AIDS foundation.
    Nature medicine, 2000, Volume: 6, Issue:7

    Topics: Acquired Immunodeficiency Syndrome; Female; Foundations; Humans; Infectious Disease Transmission, Ve

2000
The mother of all HIV challenges.
    Science (New York, N.Y.), 2000, Jun-23, Volume: 288, Issue:5474

    Topics: Africa South of the Sahara; AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Clinical Trials as

2000
Pharmacological implications of lengthened in-utero exposure to nevirapine.
    Lancet (London, England), 2000, Jun-17, Volume: 355, Issue:9221

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Fetal Blood; Half-Life; HIV Infections; HIV-1

2000
Mbeki gives AIDS scientists the cold shoulder.
    Nature, 2000, Jul-13, Volume: 406, Issue:6792

    Topics: Acquired Immunodeficiency Syndrome; Adult; Breast Feeding; Enzyme-Linked Immunosorbent Assay; Female

2000
Diplomatic Mandela calls for action on HIV...as South Africa considers its options after free drugs offer.
    Nature, 2000, Jul-20, Volume: 406, Issue:6793

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Child; Drug Costs; Drug Industry; Female

2000
South African government continues policy of inactivity.
    Nature medicine, 2000, Volume: 6, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Female; HIV Infections; Humans; Maternal-Fetal

2000
AZT blues.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2000, Volume: 90, Issue:7

    Topics: Anti-HIV Agents; Counseling; Female; Foster Home Care; HIV Infections; HIV-1; Humans; Infant, Newbor

2000
Prevention of mother-child HIV transmission: progress and problems.
    Prescrire international, 2000, Volume: 9, Issue:47

    Topics: Africa; Antiviral Agents; Breast Feeding; Cesarean Section; Clinical Trials as Topic; Cohort Studies

2000
Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa.
    Journal of acquired immune deficiency syndromes (1999), 2000, Aug-01, Volume: 24, Issue:4

    Topics: Africa South of the Sahara; AIDS Serodiagnosis; Anti-HIV Agents; Cost-Benefit Analysis; Decision Sup

2000
Inexpensive AIDS drug still reduces HIV transmission from mother to child after 1 year.
    The AIDS reader, 2000, Volume: 10, Issue:9

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Follow-Up Studies

2000
No turning back now.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2000, Volume: 90, Issue:9

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmis

2000
Human immunodeficiency virus type-1: mother-to-child transmission. Meeting of World Federation of Scientists in Erice, Italy, August 2000. Joint report of AIDS/Infectious Diseases PMP and Mother and Child PMP.
    Acta paediatrica (Oslo, Norway : 1992), 2000, Volume: 89, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Africa South of the Sahara; Age Factors; Anti-HIV Agents; Breast

2000
Future directions.
    Annals of the New York Academy of Sciences, 2000, Volume: 918

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Counseling; Fem

2000
Antiretroviral pharmacology in pregnant women and their newborns.
    Annals of the New York Academy of Sciences, 2000, Volume: 918

    Topics: Administration, Oral; Anti-HIV Agents; Delivery, Obstetric; Female; HIV Infections; Humans; Infant;

2000
The cost effectiveness of a single-dose nevirapine regimen to mother and infant to reduce vertical HIV-1 transmission in sub-Saharan Africa.
    Annals of the New York Academy of Sciences, 2000, Volume: 918

    Topics: Acquired Immunodeficiency Syndrome; Africa South of the Sahara; Anti-HIV Agents; Computer Simulation

2000
Further views by the Erice working group on mother-to-child transmission of HIV type 1.
    Acta paediatrica (Oslo, Norway : 1992), 2001, Volume: 90, Issue:1

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease T

2001
South Africa's AIDS activists say new neviripine programme is not enough.
    Lancet (London, England), 2001, Feb-10, Volume: 357, Issue:9254

    Topics: Anti-HIV Agents; Costs and Cost Analysis; Female; Financing, Government; Health Care Rationing; HIV

2001
South Africa cuts agreement for one AIDS drug but ignores another.
    IAPAC monthly, 2001, Volume: 7, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cost Savings; Drug Indust

2001
Two studies suggest nevirapine benefit for children.
    AIDS patient care and STDs, 1997, Volume: 11, Issue:3

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Female; HIV Infect

1997
Nevirapine: ethical dilemmas and care for HIV-infected mothers.
    Focus (San Francisco, Calif.), 1995, Volume: 10, Issue:7

    Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Counseling; Ethics, Medical; F

1995
Nevirapine approved by FDA. Food and Drug Administration.
    NIAID AIDS agenda, 1996

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Approval; Drug Th

1996
Pregnant women eligible for single-dose nevirapine study.
    AIDS treatment news, 1997, Oct-03, Issue:No 280

    Topics: Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transm

1997
Perinatal HIV down as treatment increases.
    AIDS alert, 1997, Volume: 12, Issue:11

    Topics: Adult; Clinical Trials as Topic; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant,

1997
Preventing HIV infection in infants in developing countries: NIAID's role. National Institute of Allergy and Infectious Diseases.
    NIAID AIDS agenda, 1997

    Topics: Anti-HIV Agents; Child; Child, Preschool; Clinical Trials as Topic; Developing Countries; Ethiopia;

1997
Thai study success affects ongoing placebo trials.
    AIDS alert, 1998, Volume: 13, Issue:4

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectio

1998
Unequal care sustains vertical transmission rate.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1999, Volume: 13, Issue:2

    Topics: Anti-HIV Agents; Cesarean Section; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans;

1999
Single-dose Nevirapine during pregnancy.
    AIDS clinical care, 1999, Volume: 11, Issue:10

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmis

1999
Prevention of perinatal HIV infection: cause for optimism.
    AIDS clinical care, 1999, Volume: 11, Issue:12

    Topics: AIDS Serodiagnosis; Anti-HIV Agents; Cesarean Section; Clinical Trials as Topic; Drug Therapy, Combi

1999
Perinatal transmission.
    AIDS policy & law, 1999, Sep-17, Volume: 14, Issue:17

    Topics: Anti-HIV Agents; Developing Countries; Female; Foundations; HIV Infections; Humans; Infant, Newborn;

1999
Hope for Africa's next generation.
    WORLD (Oakland, Calif. : 1993), 1999, Issue:No 100

    Topics: Administration, Oral; Clinical Trials as Topic; Drug Administration Schedule; Female; HIV Infections

1999
Study offers hope for Africa's next generation.
    WORLD (Oakland, Calif. : 1993), 1999, Issue:No 101

    Topics: Administration, Oral; Anti-HIV Agents; Breast Feeding; Clinical Trials as Topic; Drug Administration

1999
Can a $4 drug stop vertical HIV transmission?
    AIDS alert, 1999, Volume: 14, Issue:11

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Health Services Accessibility; HIV Infections

1999
Perinatal transmission.
    AIDS policy & law, 1999, Aug-06, Volume: 14, Issue:14

    Topics: Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infe

1999
Global strategies for the prevention of HIV transmission from mothers to infants: the second conference.
    Journal of the International Association of Physicians in AIDS Care, 1999, Volume: 5, Issue:12

    Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Clinical Trials as Topic; Congresses as Topic; De

1999
Simpler regimens for preventing mother-to-child HIV transmission.
    Project Inform perspective, 1999, Issue:28

    Topics: Delivery, Obstetric; Developing Countries; Drug Administration Schedule; Female; HIV Infections; Hum

1999
Preventing mother-to-child transmission of HIV in developing countries: recent developments and ethical implications.
    Reproductive health matters, 2000, Volume: 8, Issue:15

    Topics: Anti-HIV Agents; Developing Countries; Ethics, Medical; Female; HIV Infections; Humans; Infant, Newb

2000
Rwanda to receive cheaper anti-HIV drugs for chronic treatment and free viramune to prevent viral transmission from mother to child.
    SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging, 2001, Volume: 56, Issue:4

    Topics: Anti-HIV Agents; Chronic Disease; Developing Countries; Drug Costs; Drug Industry; Female; HIV Infec

2001
South Africa in crisis on HIV/AIDS treatment.
    Science (New York, N.Y.), 2001, Jun-29, Volume: 292, Issue:5526

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Industry; Female; Health Policy; Health Se

2001
New drug regimen helps prevent HIV infection in infants.
    Health care financing review, 1999,Fall, Volume: 21, Issue:1

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

1999
Taking HIV to court.
    Lancet (London, England), 2001, Sep-01, Volume: 358, Issue:9283

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2001
To test or not to test--ethical dilemmas and practical realities in the use of co-trimoxazole and nevirapine in HIV-infected adults.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2001, Volume: 91, Issue:8

    Topics: Adult; AIDS Serodiagnosis; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Developing Countr

2001
South Africa's stance on nevirapine on trial.
    Lancet (London, England), 2001, Nov-03, Volume: 358, Issue:9292

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infant; Infant, Newborn; Infectious

2001
Zambian women's attitudes toward mass nevirapine therapy to prevent perinatal transmission of HIV.
    Lancet (London, England), 2001, Nov-10, Volume: 358, Issue:9293

    Topics: Anti-HIV Agents; Attitude to Health; Female; HIV Infections; Humans; Infectious Disease Transmission

2001
Experience of nevirapine use in a London cohort of HIV-infected pregnant women.
    HIV medicine, 2001, Volume: 2, Issue:2

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; HIV-1; Humans;

2001
I want to see them grow up.
    WORLD (Oakland, Calif. : 1993), 2001, Issue:127

    Topics: Anecdotes as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission

2001
The faces of AIDS in Uganda: Mulago Hospital.
    WORLD (Oakland, Calif. : 1993), 2001, Issue:127

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Nevirapine; Pregnan

2001
South Africa: activists, physicians sue government to prevent maternal transmission, ask international support.
    AIDS treatment news, 2001, Nov-23, Issue:374

    Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Internat

2001
Primary HIV-1 drug resistance in Abidjan (Côte d'Ivoire): a genotypic and phenotypic study.
    AIDS (London, England), 2002, Feb-15, Volume: 16, Issue:3

    Topics: Adult; Anti-HIV Agents; Cohort Studies; Cote d'Ivoire; Drug Resistance, Viral; Female; Genotype; HIV

2002
S Africa state offers HIV drug to pregnant women.
    Lancet (London, England), 2002, Feb-02, Volume: 359, Issue:9304

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V

2002
South African government procrastinates over policy on HIV drug.
    Lancet (London, England), 2002, Feb-09, Volume: 359, Issue:9305

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infant, Newborn; Infectious Disease

2002
South African President hints at expansion of HIV-drug pilot programmes.
    Lancet (London, England), 2002, Feb-16, Volume: 359, Issue:9306

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi

2002
Effect of nevirapine toxicity on choice of perinatal HIV prevention strategies.
    American journal of public health, 2002, Volume: 92, Issue:3

    Topics: Anti-HIV Agents; Cohort Studies; Decision Support Techniques; Female; Fetal Death; HIV Infections; H

2002
Confusion over Mandela's "support" of ANC HIV policy.
    Lancet (London, England), 2002, Mar-09, Volume: 359, Issue:9309

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infectious Disease Transmission, Ver

2002
A South African perspective on 2001.
    Science (New York, N.Y.), 2002, Mar-15, Volume: 295, Issue:5562

    Topics: Anti-HIV Agents; Drug Industry; Female; HIV Infections; Humans; Infant; Infectious Disease Transmiss

2002
Stage of the epidemic and viral phenotype should influence recommendations regarding mother-to-child transmission of HIV-1.
    The Lancet. Infectious diseases, 2002, Volume: 2, Issue:2

    Topics: Anti-HIV Agents; Breast Feeding; Disease Outbreaks; Female; HIV Infections; HIV-1; Humans; Infant; I

2002
South African judge reaffirms judgement to expand access to AIDS drug.
    Lancet (London, England), 2002, Mar-16, Volume: 359, Issue:9310

    Topics: Anti-HIV Agents; Female; HIV Infections; HIV Seropositivity; Humans; Infectious Disease Transmission

2002
Feasibility of antenatal and late HIV testing in pregnant women in Phnom Penh Cambodia: the PERIKAM/ANRS1205 study.
    AIDS (London, England), 2002, Apr-12, Volume: 16, Issue:6

    Topics: AIDS Serodiagnosis; Cambodia; Counseling; Feasibility Studies; Female; HIV Infections; HIV Seropreva

2002
Enough time wasted in South Africa.
    The Lancet. Infectious diseases, 2002, Volume: 2, Issue:4

    Topics: Anti-HIV Agents; Female; Government Programs; HIV Infections; Humans; Legislation, Drug; Nevirapine;

2002
South African court again tells government to increase access to AIDS drug.
    Lancet (London, England), 2002, Mar-30, Volume: 359, Issue:9312

    Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; HIV Seropositivity; Humans; Infant, Newborn;

2002
South African nevirapine policy faces growing pressure.
    The Lancet. Infectious diseases, 2002, Volume: 2, Issue:3

    Topics: Anti-HIV Agents; Female; Government Programs; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnan

2002
Mothers, orphans, and prevention of paediatric AIDS.
    Lancet (London, England), 2002, Apr-06, Volume: 359, Issue:9313

    Topics: Anti-HIV Agents; Female; Foster Home Care; HIV Infections; Humans; Infant, Newborn; Infectious Disea

2002
South African leader relents in storm over HIV drugs for women.
    Nature, 2002, Apr-25, Volume: 416, Issue:6883

    Topics: Anti-HIV Agents; Female; Government; HIV Infections; Humans; Infectious Disease Transmission, Vertic

2002
FDA application withdrawn to market Viramune for new use.
    AIDS policy & law, 2002, Apr-12, Volume: 17, Issue:7

    Topics: Drug Approval; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine

2002
Let nevirapine do what it does best.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 2002, Volume: 16, Issue:3

    Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr

2002
Paying to waste lives: the affordability of reducing mother-to-child transmission of HIV in South Africa.
    Journal of health economics, 2002, Volume: 21, Issue:3

    Topics: Adult; Anti-HIV Agents; Child Welfare; Child, Preschool; Cost of Illness; Cost-Benefit Analysis; Fem

2002
Judasa, HPCSA and CMSA take up cudgels.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2002, Volume: 92, Issue:3

    Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Nevirapine; Patient Advocacy; Pregnancy; Pregnancy

2002
PMTCT--who decides on the right to life?
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2002, Volume: 92, Issue:4

    Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Male; Nevirapine; Practice

2002
No acceptable excuse for inaction.
    IAPAC monthly, 2002, Volume: 8, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Female; Health Priorities; Health Services Accessibility; Humans

2002
Policy watch. Good news, bad news.
    The AIDS reader, 2002, Volume: 12, Issue:4

    Topics: Anti-HIV Agents; Bioterrorism; Budgets; Female; Health Policy; HIV Infections; Humans; Infant, Newbo

2002
Court orders South Africa to treat pregnant HIV-positive women with nevirapine.
    Bulletin of the World Health Organization, 2002, Volume: 80, Issue:4

    Topics: Female; Health Services Accessibility; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy Comp

2002
Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002, Jul-15, Volume: 774, Issue:2

    Topics: Calibration; Chromatography, High Pressure Liquid; Female; HIV Protease Inhibitors; Humans; Lopinavi

2002
HIV does cause AIDS but it's hard to prescribe the drugs, says South Africa's ANC.
    Bulletin of the World Health Organization, 2002, Volume: 80, Issue:5

    Topics: Female; Health Services Accessibility; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy Comp

2002